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Abstract
Dietary obesity after middle age is associated with insulin resistance and oxidative 
stress and is a major risk factor for the development of cardiovascular diseases. 
However it remains unclear about the effects of high-fat diet (HFD) on vascular 
oxidative status and endothelial function, and both of them are interactive and pivotal 
to the development of obesity-associated cardiovascular disease, such as 
atherosclerosis. Nox2 is a major source of vascular reactive oxygen species (ROS); 
however its role in diet-induced metabolic disorders and vascular dysfunction is 
unclear. Therefore, the objective of this PhD project is to investigate the role o f Nox2 
and oxidative stress in HFD-induced metabolic disorders and endothelial dysfunction 
in mice.
Male C57BL/6J wild-type (WT) mice and Nox2 knockout (KO) mice at 7 month of 
age were fed with a HFD or a normal chow diet (NCD) for 16 weeks. Body weight, 
blood pressure (BP) and fasting blood samples were taken before and after diet 
intervention. Mice were sacrificed for assessment of aortic function ex vivo. 
Compared to NCD-fed mice, WT mice fed with HFD showed significant increases in 
body weight, fasting glucose and insulin levels with elevated lipids profiles and BP. 
These changes were accompanied by significant increases in nicotinamide adenine 
dinucleotide phosphate (NADPH)-dependent ROS production by aortas and a 
decrease in endothelium-dependent vessel relaxation and this was reversed back to 
control levels by adding superoxide scavenger tiron. Compared to WT mice, Nox2 
KG mice fed with HFD has no significant increase in fasting glucose with less 
augmented lipids profiles and unaltered BP. The aortic NADPH-dependent ROS 
production remained unchanged and the endothelium-dependent vessel relaxation was 
well preserved. In a parallel study, HFD-fed WT mice were supplied with a Nox2 
inhibitor apocynin in drinking water. Apocynin treatment significantly attenuated the 
HFD-induced overweight, the high lipids levels and the high BP, but had no 
significant effect on blood glucose levels. Apocynin treatment also preserved the 
endothelium-dependent vessel relaxation to acetylcholine in HFD group. To further 
investigate the relationship between HFD and the pathogenesis of atherosclerosis, we 
fed HFD to apolipoprotein E (apoE) KO mice at age of 6  weeks for 10 weeks. The 
HFD promoted obesity, hyperglycaemia, hyperinsulinemia, type 2 diabetes-like
I
insulin resistance and accelerated the accumulation of low-density lipoprotein in apoE 
KO mice. HFD also attenuated the endothelium-dependent relaxation responses of 
aortas accompanied with higher BP in apoE KO mice.
In conclusion, HFD increases the levels of ROS production in the vasculature. 
Activated Nox2 and induced oxidative stress by diet-induced obesity contribute to 
metabolic disorders including impaired glucose and lipids metabolism, and 
endothelial dysfunction. Deletion or inhibition o f Nox2 attenuates these detrimental 
pathological progresses. Therefore, Nox2 and Nox2-derived ROS play a key role in 
mediating dietary obesity-related metabolic disorders and endothelial dysfunction 
after middle-age.
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1. General Introduction
1.1. Obesity and cardiovascular disease
1.1.1. Epidemiology of obesity and obesity-associated diseases
Body mass index (BMI) is measure o f adiposity that is used to classify individuals as 
underweight, overweight and obese. It is defined as a person’s body weight divided 
by the square of the height o f that person, i.e. BMI = Body mass (kg) / (height (m)) 
As an experimental proxy for human body fat, the use o f BMI commenced from 
1970s (Keys et al., 1972) with the interest in assessing body fat due to 
overweight/obesity becoming a noticeable issue in the majority o f Western countries. 
Currently, most epidemiological and clinical studies have applied the BMI thresholds 
proposed by World Health Organization reports (WHO/NUT/NCD) (Barba et al., 
2004; WHO, 2000). Numerically, a BMI of 25.0-29.9 kg/m^ represents overweight; 
with a BMI > 30kg/m^ defining obesity, the ‘overweight’ cut-off of a BMI higher than 
25 kg/m^ enclosed all categories o f overweight, including obesity. However, the term 
‘overweight’ is frequently used to quote a BMI in the range of 25-29.9 kg/m^, and this 
convention is applied throughout the thesis.
The global pandemic of obesity is currently recognized as one of the most essential 
healthcare issues in modem societies (Figure 1.1). Epidemiological surveys show that 
the prevalence o f overweight and obese individuals is rapidly increasing globally. 
WHO has evaluated that there were 800 million overweight people worldwide in 
2005, with almost 400 million obese. By the year of 2015, it is predicted that these 
figures will add up to 1.6 billion overweight and 700 million obese, representing 
alarming 10-year increases of 100% and 75%, respectively (Figure 1.2).
Figure 1.1 World map o f proportion o f obese adults in global population in 2005
O bese  adults in 
population %
3 0 - 40%
■  1 0 - 20%
5 - 10%
No data
%
A
Data from World Health Organization (2005) and figure adjusted from British 
Broadcasting Corporation website: http://news.bbc.co.Uk/l/hi/health/7151812.stm.
Figure 1.2 Worldwide prevalence of overweight and obesity up to 2008 with 
prediction up to 2015.
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Data from World Health Organization website (http://www.who.int/mediacentre/ 
factsheets/fs311/en/index. html).
As the prevalence o f obesity continues to rise, there is growing concern that it will 
lead to an increase in the incidence o f chronic diseases (such as osteoarthritis, diabetes, 
and cardiovascular diseases), higher mortality rate and overwhelming financial 
demands on healthcare systems worldwide. In fact, obesity and obesity-associated 
diseases impose huge costs which drain social resources and have significant 
economic and social impact to the whole societies as well as involved individuals 
(AmericanDiabetesAssociation, 2008; Petersen, 2003). In Britain alone, the clinical 
consequences o f obesity are predicted to cost the nation 50 billion pounds -  half the 
National Health System budget for a year -  by 2050 if the trend continues. (Data from 
the website o f the Department of Health (UK); http://www.dh.gov.uk/en/Publichealth/ 
Obesity/DH_ 078098)
1.1.2. The risks of development of obesity-associated CVD
Obesity has detrimental effects on metabolic homeostasis and affects numerous organ 
systems including heart, liver, kidney, and vascular system (Roberts et al., 2005). 
Indeed, obesity is an independent risk factor for several conditions that predispose to 
cardiovascular disease (CVD) including hypertension, diabetes, stroke and ischaemic 
heart disease (Burke et al., 2008; Lavie et al., 2009; Lawson, 2006; Mokdad et al., 
2003; Wilson et al., 2002) as shown in figure 1.3. Clinically, obesity is often strongly 
associated with a group of risk factors or disorders such as impaired glucose 
homeostasis, dyslipidaemia, hypertension, and insulin resistance which are commonly 
clustered together and termed the ‘metabolic syndrome’ (Lorenzo et al., 2007). People 
with 3 or more o f these key abnormalities have 2-3 times bigger risk o f being affected 
by a heart attack or stroke and 3-5 times greater risk o f developing type 2 diabetes 
(Lorenzo et al., 2007).
Figure 1.3 Percentage o f risk o f cardiovascular diseases attributed to obesity.
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CVDs are the principal cause of death and disability in the Western world. Each year 
in Europe, CVDs cause an estimated 4.3 million death and contribute to 48% of all 
deaths (54% of deaths in women and 43% of deaths in men) (Conroy et al., 2003). In 
the UK alone CVDs are responsible for 37% of all deaths (Bhatnagar et al., 2011). 
Thus it is not hard to understand why a vast amount of research has been undertaken 
both into the causes of obesity-associated CVDs and how they can best be treated.
1.1.3. Obesity-associated cardiovascular diseases
Despite intensive research in the last decades, the mechanisms by which obesity 
promotes CVD are still not fully understood. Nevertheless, obesity, particularly in 
those with metabolic syndrome, has been postulated to be a cardiovascular risk state 
and causes CVD mediated through a variety of pathways (Fortune et al., 2003; 
lacobellis et al., 2002). Because of the anatomical location of intra-abdominal adipose
tissue, the secreted products of the excess adipose tissue, such as free fatty acids 
(FFA), Interleukin 6, and various adipokines, are delivered directly to the liver and 
promptly to cardiovascular system having adverse effects on target organs and 
increasing cardiovascular risk (Table 1.1). Furthermore, excess body weight may be 
associated with an increase in cardiac output due mostly to increases in stroke volume 
(Di Bello et al., 2006). This hyperdynamic state enlarges the volume loading of the 
left ventricle particularly and may result in left ventricular hypertrophy which is a 
major risk factor for congestive heart failure, coronary heart disease, arrhythmias and 
all-cause cardiovascular mortality (Dorbala et al., 2006). Additionally, there is 
accumulating evidence that obesity-induced insulin resistance and hyperinsulinemia 
contribute to increased tendency for development of primary hypertension via 
multiple pathways including activation in sympathetic nervous system (Sowers and 
Bakris, 2000) and augmented renal sodium retention (Sowers et al., 1994).
An increased oxidative stress has been determined to be one o f major pathological 
changes in obesity and obesity-associated CVD (Berry et al., 2001; Roberts et al., 
2006; Urakawa et al., 2003). There is evidence that oxidative stress caused by 
hyperglycaemia and excess FFA occurs before the cardiovascular complications of 
obesity become clinically evident (Berry et al., 2001; Zalba et al., 2001). Meanwhile 
studies have suggested that excess dietary fat can detrimentally affect the 
cardiovascular system at least in part via increases in oxidative stress (Roberts et al., 
2006). Furthermore several oxidative stress-activated signalling pathways, such as 
nuclear factor-kappa B (NF-kB), protein kinase C (PKC), mitogen-activated protein 
kinase (MAP kinase) and c-Jun N-terminal kinase (JNK) have been identified taking
part in the development of obesity-associated CVD (Evans et ah, 2002; Ichijo et al., 
1997; Silver et al., 2007).
Obesity is also commonly linked with an impairment o f endothelium function or 
endothelial dysfunction, a key feature of numerous CVDs (Avogaro and de 
Kreutzenberg, 2005). Westem-style high-fat diet-induced obesity can give rise to type 
2 diabetes-like insulin resistance and hypercholesterolemia which have been 
implicated in the onset o f endothelial dysfunction (Arcaro et al., 1999; Caballero, 
2003) even though the principal mechanisms are not fully revealed. Clinical 
observations demonstrated that even a single meal with high-fat content can cause a 
short-term endothelial dysfunction, determined as diminished relaxation responses of 
brachial artery to occlusion in healthy subjects (Cuevas et al., 2000; Plotnick et al., 
1997). These studies implicated a crucial role of dietary fat composition in the 
development of obesity-associated endothelial dysfunction.
1.1.4. Diabetes and cardiovascular diseases
The interactions between diabetes and CVDs are complex. The mechanisms 
underlying diabetic CVD remain to be clarified. Based on the observation of 
decreases in endothelium dependent vasodilatation in patients with obesity and type 2 
diabetes (Steinberg et al., 1996), it has been demonstrated that enhanced oxidative 
stress caused by hyperglycaemia leads to increased formation o f peroxynitrite, 
disruption of nitric oxide synthase (NOS) dimers, inactivated nitric oxide (NO) 
bioavailability (Da Ros et al., 2005).
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Insulin resistance is a fundamental component o f the cardiometabolic syndrome 
which often progresses to type 2 diabetes and CVDs. Therefore, investigating the 
influence o f impaired insulin signalling on vascular ftinction is important to 
understand the relationship between diabetes and CVD. Evidence shows that the 
abnormalities o f insulin signalling or homeostasis may impact endothelial function via 
a complementary pathway for endothelial NOS (eNOS) activation involving its 
phosphorylation (Dimmeler et ah, 1999; Fulton et ah, 1999; Muniyappa et ah, 2007; 
Wheatcroft et ah, 2004; Zeng et ah, 2000; Zeng and Quon, 1996). Moreover, an 
elegant study (Vicent et ah, 2003) showed that targeted knockout of the insulin 
receptor in endothelial cells resulted in reduction of eNOS expression and alteration 
of expression of vasoactive mediators and therefore may play a role in maintaining 
vascular tone.
Hyperglycaemia caused by diabetes leads to advanced glycation end products (AGE), 
which has been shown to quench NO and impair endothelial function, as evidenced by 
inhibition of advanced glycosylation with aminoguanidine (Bucala et ah, 1991). AGE 
induce ROS and promote vascular inflammation, with enhanced expression of lL-6, 
VCAM-1, and MCP-1 (Zhang et ah, 2003). Additionally, acute hyperglycaemia itself 
can reduce NO (Giugliano et ah, 1997) and attenuate endothelium-dependent 
vasodilatation in human in vivo (Williams et ah, 1998).
1.2. ROS and obesity-associated CVD
1.2.1. Reactive oxygen species
Reactive oxygen species (ROS) are a group of ubiquitous reactive derivatives of 
oxygen metabolism and include superoxide anion (O2 '), hydrogen peroxide (H2O2)
hydroxyl radical (HO ), hypochlorous acid (HOCl) and peroxynitrite (ONOO ). ROS 
formation in the body usually begins with one electron reduction of molecular oxygen 
(O2), resulting in a superoxide anion. This highly reactive molecule either directly 
reacts with NO to form peroxynitrite, or is rapidly dismutated by antioxidant system 
in the body such as superoxide dismutase (SOD) to form less reactive hydrogen 
peroxide. By the action of catalase or glutathione peroxidase, hydrogen peroxide is 
converted into water, but it can also lead to the formation of other ROS derivatives 
such as hydroxyl radical and hypochlorous acid (see Figure 1.4).
Figure 1.4 Biochemical reactions o f ROS formation
e" e" e' e"
O , ^  H A  * OH  ^  H ,0
2H+ H+ HjO H+
NO'- ■
ONOO'
Superoxide is the primary and major form of ROS production in the body because its 
two unpaired electrons are situated in different molecular orbitals and have parallel 
spin states (Madamanchi et al., 2005); therefore the loss o f one electron and univalent 
reduction of O2 to form O2 ’ is common under oxidative stress conditions. However 
this negatively charged radical is unstable in aqueous solution with a half-life of a few 
seconds and is generally restricted to the cell compartment in which it is produced 
because of its poor cell membrane permeability (Li and Shah, 2004). In presence o f 
SOD, superoxide is rapidly transformed to hydrogen peroxide, a more stable and 
diffusible form of ROS, taking part in mediating biological functions of cells. 
Interestingly, superoxide reacts with NO at a higher rate compared with that with
SOD, therefore NO may outcompete SOD and react with superoxide under certain 
circumstance to generate ONOO , which plays an important role in the pathogenesis 
of endothelial dysfunction (Li and Shah, 2004). HO may be produced through the 
Haber-Weiss or Fenton reaction which uses H2O2 in a redox reaction (H2O2 + Fe^ "^  
HO' + HO + Fe^^). The Fenton derived HO' has been shown to be a major contributor 
to atherosclerosis especially due to high levels o f lipid peroxidation of cell membrane 
polyunsaturated fatty acids (Kanter et al., 2007).
Classically, ROS were considered to be harmful through their reaction with cellular 
membranes, DNA, macromolecules and proteins. This is recognized to be important 
in the pathology o f some diseases such as reperfusion injury (Droge, 2002). Recently 
ROS have been found having various effects through redox signalling on cellular 
functions. Many o f these functions, within the cardiovascular system, are associated 
with maintaining cardiovascular integrity as well as involving in pathological changes 
in obesity-associated CVDs (Yung et al., 2006).
1.2.2. The physiological role of ROS in the vasculature
ROS have various effects on cellular function depending on the amount and sub- 
cellular location they have been generated. ROS are produced in a controlled manner 
at low concentrations under physiological conditions and regulate vascular function 
by modulating cell growth, apoptosis, migration, inflammation, secretion and 
extracellular matrix protein production and inactivating NO, and stimulating many 
kinases and proinflammatory genes (Guzik et al., 2006). Physiological changes in 
intracellular ROS levels are critical for cellular signalling and survival. For example 
ROS are needed to activate the transcription factor activator protein-1 (AP-1) which
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controls the expression o f many genes including members o f the Fos and Jun 
immediate-early response genes (Wolin, 2000). Therefore antioxidant systems in the 
body will not remove ROS entirely but will keep them at an optimum basal level as to 
avoid damage to cells but to have continued beneficial actions.
More importantly, ROS are involved in the physiological regulation of vascular tone 
either by reaction with NO or via the direct effects of H2O2. NO is a well-known 
endothelium-derived relaxing factor and plays a key role in balancing of blood flow 
and vascular tone; therefore it is of importance in these activities in endothelium that 
the physiological topical generation of O2' and rapid reaction with NO resulting in 
inactivation of NO. For instance a physiological stimulus of increasing blood flow can 
trigger the generation o f both O2' and NO (Laurindo et al., 1994). while H2O2 
converted from O2' in endothelium directly takes part in flow-induced dilatation in 
certain vascular beds such as murine mesenteric arteries (Shimokawa and Morikawa, 
2005) and human coronary arteries (Arora et al., 2010).
1.2.3. Oxidative stress
At low concentrations ROS are necessary for intracellular signalling and principally 
redox signalling; however when ROS are produced faster than they can be removed 
by cellular defence mechanisms resulting in high concentrations, ROS can cause 
damage to lipids, proteins, and DNA resulting in cellular damage and the pathological 
conditions o f CVDs (Lau et al., 2008; Shi et al., 2004; Thannickal and Fanburg, 
2000). This steady state level of oxidative damage in the body caused by excess ROS 
is defined as oxidative stress in which pro-oxidants overwhelm anti-oxidant capacity.
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A long standing notion is that vascular oxidative stress with an increased production 
of ROS induces many identified risk factors linking with CVDs, including 
hypertension, hyperlipidaemia, and diabetes (Jose et ah, 2008) and it also directly 
affects endothelial function, causes myocardiac damage and contributes to CVDs (Fan 
et ah, 2009a; MacCarthy et ah, 2001a; Stocker and Keaney, 2004). For example, an 
increased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase derived 
ROS production is found responsible for impaired endothelial regulation of 
ventricular relaxation in aortic banding-induced left ventricular hypertrophy in animal 
models (Li et ah, 2002a; MacCarthy et ah, 2001a). Treatment with antioxidants 
improves vascular function, reverses vascular structure, and decreases blood pressure 
in animal models (Hoagland et ah, 2003) and in human hypertension (Mullan et ah, 
2002). Furthermore, mouse models deficient in ROS-generating enzymes have lower 
blood pressure compared with wild-type counterparts and inftision o f angiotensin 11 to 
these mice fails to induce hypertension (Li and Shah, 2003a).
Obesity potentially promotes cardiovascular diseases through a series o f metabolic 
disorders including accumulation of adipose tissue, elevated blood pressure, 
dyslipidaemia, and diabetes, which are all associated with vascular oxidative stress 
(Van Gaal et ah, 2006). In obesity, increased ROS production from accumulated fat 
leads to an increase in oxidative stress in blood, affecting other organs and contributes 
to diabetes, vascular dysfunction, dysregulation o f lipids (Carmiel-Haggai et ah, 2005; 
Furukawa et ah, 2004). There is considerable evidence that hyperglycaemia results in 
the generation o f ROS via multiple pathways (Cai and Harrison, 2000a) which 
ultimately leads to oxidative stress in various tissues including cardiovascular system 
(Roesen et ah, 2001).
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1.2.4. ROS and CVDs
1.2.4.1. Physiological function of Endothelium
A single layer o f endothelial cells forms the endothelium which is the interior surface 
of entire circulatory system. Endothelial cells not only form a semi-permeable barrier 
between tissues and blood but also constantly produce vasoactive and trophic 
substances that cause changes in hemodynamic forces, ambient PO2, and local blood- 
borne signals and respond with appropriate functional changes to maintain 
cardiovascular homeostasis (Li and Shah, 2004). Furthermore, endothelial cells can 
modulate the equilibrium between potentially opposing processes in vessels such as: 
( 1) vasodilatation and vasoconstriction, in this manner regulating vascular tone; (2 ) 
antithrombotic and pro-coagulant effects, thereby influencing haemostasis; and (3) 
cell proliferation and apoptosis, thus modulating cell growth and number in vessel 
walls (Esper et al., 2006).
1.2.4.2. Endothelial dysfunction
In the arterial system, endothelial cells are both the source and target of factors 
contributing to the development of cardiovascular disease. Endothelial vasoactive 
factors regulate vascular homeostasis under physiological conditions and maintain 
basal vascular tone. Cardiovascular risk factors, such as obesity, result in an 
imbalance between endothelium-derived vasoactive factors favouring 
vasoconstriction, cell growth and inflammatory activation. The abnormal regulation of 
these factors due to endothelial cell dysfunction is both consequence and cause of 
vascular disease processes.
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The earliest detectable changes in vascular disease states are abnormalities of the 
endothelium or endothelial dysfunction, resulting in loss of the endothelium’s normal 
homeostatic functions that normally act to inhibit disease-related processes such as 
inflammation and thrombosis. Endothelial dysfunction is a crucial step in the 
pathogenesis o f several CVDs including heart failure, hypertension, and 
atherosclerosis (Li and Shah, 2004). Pathophysiologically, endothelial dysfunction 
can be characterized by an impairment o f endothelium-dependent vasorelaxation 
caused by a reduction in the bioavailability of the endothelial NO (Walia et al., 2003). 
The mechanisms that result in loss of NO bioavailability in vascular disease have 
remained less clear. It may be caused by decreased production of the eNOS (Szocs et 
al., 2002), a lack o f substrate or cofactors for eNOS (Pou et al., 1992), and accelerated 
NO degradation by ROS (Harrison, 1997).
1.2.4.3. Pathophysiology o f endothelial dysfunction: the role of ROS 
Compelling evidence supports a causal role for the enhanced production of ROS by 
vascular cells involved in the pathologic mechanisms of endothelial dysfunction (Li 
and Shah, 2004). Data from experimental models suggest that increased ROS 
production directly react with and inactivate endothelium-derived NO contributing to 
the initiation and progression of endothelial dysfunction (Li et al., 2001; Li and Shah, 
2004). The reaction between O2 ' and NO occurs at an almost diffusion-limited rate, 
six times greater than the removal of O2 " by copper-zinc superoxide dismutase. In 
addition to the direct interaction with NO, ROS, as second messengers, have 
significant indirect effects on endothelial cells through modulating varied redox- 
sensitive signalling pathways including endothelial cell growth, proliferation, 
migration, survival, cytoskeletal reorganization, adhesion molecule expression.
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permeability, and secretion of inflammatory cytokines (Dworakowski et al., 2008; Li 
and Shah, 2004). Furthermore, ONOO , formed by the NO- O2 ' reaction, has 
additional detrimental effects on vascular function, either by oxidation of cellular 
proteins and lipids, i.e. LDL particles (White et al., 1994) or by direct cell toxicity 
(Ballinger et al., 2000).
Using dihydroethidium (DHB) fluorescence as a marker of superoxide production in 
human blood vessels reveals marked superoxide production from the media and 
adventitia and a modest proportion directly from the endothelium; endothelial 
superoxide production appears to be prominent in vessels from patients with diabetes. 
It is well known that diabetes and cardiovascular disease are associated with disturbed 
microcirculation, and it has been considered that the key event developing early on is 
endothelial dysfunction (Busija et al., 2005; Caballero, 2003; Cai and Harrison, 
2000a; Frisbee and Stepp, 2001; Sowers et al., 2001). Increased ROS generation in 
diabetes is an important feature of microvascular dysfunction and interferes with 
several mechanisms in endothelium, such as NO mediation, giving rise to impaired 
endothelium-dependent vasodilation (Busija et al., 2005; Frisbee and Stepp, 2001; 
Roller, 2002). It has also been observed that excess production o f superoxide in the 
vasculature reduces flow- and agonist-induced dilation of coronary arterioles by 
reacting with endothelium-derived NO in a mouse model o f diabetes (Erdei et al.,
2006). Moreover, in skeletal muscle arterioles, researchers have found that, in type 2 
diabetic and hypertensive obese Zucker rats, increased superoxide production results 
in impaired NO mediation of arteriolar dilations (Frisbee and Stepp, 2001).
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1.2.4.4, Sources of ROS in vascular cells
ROS are generated by several different mechanisms in the vasculature, including (1) 
ionizing radiation on biological molecules; (2 ) as an unavoidable by-product during 
cellular respiration; and (3) synthesized by enzymes (Klaunig and Kamendulis, 2004; 
Martindale and Holbrook, 2002; Poli et al., 2004). It has been suggested that several 
enzyme systems in the vasculature have the capability of transferring electrons to 
molecular oxygen to produce ROS with four systems being of major importance. 
These include uncoupled eNOS (Cosentino and Katusic, 1995; Vasquez-Vivar et al., 
1998b), enzymes of the mitochondrial respiratory chain (Nishikawa et al., 2000), 
xanthine oxidase (Bagi et al., 2002; Ohara et al., 1993), and NADPH oxidases 
(Bedard and Krause, 2007a).
Uncouplins o f  Nitric oxide synthase
The enzyme nitric oxide synthase catalyses the following reaction:
NADPH NADP+
L-arginine+02 — ------—  > CitruIline + NO
NOS
eNOS is the most highly expressed isoform in the vasculature under physiological 
conditions and is a major determination of the control o f vasodilation through NO 
production (Wolin et al., 1999). eNOS is a homodimeric enzyme, each subunit 
consists o f a reductase (C-terminal) domain and an oxygenase (N-terminal) domain. 
The C-terminal domain embrace NADPH, flavine adenine dinucleotide (FAD), 
flavine mononucleotide (FMN) and Ca^VCaM binding sites, and the N-terminal 
domain comprise binding sites for 5,6,7,8 -tetrahydrobiopterin (BH4), heme and L- 
arginine. The BH4 is necessary for dimerization of eNOS in its active form. eNOS
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catalyses L-arginine to NG-hydroxy-L-arginine and then oxidizes NG-hydroxy-L- 
arginine to citrulline and NO (Schulz et al., 2005). eNOS active site requires a transfer 
of electrons down the electron transport chain. This electron transfer begins with 
NADPH binding to the reductase domain. Electrons are transferred from NADPH to 
FAD and then to FMN, from FMN an electron is transferred to the heme of the 
oxygenase domain and converts the ferric heme (Fe^^) to ferrous (Fe^^) which binds 
oxygen actively.
If the availability of L-arginine or BH4 decreases then eNOS turns from the coupled 
state into the uncoupled status in which O2 ', instead of NO, is formed. Evidence for 
eNOS uncoupling has been obtained by depletion of BH4 causing uncoupling of 
oxygen reduction and arginine oxidation resulting in the production of O2 " and 
consequently ONOO (Klatt et al., 1996). In atherosclerosis the amount of BH4 is 
reduced due to oxidation catalysed by the generation of ONOO (Schulz et al., 2005). 
This lack of BH4 accelerates atherosclerosis by increasing the production of ROS by 
eNOS (Kawashima and Yokoyama, 2004) and also increasing the uncoupling of 
eNOS (Wamholtz et al., 2001). When eNOS is exposed to oxidative stress, it 
uncouples to the monomeric form and generates O2 ' instead of NO. In 
hypercholesterolaemia, chronic exposure of the endothelial cells to oxidized LDL 
results in an increased production of O2 ’ by an eNOS-dependent mechanism. In 
atherosclerosis these is upregulation of eNOS. In the atherosclerotic plaques, 
macrophages release large amounts of ROS and macrophage-derived O2 ' results in 
the production o f ONOO (Vendrov et al., 2007). However O2 " is also broken down 
by SOD to produce H2O2 which is a potent stimulus for eNOS expression. This is 
seen particularly in endothelial cells overlying atherosclerotic lesions. In addition as
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NO production has a cardioprotective effect then a decrease in NO induced by ROS 
may result in cardiovascular damage. NO takes part in the antiatherosclerotic 
properties of the endothelial cells through interfering with key events of 
atherosclerosis such as monocyte and leukocyte adhesion to the endothelium and 
reduction in endothelial permeability. In addition, NO production prevents smooth 
muscle cell proliferation within the heart, and in experimental animal models the 
inhibition of eNOS caused an accelerated atherosclerosis (Takaya et al., 2007).
Mitochondrial electron transport chain
The electron transport chain (ETC) carriers are located within the inner membrane of 
the mitochondria. The mitochondrial ETC involves the transfer o f electrons from 
NADH or FADH2 to O2 which provides energy for the body in the form of ATP 
through oxidative phosphorylation. ROS such as O2 ' are produced abundantly under 
oxidative stress by the mitochondrial ETC; this is facilitated by O2 reacting with redox 
active compounds such as semi-ubiquinone (Nishikawa et al., 2000). In oxidative 
stress, the ETC may become uncoupled leading to an increased O2 ' and H2O2 
production. The inner mitochondrial membrane produces large amounts of NO due to 
high activity of NOS. As there is a great amount o f O2 ’ produced by the mitochondria 
this reacts with NO to form the highly reactive ONOO. This increased ONOO results 
in increased oxidative stress of the cardiovasculature due to high levels of 
mitochondria within cardiovascular system (Ramachandran et al., 2002). ROS 
production from the mitochondria can induce the formation o f the mitochondrial 
permeability transition (MPT) pore. This MPT pore is inhibited by the antioxidant 
enzyme catalase which further supports the role o f ROS in mitochondrial apoptosis 
within the cardiovasculature (Mueller et al., 2005). Although evidence suggests that
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mitochondrial dysfunction is linked with CVDs such as hypertension and 
atherosclerosis (Ramachandran et ah, 2002), the causal roles of mitochondrial O2 ’ for 
vascular disease in vivo remain to be established.
Xanthine oxidase
Xanthine oxidoreductase exists in two interconvertible forms, xanthine dehydrogenase 
(XDh) and xanthine oxidase (XO). XDh reduces NAD* ,^ whereas XO reacts with O2 
leading to the production of both O2 ' and H2O2 (Berry and Hare, 2004). XO catalyses 
the conversion o f hypoxanthine to uric acid and H2O2 in the process o f purine 
metabolism. The uric acid produced by XO is an independent risk factor for CVD and 
is often a part of clinical tests for estimating risk of CVD (Bagi et ah, 2002). In the 
breakdown of hypoxanthine, O2 ' is produced as well as H2O2. Hypoxanthine has been 
shown to accumulate in ischaemic tissue as a degradation product o f adenine 
nucleotides (Berry and Hare, 2004). LDL-induced increases in O2 ' and ONOO may 
enhance the conversion of XDh to XO therefore increasing ROS production. This is 
especially evident under oxidative stress conditions in the cell. In atherosclerosis the 
XO inhibitors oxypurinol and allopurinol are used to improve vasodilation by 
reduction of ROS (Cardillo et ah, 1997). Furthermore oxypurinol can preserve 
endothelium-dependent vascular relaxations to acetylcholine via reducing 
ROS production in blood vessels from hyperlipidémie rabbits (Ohara et ah, 1993) 
which suggests xanthine oxidase contributes to the pathogenesis o f endothelial 
dysfunction in presence of hypercholesterolemia. However there is controversy in the 
literature of clinical studies regarding the role of xanthine oxidase in CVDs. Some 
researchers reported an improvement of endothelial dysfunction in 
hypercholesterolemic and diabetic patients with oxypurinol (Butler et ah, 2000b;
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Cardillo et al., 1997), others failed to show an effect with allopurinol (O'Driscoll et 
al., 1999).
NADPH oxidases
Interestingly, among the aforementioned sources, ROS production appears to be 
minimal when the enzymes are functioning normally (Madamanchi et al., 2005; Yung 
et al., 2006). This implies that eNOS, mitochondria and xanthine oxidase are not 
responsible for the initial increases of ROS production in vascular diseases.
NADPH oxidases have been demonstrated to be the major source o f ROS in human 
vessels as they are in several animal models of vascular diseases, including diabetes 
(Guzik et al., 2000a). NADPH oxidases appear to be the enzymes solely dedicated to 
ROS production. Evidence shows that an initial generation of ROS by NADPH 
oxidases also triggers the release of ROS by other enzymes (Landmesser et al., 2003). 
Furthermore, NADPH oxidases have unique roles in oxidant signalling because they 
are a basal source of superoxide production in vascular cells, which are subject to 
regulation by receptor activation, stimuli such as stretch, and metabolic stress such as 
insulin resistance. Therefore the structures and the functions o f NADPH oxidases in 
cardiovascular system will be discussed extensively in the following parts of this 
chapter.
1.3. NADPH oxidases and CVDs
1.3.1. NADPH oxidases
NADPH oxidases (Nox) were first recognized as the enzymes responsible for the 
respiratory burst of ROS produced by professional phagocytes taking part in
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nonspecific host defense against invading micro-organisms. They are now known as a 
universal existing multi-component enzyme complex that catalyses ROS production. 
They have a wide range of physiological functions and are involved in multiple 
pathological processes in development o f many diseases. To date, 7 isoforms of the 
Nox enzymes have been identified in mammals including N oxl through Nox5 as well 
as Duoxl and Duox2 according to their homologous catalytic subunit by which 
electrons have been transferred. The activity of Nox 1-4 requires the association with 
one or more regulatory subunits i.e. p li''"" ', p47>’''“ /N 0X 01, p67>’''‘”‘/NOXAl, 
p4 QP'’ox gjjj Rac-1/2, while Nox5-, Duoxl- and Duox2-containing isoforms o f Nox are 
activated in a calcium dependent manner. (Lambeth et al., 2007; Ris-Stalpers, 2006). 
(See table 1.3)
Members of Nox family are found to be expressed in many cells and tissues and 
regulate various biological functions in the body. Noxl was found mainly to be 
expressed in colon and blood vessels involving in innate immune response and cell 
cycle; Nox2 was found firstly highly expressed in neutrophils and macrophages as the 
catalytic subunit of the respiratory burst oxidase, but now is found in vascular, 
cardiac, neural, and renal cells and have a wide range of functions; Nox3 is expressed 
in fetal tissues and the adult inner ear and plays a role in vestibular function; Nox4 is 
abundant in kidneys but also can be found in vascular cells and osteoclasts; and Nox5 
is found in testis, lymphoid tissue, and in vascular cells o f some species. Duoxl and 
Duox2 are found in the thyroid gland, and play a role in thyroid hormone biosynthesis 
(Bedard and Krause, 2007a).
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1.3.2. Cellular location and structure assembly of Nox in the vascular wall
Of all 7 Nox isoforms of NADPH oxidases mentioned above, only 4 isoforms have 
been identified, namely N oxl-, Nox2-, Nox4- and Nox5-containing NADPH oxidases 
are found to be expressed constitutively by vascular cells (i.e. intimai endothelial 
cells, medial vascular smooth muscle cells and adventitial fibroblasts) which are 
differentially distributed in the cellular compartments and direct several redox- 
dependent processes (see table 1.2). In addition, high levels of Nox2 are also 
expressed in immune cells such as monocytes, macrophages and lymphocytes which 
may also take up residence in the vessel wall under pathophysiological conditions. 
While the Nox5 gene is not present in the genome of rodents (BelAiba et al., 2007), 
the other three Nox enzymes are the primary source of ROS production in mammalian 
vasculature and are critical for normal biological responses as well as contributive to 
the development of a diversity of CVDs.
Table 1.2 Cellular location of Nox enzymes in the vasculature
Nox
enzymes
Components of vessel wall
Endothelium
(endothelial
cells)
Media
(VSMC)
Adventitia
(fibroblasts)
References
Noxl - V - (Suh et al., 1999)
Nox2 V V V (Li and Shah, 2002; Pagano et al., 1997; Petry et al., 2006)
Nox4 V V V (Clempus et al., 2007; Petry et al., 2006)
Nox5 V - - (Petry et al., 2006)
v/-, presence/absence in the relevant vascular cells; VSMC, vascular smooth muscle cells.
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The assembly o f Nox for activation process in the cardiovascular system is distinct 
from the way found in neutrophils. In neutrophils, the Nox is inactive in resting cells. 
In response to a variety of stimuli, the cytosolic subunits o f Nox translocate to and 
associate with membrane-bound cytochrome 655g (a heterodimer o f p2 2 ^^ °^  and 
Nox2), a process that causes neutrophil oxidase activation and the production of huge 
amounts of O2 ' to kill invading micro-organisms. However, in the vasculature, the 
Nox is preassembled even without the presence of agonist stimulations. It is located 
intracellularly and generates continuously a basal level of O2 ’ with low concentrations 
that serves as a signalling molecule involved in the regulation of cardiovascular 
function (Li and Shah, 2002).
1.3.3. Functions of vascular Nox enzymes
Despite the fact that all components of the classical neutrophil-type NADPH oxidases 
expressed at both mRNA and protein level in endothelial cells, the vascular Nox 
enzymes exhibit a number of striking differences in terms of their activity and 
functions. Physiologically, vascular Nox enzymes are preassembled, constitutively 
active and generate ROS intracellularly in a slow and sustained manner which acts as 
intracellular signalling molecules (Li and Shah, 2002).
In endothelial cells, Nox-derived superoxide affects the local bioavailability o f NO 
(Jung et al., 2004; Tavernier et al., 2001). Therefore the effects of Nox enzymes in the 
endothelial cells might be due to depletion o f the vasorelaxant NO. Additionally Nox 
can regulate endothelial cell cycle arrest and apoptosis (Loffredo et al., 2007). 
Moreover, the phosphorylation of Nox subunit p47^ *^ °^  with the activation o f Nox is 
found involved in TNF-a activated redox signalling cascade in microvascular
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endothelial cells (Li et ah, 2005b) and in angiotensin Il-dependent cellular responses 
in endothelial cells (Li and Shah, 2003a; Thakur et ah, 2010).
Nox enzymes are also involved in signalling in vascular smooth muscle cells (VSMC). 
Nox-derived ROS in VSMC regulate the activity of the signalling proteins, such as 
p38 MAP kinase and Akt (Brandes and Kreuzer, 2005), and are important for 
angiotensin Il-induced calcium fluxes (Lambeth, 2007). In cardiomyocytes, Nox 
elaborate a majority of ROS and contributes to the activation of redox-sensitive 
kinases (Li et al., 2002a). Furthermore, Nox-derived ROS interfere with the 
extracellular matrix, influence gene expression, and might also take part in cell 
proliferation and differentiation in the vasculature. Under pathophysiologic 
conditions, however, the functions of different Nox enzymes are dependent on their 
localization to particular cells and subcellular compartments as well as on their mode 
of activation. The following paragraghs will focus on the pathophysiologic functions 
specifically attributed to N oxl, 2, 4 and 5 proteins based on experimental research in 
the vasculature.
1.3.3.1. Noxl
Noxl is expressed in the plasma membrane of VSMCs (Matsuno et al., 2005; Rivera 
et al., 2010). As its expression is relatively low under basal conditions, Noxl is 
significantly up-regulated in vascular injury in an agonist-dependent fashion by 
various stimuli such as angiotensin II, basic fibroblast growth factor (bFGF), platelet- 
derived growth factors, and prostaglandin F2« (Dikalov et al., 2008; Matsuno et al., 
2005; Wind et al., 2010). Moreover, Noxl is markedly overexpressed in the 
vasculature in experimental animal models of CVDs including
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hypercholesterolaemia-induced atherosclerosis in mice (Bengtsson et ah, 2003), 
angiotensin Il-induced hypertension in mice (Matsuno et ah, 2005), and 
streptozoticin-induced diabetes in rats (Wendt et ah, 2005). Noxl expression is also 
significantly up-regulated in transgenic hypertensive rats (Wingler et ah, 2001) and in 
stroke-prone spontaneously hypertensive rats (Akasaki et ah, 2006). In mice, 
overexpression of N oxl in VSMCs causes a significant increase in systolic blood 
pressure and hypertrophy in response to angiotensin II (Dikalova et ah, 2005). 
Reduction of N oxl using ribozymes, on the other hand, protects against hypertrophy 
(Katsuyama et ah, 2002). Furthermore, a complete protection against angiotensin Il- 
induced hypertension is observed in Noxl knockout mice (Matsuno et ah, 2005).
1.3.3.2. Nox2
During physiological conditions, Nox2 expression is mainly restrained to endothelial 
cells and adventitial fibroblasts. Unlike in phagocytic cells, a slight proportion of 
Nox2 is expressed on the plasma membrane of endothelial cells. Instead, a substantial 
proportion o f Nox2 is expressed intracellularly in endothelial cells and is 
constitutively assembled as functional complexes. More specifically, Nox2 displays a 
perinuclear distribution associated 'with the cytoskeleton in endothelial cells (Li and 
Shah, 2002). It remains unknown that what the exact functional role of Nox2 is at 
these sites during normal physiology although Nox2 is shown to be the major 
contributor of ROS production in endothelial cells under physiological conditions 
(Bedard and Krause, 2007a).
In response to pathophysiological stimulations, such as shear stress, angiotensin II or 
inflammatory cytokines, the activity of Nox2 is up-regulated in company with several
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of its regulatory subunits, such as and p40^^°^, mediating agonist-induced ROS
production. The excessive ROS production from Nox2 outstrips endogenous 
antioxidant defense and cause endothelial dysfunction which is involved in the 
pathogenesis o f inflammation and many cardiovascular disorders such as 
atherosclerosis, hypertension, and diabetes (Fan et al., 2009b; Li et al., 2002c). In the 
endothelium, up-regulated Nox2 inactivates endothelial NO to form peroxynitrite, and 
elicits endothelial dysfunction (Jung et al., 2004). Nox2 has been implicated in the 
development o f hypertension. Nox2 gene, located on the X chromosome, is inducible 
and is highly regulated by angiotensin II and stretch and is upregulated in various 
forms of hypertension (Anilkumar et al., 2008; Dikalov et al., 2008; Oliveira-Sales et 
al., 2008). In an experimental mouse model o f renovascular hypertension, Nox2- 
derived ROS impaired NO bioavailability, while in the Nox2 knockout mice there was 
obvious protection from hypertension (Jung et al., 2004). In low renin salt-sensitive 
hypertension, inhibition o f Nox2 activity resulted in normalised ROS production and 
endothelial function (Zhou et al., 2006). Nox2 is also activated during ischemia / 
reoxygenation and takes part in the disruption of the endothelial barrier (Kahles et al.
2007). Knockout of Nox2 prevents reperfusion injury in lung and heart (Al-Mehdi et 
al., 1998), as well as reoxygenation-induced vasoconstriction (Liu et al., 2004).
In adventitia, activated Nox2 mediates fibroblast proliferation and connective tissue 
deposition via regulating expression of various atherogenic proinflammatory genes 
(Chamseddine and Miller, 2003). Furthermore, infiltrating monocytes, macrophages 
and T-cells represent activated Nox2 and Nox2-derived ROS production during 
development of CVDs. Large amounts of Nox2 and increased vascular ROS 
formation is expressed in human atherosclerotic plaques (Zhou et al., 2006).
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Oscillatory sheer stress, one of the risk factors associated with atherogenesis, causes 
induction of Nox2 in vascular endothelium (Hwang et ah, 2003).
1.3.3.3. Nox4
Nox4 is expressed at relatively high levels in all o f the vascular constitutive cells 
under physiological conditions. Particularly, it has high level in endothelial cells 
based on the gene expression (Petry et ah, 2006). Nox4 is located intracellularly and 
its activity is dependent only on its association with p22^^°^ (Anilkumar et ah, 2008; 
Bedard and Krause, 2007a). Nox4 has been described as a constitutively active Nox 
isoform with the lack o f requirement for Rac or any other known cytosolic subunits 
for its activation (Rivera et ah, 2010). The biologically reactive product derived from 
Nox4 is H2O2 instead of O2 ' as of the other Nox isoforms (Ray et ah, 2011). The 
difference in the products generated by Nox4 and other Nox may contribute to the 
distinct role of Nox4 in cell signalling which has been implicated in cell migration, 
proliferation, angiogenesis and cell differentiation (Chen et ah, 2008; Petry et ah, 
2006; Schroeder et ah, 2009; Ushio-Fukai, 2006).
There is growing evidence to suggest a role for Nox4 in vascular aging (Bengtsson et 
ah, 2003). McCann et ah recently found that Nox4 expression increases with age in 
rat aortas and isolated vascular smooth muscle cells (McCrann et ah, 2009). 
Additionally, Nox4 appears to cause apoptotic and necrotic cell death and promote 
endothelial cell senescence following TNF-a treatment. Moreover, Nox4 has been 
implicated in endothelial dysfunction (Bedard and Krause, 2007a). Nox4 is also 
implicated in adipocyte differentiation (Schroeder et ah, 2009), which may be 
important in perivascular adipose tissue biology in ageing. Down-regulation of Nox4
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by siRNA induction shows that Nox4 takes part in the differentiation of 
myofibroblasts (Cucoranu et al., 2005) and VSMCs (Clempus et al., 2007). 
Furthermore, it has been proposed that Nox4 is involved in the stimulation of 
proliferation (Brandes and Schroder, 2008) and apoptosis induction (Pedruzzi et al., 
2004).
1.3.3.4. Nox5
Nox5 is the most recent member of Nox family to be discovered. The Nox5 gene is 
expressed in humans but not in rodents which makes the study of this enzyme difficult 
since no mouse or rat models of Nox5 are available (Bedard and Krause, 2007a). 
Nox5 was first found and characterized in spleen, testis and kidney and recent 
discovered in vascular cells such as endothelial cells. Unlike the other vascular Nox 
enzymes, the activation of Nox5 does not need the other NADPH oxidase subunits 
and it is activated directly by intracellular Cai^ (Banfi et al., 2001). The role of Nox5 
in cardiovascular biology is unclear, although it has been implicated in several 
pathological processes such as endothelial cell proliferation and angiogenesis, 
platelet-derived growth factor-induced proliferation of vascular smooth muscle cells, 
and oxidative damage in atherosclerosis(Bedard and Krause, 2007a).
1.4. Animal models of Obesity and diabetes
1.4.1. Obesity-related genes in mice
Obesity and diabetes are diseases promoted by multiple genetic and environmental 
factors. Due to complex interaction among multiple susceptibility genes and between 
genetic and environmental factors, multifactorial diseases in humans are complicated 
for genetic analysis with poor outcomes. On the other hand, inbred animal models
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with homogeneous genetic background and easy-controlled environmental factors are 
therefore valuable in genetic analysis of multifactorial diseases. Particularly, the 
rodent models, with their genetic similarity to humans and their well-developed 
genetic tools, are essential components of genetic investigations to understand the 
etiology of obesity/diabetes. Identification of these obesity-related genes has led to 
new insights into the etiology of obesity and diabetes and provided promising targets 
for therapeutic intervention (See table 1.4).
1.4.2. Animal models of diabetes
Apart from the genetic obesity mouse models with diabetes listed in table 1.4, many 
mouse models use streptozotocin or other chemicals to induce a form of diabetes 
(Indolfi et al., 2001; Kako et al., 1999; Park et al., 1998; Reaven et al., 1997; Renard 
et al., 2004). One of the problems for chemical treatment is that it often increases 
serum lipids in atherosclerosis-prone and hyperlipidémie mice. This can make it 
difficult to determine whether increases in atherosclerotic lesions are because of 
diabetes or worsening o f the lipoprotein profile (Park et al., 1998; Renard et al., 
2004). In addition, such models do not reflect the human disease in which diabetes 
usually develops in susceptible individuals in conjunction with obesity (Rerup, 1970).
Whereas obesity often precedes the appearance of type 2 diabetes and is a major risk 
factor, induced obesity has not been shown to produce diabetes in normal individuals 
(Olefsky, 1981). On the other hand, syndromes resembling type 2 diabetes have been 
identified in several animal species, but there has been no entirely satisfactory model 
of this disease. Commonly used models have numerous problems making them unlike
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the human disease, e.g., the obese mouse (C57BL/6J ob/ob) develops its pathology in 
conjunction Avith genetically determined obesity and has multiple associated 
endocrine abnormalities (Coleman, 1978). Furthermore, this animal model may 
exhibit significant hyperglycaemia only during periods of stress (Surwit et al., 1984).
1.4.3. High-fat diet-induced obesity models
Because the majority o f type 2 diabetes patients are overweight (Stem and Haffner, 
1986), seeking to create a mouse model o f diet-induced obesity with cardiovascular 
phenotypes is therefore cmcial for understanding the pathology of this disease. In 
such a diet-induced obesity model, obesity and diabetes are likely to be the result of 
the high-fat content of diet rather than in genetic models of obesity and type 2  
diabetes, such as obese db/db mice, animals have a non-fiinctional leptin receptor 
which results the extreme amount of food consumption and high caloric intake and 
provides a model o f overfeeding-induced obesity and type 2  diabetes.
Numerous attempts have been made to create diabetes in healthy animals by dietary 
manipulation alone. So far, C57BL/6J mice on Westem-type high-fat diet (HFD) or 
diet-induced obesity (DIO) mice are a well-established and widely used animal model 
for human obesity (Parekh et al., 1998). In DIO mice, HFD promotes central obesity, 
hyperglycaemia, hyperinsulinemia, hypertension and atherosclerosis. DIO also results 
in aortic endothelial dysfunction and contributes to vasoconstriction instead of 
vasodilatation (Barton et al., 2000; Molnar et al., 2005; Mundy et al., 2007; Noronha 
et al., 2005; Traupe et al., 2002a; Traupe et al., 2002b). These effects of obesity have 
been attributed to increases in white and brown fat growth and lipolysis (Kraegen et
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al., 1986; Storlien et al., 1986), decreases in insulin-receptor activity (Gavin et al., 
1974; Olefsky, 1976), and possible postreceptor changes (Kolterman et al., 1980).
Studies on diet-induced obesity model have been established to investigate the 
underlying mechanisms by which long-term HFD may result in endothelial 
dysfunction and promote a variety of CVDs. These studies demonstrated that food 
containing high-fat content impairs endothelium-dependent relaxation of the large 
conductance arteries. For example, in pigs fed with HFD, vessel relaxation to 
acetylcholine and bradykinin were decreased both in coronary and brachial arteries 
(Henderson et al., 2004; Woodman et al., 2003). A reduced femoral artery relaxation 
to the endothelium-dependent dilator acetylcholine was observed in mice fed with 
HFD for 9 weeks (Molnar et al., 2005). The key role for high-fat feeding was further 
proved by the findings showing that HFD-induced impairment of endothelium- 
dependent relaxation was normalised to control levels when the diet was switched off 
(Reil et al., 1999). Collectively, these studies have proposed a pathological role for 
high-fat content of diet in the development of endothelial dysfunction in arteries. 
Meanwhile, evidence shows that short term feeding o f the HFD (1 week) failed to 
changes metabolic parameters and arterial vasomotion was unaltered in comparison to 
mice fed with chow diet. These data implicated that HFD itself had no early direct 
effects on arterial vasomotion and suggested a strong association between metabolic 
disorders and endothelial dysfunction.
1.5. Hypothesis and aims of the thesis
Middle-age obesity is often associated with multiple organ oxidative stress and insulin 
resistance and is a major risk factor for the development of CVDs. The importance of
33
vascular ROS derived by Nox enzymes in the pathogenesis of CVD has also been 
demonstrated. However the effects of HFD on vascular oxidative status and 
endothelial function remain unknown. Furthermore, the role of Nox2, a major source 
of vascular ROS, in diet-induced metabolic disorders and vascular dysfunction in 
mice at middle age is unclear.
The hypothesis of this thesis is that vascular Nox-derived ROS, especially which 
derived from Nox2, play an important role, in obese subjects, in the development of 
key pathological changes in obesity-associated CVDs such as hypertension, 
atherosclerosis, and diabetes. Therefore, the objective o f this PhD project is to 
investigate the role o f Nox2 and oxidative stress in high-fat diet-induced metabolic 
disorders and endothelial dysfunction which are both interactive and pivotal to 
develop obesity-associated CVDs, such as atherosclerosis, in middle-aged mice.
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2. Materials and Methods
2.1. Equipment and Materials
All equipment and materials used in the experiments were commercially available and 
listed in tables at the end o f this chapter (appendix table 2.13-2.16). The models of 
equipment and catalogue numbers of materials with suppliers’ details were provided 
as well.
The chemicals and reagents used in the experiments are high performance liquid 
chromatography (HPLC) reagent grade or molecular biology reagent grade. The 
instruments used for experiments are already existed in the main laboratory (23AY02) 
or animal facility in the Faculty of Health and Medical Sciences (FHMS) at the 
University of Surrey. The training of using them was given by technicians, 
postdoctoral scientists and supervisors in FHMS.
Rodent food used in this project was purchased from LabDiet Ltd., UK (for NCD) and 
Special Diets Services, UK (for HFD). Details of the ingredients and nutrition 
information of these diets are listed in appendix table 2.17.
2.2. Animal Experiments and Physiological Assessments
2.2.1. Animals
All animal procedures were performed in accordance with the Guidance on the 
Operation of the Animals (Scientific Procedures) Act, 1986 (Home Office, UK).
C57BL/6J WT and apoE KO mice on C57BL/6 background were purchased from 
Charles River (Margate, England). Nox2 KO mice on C57BL/6J background were
35
originally obtained from The Jackson Laboratory Inc. (Bar Harbor, Maine, USA). 
Colonies were established in the animal facility of University of Surrey. All mice used 
in the experiments for this thesis were propagated from homozygous or heterozygous 
mice and genotyped by polymerase chain reaction (PCR) amplification o f tail lysates 
in our institution (see 2 .2 .2 ).
Mice were weaned at 3 weeks of age and housed in sterile cages in specific pathogen 
free conditions in our animal facility with a 12 -hour-light/-dark cycle (illuminated 
from 7am to 7pm) under constant temperature (22 ± 1°C) and humidity (45-50%). 
Mice had free access to food and drinking water except for fasting glucose 
measurements (see 2.2.5). Foods were irradiated and drinking water autoclaved to 
prevent exposure of mice to any infectious agents.
Nox2 knockout mice on the genomic background of C57BL/6J strain were generated 
by gene targeting (knockout) technology. A neomycin resistance gene 
was inserted into exon 3 of the Nox2 gene (Cybb) involved in X-linked chronic 
granulomatous disease (CGD) which encodes the 91 kD subunit of the oxidase 
cytochrome b (Pollock et al., 1995). Affected hemizygous male mice lack phagocyte 
superoxide production, manifest an increased susceptibility to infection. Western blot 
analysis on extracts of neutrophil-rich peritoneal exudate cells from hemizygous male 
mice confirmed that no detectable protein was expressed (Morgenstem et al., 1997; 
Pollock et al., 1995).
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To produce litter-mate wild-type and Nox2 knockout mice, a male Nox2 knockout 
mouse was paired with its heterozygous sister from the same litter at 10 weeks o f age 
following a brother-sister inbreeding strategy as shown in see figure 2 .1 .
Figure 2.1 Diagrammatic description of mouse mating and breeding
Nox2 KO Nox2 KO Nox2
X Y
Nox2 knockout 
male
X X
Heterozygote
female
Nox2 KO Nox2 Nox2 KO Nox2 KO Nox2 KO H M Nox2
X Y
Nox2 knockout
male
X Y
Wild-type
male
X X
Nox2 knockout 
female
X X
Heterozygote
female
Nox2 gene and its mutant gene (Nox2 KO) are located in X  chromosome (Xp21.1). 
Male litter-mate wild-type and Nox2 knockout mice can be obtained by mating male 
Nox2 knockout mice with female heterozygous mice.
2.2.2. Genotyping
The genotype of mice was verified by performing PCR-based genotyping technology 
using genomic deoxyribonucleic acid (DNA) samples extracted from mouse tail-tip 
tissue.
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DNA extraction
At 14-16 days of age, each mouse was labelled with specific marker by tail marking 
before the tail tip (2-3 mm) was snapped with clean scissors and placed in a pre­
labelled DNase-free 1.5ml centrifuge tube. Each tail-tip tissue was digested overnight 
(5pm - 9am) in 150 pi tail lysis mix (recipe see table 2.1) at 55°C in a water bath 
(Clifton shaking water bath. Nickel Electro Ltd, UK) with gentle agitation (linear 
shaking at 50 strokes/minute). The next morning, after proceeded by heat deactivation 
of proteinase K at 95°C for 5 minutes, samples were then briefly vortexed and 
centrifuged at 13,000 times gravity for 5 minutes to pellet debris. The supernatant 
containing genomic DNA was used for PCR analysis.
Table 2.1 Recipe of tail lysis mix
Reagents Concentrations
KCl 50 mM
MgCli 1.5 mM
Tris HCl (pH 7.5) 10 mM
Gelatin 0 .0 1 %
Nonidet P-40 0.45%
Tween-20 0.45%
Proteinase K 2 0 0  pg/ml
Standard PCR procedure
A common primer, a wild-type reverse primer, and a mutant (Nox2 KO) reverse 
primer, designed to identify the genotype of mice, were synthesised from Eurofins 
MWG Operon (Germany), and the sequence information (see table 2.2) was obtained 
from The Jackson Laboratory.
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Table 2.2 Sequence o f primers for genotyping
Primers Code Sequences
Common
(forward)
Wild-type
(reverse)
Nox2 KO
(reverse)
A 5'-AAG AGA AAC TCC TCT GCT GTG AA-3'
B 5'-CGC ACT GGA ACC CCT GAG AAA GG-3'
C 5'-GTT CTA ATT CCA TCA GAA GCT TAT CG-3'
The PCR mix was made on ice following the recipe (see table 2.3) with the same 
order. The PCR procedure was performed on a PCR machine (2720 Thermal Cycler, 
Applied Biosystems, USA) according to cycling parameters shown in table 2.4 
(obtained from The Jackson Laboratory Inc.).
Table 2.3 Recipe of PCR mix
Reagents Stockconcentrations
Final
concentrations Volume (pi)
d-HzO - - 5 J8
Flexi buffer 5 x 1 X 2.4
MgClz 25 mM 2.5 mM 1 .2
dNTP 10 mM 0.2 mM 0.24
Primer A 50 pM 1 pM 0.24
Primer B 50 pM 1 pM 0.24
Primer C 50 pM 1 pM 0.24
Polymerase 5U /pl 0.3 U/reaction 0.06
DNA Sample - - 2
Total volume - - 12
Electrophoresis
3% agarose gel was used to run the PCR products. Firstly, 3 gram agarose was poured 
into a 250 ml glass bottle containing 100ml Tris-acetate-EDTA (TAE) buffer
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composed of 40 mM Tris acetate and 1 mM ethylenediaminetetraacetic acid (EDTA) 
and heated in a microwave oven with lid loose until totally dissolved. Secondly, 5 pi 
ethidium bromide solution (1 0  mg/ml) was added into 1 0 0  ml agarose solution before 
it was poured into a gel rack. Finally, when it turned solid, the gel with the rack was 
set into an electrophoresis chamber (Electrophoresis system FB300, Fisher Scientific, 
UK) filled with TAE buffer.
Table 2.4 Thermal cycling parameters of PCR for genotyping
Steps Tem perature Time Notes
1 94°C 3 minutes -
2 94°C 2 0  seconds -
3 64°C 30 seconds Minus 0.5°C per cycle
4 72°C 35 seconds Go to step 2, repeat 12 times
5 94°C 2 0  seconds -
6 58°C 30 seconds -
7 72°C 35 seconds Go to step 5, repeat 25 times
8 72°C 2  minutes Hold at 10°C
The amplified PCR products (12 pi) were loaded into the agarose gel. To identify the 
band size, 5 pi 100 bp DNA ladder (0.1 pg/pl) was also loaded into gel. The gel was 
run under 5 Voltage/cm current for about 45 minutes to separate negatively-charged 
DNA which migrated from the cathode (-) to the anode (+).
Visualisation of DNA bands
After electrophoresis, DNA fragments were visualised by exposing the gel on a UV 
transilluminator (Genegenius, Syngene Ltd, UK) and captured using GeneSnap 
software. The PCR product produced from the wild-type allele of the Nox2 gene was
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240bp in size; whereas the 195bp PCR product was formed from the genetic modified 
Nox2 knockout gene.
Figure 2.2 Photograph showing the PCR products of the genotyping reaction for Nox2 
gene separated by gel electrophoresis.
Lanes 1 2 3 4 5 6 7 8 9  10 11
... ....... . ^
\{X:
 .
'  A*. '-  ,v.* /:•■ .  ^  :
240bp (wild-type) 
195bp (knockout)
Lam 9 shows a single band representing the wild-type gene with 240 bp. The bands in 
lanes 5,6,7,8 and 10 represent the Nox2 knockout gene with 195 bp. The double bands 
in lanes 2, 3 and 4, one o f which is at 240 bp and another at 195 bp, stand for  
heterozygote.
2.2.3. Food intake measurement
Mice were individually housed allowing the measurement of food intake. For each 
cage, food with the container was weighed daily on balance at 6  pm before the dark 
cycle for 1 week. Food intake was determined to the nearest 0.1 gram and weighing 
error due to food spillage was minimized by using whole food pellets throughout the 
study and by including in any food remnants (> 0.1 g) found in cage bedding. The net
41
food intake per mouse per day was calculated as the daily reduction o f the weight of 
the food and the container.
2.2.4. Body weight measurement
The living mouse was placed into in an aluminium container specially designed by 
our animal facility and the average of 4 constant readings of body weight was taken 
using an electronic balance (OC061, Oertling Ltd, UK).
2.2.5. Fasting blood glucose measurement
Prior to the measurement the mouse were transferred to new cages with water but no 
food and were fasted for 8-10 hours (overnight, from 12 midnight to 8 am). On the 
following day, the mouse was restrained in the restraining device with the tail 
exposed. The tip of the tail was cut using a sterilised scalpel blade. A small drop of 
blood (~ 5 pi) was placed on the test strip of the blood glucose meter (Contour, Bayer 
health care, UK) and the reading was recorded. All the measurements were conducted 
at approximately the same time of the day (~ 9 am).
2.2.6. Intraperitoneal glucose tolerance test
The glucose tolerance test measures the clearance of an intraperitoneally injected 
glucose load from the body. Mice were fasted for approximately 16 hours, a solution 
of glucose was administered by intraperitoneal (IP) injection and blood glucose level 
was measured at different time points during the following 2 hours. The experiments 
were conducted at approximately the same time of the day (~ 9 am).
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Mice were fasted for 14-16 hours (overnight; from 6  pm to 8 am) with free access to 
drinking water. The following morning the mice were weighed and then restrained in 
the restraining device with the tail exposed. The tip of the tail was nicked with a 
sterilised scalpel blade by a cut o f the very end. Baseline blood glucose level was 
measured by a glucose meter as described in 2.2.5. Mice were then placed 
individually in labelled clean cages with water only (no food). 2  g/kg body weight of 
2 0 % glucose solution (dissolved in saline solution) was drawn up in an insulin syringe 
with one unit (10 pi) of glucose solution for every gram of body weight. When all 
syringes and mice have been prepared the test was begun. The appropriate amount of 
glucose solution was injected into the intraperitoneal cavity of mouse. The blood 
glucose levels were measured at 15, 30, 60 and 120 minutes after injection by 
removing the blood clot from the first incision on the tail and gently massaging a 
small drop of blood onto the strip of the glucose meter. Any further blood loss from 
the incision was minimal by applying pressure to the incision for around 1 minute 
after each measurement. Glucose injections and blood glucose sampling was timed to 
take approximately the same amount o f time per mouse (i.e. 10  mice were injected in 
10  minutes and blood glucose sampling o f those same 10  mice should also take about 
10  minutes) so that the sample times were accurate for each mouse.
2.2.7. In vivo blood pressure measurement
Mouse blood pressure (BP) was measured by using a computerised non-invasive 
blood pressure measurement system (Kent Scientific Corporation, USA) on conscious 
mice. The system applied a volume pressure recording (VPR) technology which 
determines the blood flow and blood volume in the mouse tail utilising a VPR sensor 
and an occlusion tail-cuff (Wheatcroft et al., 2003). The procedures were performed in
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a quiet room at the animal facility with the room temperature at or above 26°C. An 
animal warming platform (Kent Scientific Corporation, USA) was used to keep mice 
warm (Wheatcroft et ah, 2003; Wheatcroft et ah, 2004) and the mouse body 
temperature was monitored by using a Infra-red thermometer (Infi"a-red Thermometer 
IR-101, La Crosse Technology, USA) throughout the measurement. These were to 
ensure that mouse core body temperature remained stable. If  the animal was to get to 
cool then it would thermo-regulate which could result in lowering blood supply to the 
tail and giving false readings.
A specific designed animal holder (Kent Scientific Corporation, USA) was used to 
restrain the mouse throughout the experiment. It is made of clear plastic with air holes 
down its length allowing the mouse to be able to be constantly watched. The nose 
cone is darkened to limit the eyesight of the mouse therefore furthering to lower any 
stress, whilst the animal’s nose protrudes from the cone for comfortable breathing (see 
figure 2.3). To use it, the rear gate of the holder was removed and the nose cone was 
pushed close to the front o f the holder, then the thumb nut was tightened. The mouse 
was trained to enter the holder freely and then pushed using gentle force to get the 
mouse completely into the holder with the tail extending out of the rear o f the holder. 
The rear gate o f the holder was closed with a tightened thumb nut. After the mouse 
was in the holder, the darkened nose cone was adjusted so the mouse was comfortable 
but not able to move excessively. The mouse never had its head bent or its body 
compressed against the back hatch in any way. Then the mouse holder was placed in 
the V-shape grooves on the animal warming platform (see figure 2.3).
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Acclimation training of mice
Prior to the proper measurements, mice were trained to be habituated to the 
restraining apparatus in the holders. The training involved placing each mouse into the 
holder for ISminutes each day for 5 continuous days at the same time of day (10-11 
am). During the last two days of training the 0-cuff and VPR-cuff were placed onto 
the tail but no pressure applied. Training the mice allows them to get accustomed to 
being placed within the holder and having the cuffs on their tail. Therefore when the 
measurements are taken the level of stress is reduced. Stress would otherwise increase 
heart rate and BP (Schubert et al., 2009).
Figure 2.3 Photographs showing the equipment used in the VPR method of taking BP 
in mice
. . , tt Warming PlatformAnimal Holder ^
Nose Cone \ Rear Gate VPR-Cuff 0-C uff Controller
Procedure of BP measurement
BP was measured on conscious mice at the same time of day as the training sessions 
of acclimation. After the mouse was comfortably restrained in the holder, the 
Occlusion cuff and VPR cuff were slid freely up to the base of the tail in sequence 
without resistance. The animal was then left for about 5 minutes for it to get adjusted 
to the environment, lowering the risk of stress and high readings. The system was then
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started. The reading of measurement was recorded by the CODA^^ proprietary 
programme on a computer. The software used an algorithm to determine the systolic, 
diastolic and mean blood pressure. If the mice had excessive movement or there was 
not enough volume of blood within the tail then it would not record that reading. The 
mean of at least five successful recordings was taken to represent BP on each mouse.
Figure 2.4 Typical CODA reading showing 0-cuff and VPR cuff pressure
Mouse!
250
210
300
0 2 5 7 10 12
Figure to show a typical and good reading o f the VPR method. The red line 
representing 0-cuff pressure and the blue line VPR-cuff pressure. From this the 
computer can then determine the systolic and diastolic pressure. I f  the mouse was 
hyperactive the blue line would be erratic and the reading void.
2.2.8. Mouse tissue collection and preparation
Dissection and tissue collection
After fasting glucose was measured as described in 2.2.5, mice were euthanized by an 
intraperitoneal injection of phénobarbital at a dose of 60 mg/kg body weight (Damy et 
al., 2010). The dead body of the mouse was sprayed with 75% ethanol to disinfect the 
skin. The abdominal cavity was then opened lengthways and a transverse cut along 
the lower costal arch was made to improve vision of operative field. The intestines 
were shifted over to the left and the liver was pushed forward to show the widest part 
of the posterior vena cava (between the kidneys) which was located as blood
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collecting point. After blood collection (described in following paragraph) the 
thoracic cavity was opened by cutting the sternum toward the head and the anterior 
thoracic wall was removed with the supradiaphragmatic and lateral wall to clearly 
visualise the heart and ascending aorta. The heart was harvested and the chambers 
were then cut open and washed in ice-cold phosphate buffered saline (PBS) to remove 
any excess and clotted blood. The heart was blotted dry and weighed before being 
snap-frozen in liquid nitrogen and stored at -80°C until it was assayed. Other organs 
(lungs, liver, kidneys and epididymal fat pats) were collected and stored following the 
same procedures as described above.
After mouse abdominal cavity was opened and posterior vena cava was seen clearly 
(see above paragraph), a 25 gauge needle with an insulin syringe was carefully 
inserted into the vein. Blood was dravm slowly to avoid the vessel wall collapses until 
no more blood was available. Whole blood was directly poured into a 1.5 ml 
centrifuge tube that contains no anti-coagulant and allowed to clot at 4°C for 6 -8  
hours before being centrifuged at 2,000 x g for 15 minutes at 4°C. The supernatant 
(serum sample) was carefully transferred and stored at -80°C for further tests.
2.2.9. E x vivo assessment of vascular function
Vascular function of mouse thoracic aortas was assessed ex vivo using an organ bath 
system (ADlnstruments Ltd, USA). The methods described below aimed to reduce 
uncertainty arising from many technical variables, to allow true differences in 
vascular function to be determined, and to maximise the analytical power o f ex vivo 
vascular pharmacology in mouse aortas.
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Aortic ring preparation
The entire aorta between heart and iliac bifurcation was cut off the body with adherent 
connective tissue on it by using a ‘no touch’ surgery technique while the heart was 
still beating and immediately immersed into ice-cold oxygenated Krebs-Henseleit 
solution (recipe see table 2.5) for organ bath studies. The aorta was pinned down at 
both ends in a clear glass dissecting dish, where the floor was covered with a layer of 
clear silicone and filled with ice-cold oxygenated Krebs-Henseleit solution. The dish 
was placed on a bed of ice and the aorta was then carefully dissected under a cool 
fibre optic light source and binocular dissection microscope (Vickers Instruments Ltd, 
UK) using Vanna’s spring scissors and Dumont forceps to remove all adherent 
connective tissues without traumatising the vessel wall (Wheatcroft et al., 2004). The 
‘naked’ aorta was either kept on ice in Krebs-Henseleit solution for organ bath studies 
or blotted dry and snap-frozen in liquid nitrogen and stored at -80°C for other use.
Table 2.5 Recipe of Krebs-Henseleit solution.
Reagents Concentration (mM)
NaCl 118
KCl 4.7
MgS0 4 1.2
NaHCOs 25
KH2PO4 1.2
CaClz 2.5
D-(+)-glucose 12
For the determination of endothelial function, the mouse aorta was straightened out by 
slightly stretching and pinning at both ends in the dissecting dish filled with ice-cold 
Krebs-Henseleit solution with special care to preserve the endothelium. The aorta was
48
then cut into transverse rings from the proximal (close to descending) to distal (close 
to abdominal) thoracic aorta with 4 mm in length (see figure 2.5) by use of a fixed 
double-bladed scalpel. This instrument can be easily made from two scalpel handles 
drilled through and screwed together.
Table 2.6 Parameters o f transducer amplifier o f PowerLab Charr5.0
Parameters Settings
Input Range 1 mV
Low Pass 20 Hz
Mains Filter YES
Calibration 2  points (1 and 2  gram)
Figure 2.5 Schematic diagrams and photographs showing preparation of mouse 
thoracic aortic rings for organ bath study
ORGAU
Photographs showing the details o f organ bath study. Left: a mouse aortic ring was 
suspended on the upper hook. Right: the reagent was added into incubating solution 
from the top o f each chamber.
49
Organ bath setup
Endothelium-dependent and -independent relaxation responses were analysed by an 
organ bath system (ML0146/C-V, ADlnstruments Ltd). The isolated aortic rings were 
mounted on hooks made from stiff stainless steel wire o f 150 pm diameter in a water- 
jacketed organ bath, containing 10 ml of Krebs-Henseleit solution, aerated 
continuously with 95% O2 / 5% CO2 and maintained at 37°C. The upper hook was 
connected to an isometric force transducer and was adjustable via a micrometre which 
allows precise measurement o f the separation of the wires when stretching the vessel. 
The lower hook was fixed to a support leg attached to the bath. The isometric forces 
were recorded digitally on a computer with a software programme PowerLab Chart 
5.0 (ADlnstruments Ltd).
Equilibration and optimisation of aortic reactivity
After being mounted on the organ bath, mouse aortic rings were equilibrated for 30 
minutes in non-stretching condition and then progressively stretched to their optimal 
passive tension (0.30 ± 0.02 g, see following paragraph) (Angus and Wright, 2000; 
Russell and Watts, 2000; Scotland et al., 2005) in 15 minutes by adjusting the 
micrometre. All subsequent measurements throughout the experiments represent force 
generated above this baseline. During this period the bath was flushed every 15 
minutes with fresh Krebs-Henseleit solution. The aortic rings were then challenged 
with a bolus concentration of KCl (50 mM) to examine contractile integrity for 10 
minutes. Subsequently, rings were washed with fresh Krebs-Henseleit solution and 
allowed to return to resting tension. The aortic rings were depolarised to KCl (50 mM) 
at least twice until reproducible responses were reached before any functional
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experiments. The brief depolarization with KCl increases the reproducibility of 
subsequent contractions.
Vessels with circumferentially arranged smooth muscle must be distended to bring the 
actin-myosin fibres into alignment for optimal force development. To determine the 
optimal passive tension of an isolated aortic ring, the ring was stretched in steps to 
raise passive force (from 0 .1  g to 1 .0  g), while the active force developed at each step 
by repeated exposures to KCl (50 mM), which rises in corresponding passive force, 
was monitored, thus allow the determination o f the optimal passive distending force 
for maximum active force development in aortic rings. Our results and those from 
other labs (Angus and Wright, 2000) showed that a passive tension with 0.30 g 
maximises the active force raised by KCl (50 mM) in mouse aortic rings.
Determination of vasoconstriction to phenylephrine
After the reproducible responses to KCl (50 mM) were reached the aortic rings were 
washed and further equilibrated for 20 minutes (flushed with fresh Krebs-Henseleit 
solution every 10  minutes) before being assessed for the contractile responses to a- 
adrenergic agonist phenylephrine (PE) which was added in an increasing cumulative 
fashion (from 1 x 10'^ M to 1 x 10'^ M, see table 2.7) to generate concentration- 
dependent response curves.
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Determination of endothelium-dependent relaxations
In mouse aorta the predominant location of muscarinic acetylcholine receptors is on 
the endothelium and acetylcholine (ACh) is considered an endothelium-dependent 
vasodilator autacoid that stimulates the release o f NO from normal endothelium.
After PE-induced contractile responses the aortic rings were washed and further 
equilibrated for 2 0  minutes and allowed to return to resting tension before being pre­
contracted with a submaximal concentration of PE (see following paragraph). Once 
the response to PE had stabilised (the plateau was attained), ACh was added in 
increasing cumulative concentrations (from 1 x lO'^M to 1 x 10'^ M, see table 2.8) to 
assess the endothelium-dependent relaxations.
The submaximal concentration of PE (0.3 to 1 x 10'^ M, according to PE-induced 
contractile responses) was selected to evoke an identical pre-contraction level o f 70- 
80% of the maximal PE-induced contraction in all groups.
Determination o f endothelium-independent relaxations
Endothelium-independent relaxation was assessed in response to a nitrovasodilator 
sodium nitroprusside (SNP) as it breaks down to release NO which relaxes the 
vascular smooth muscles and allows vessels to dilate.
After washout and re-equilibration to resting tension, the aortic rings were pre­
contracted to 70 ~ 80% of their maximal PE-induced tension as described above and 
the relaxation responses curves to cumulative addition of SNP (1 x 10'^^ M to 1 x 10'^ 
M) were constructed as showed in table 2.9.
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Table 2.7 Cumulative administration o f PE into bath chambers
Steps PE Concentrations (add to bath chambers)
Volume 
(add to bath chambers)
Cumulated PE 
concentrations 
(in bath chambers)
1 1 X 10  pi 1 X lO'^M
2 1 X lO'^M 2 0  pi 3 x  lO'^M
3 1 X lO'^M 70 pi 1 X 1 0 '* M
4 1 X IO-’ M 2 0  pi 3 x  10'* M
5 1 X 10'® M 70 pi 1 X lO'^M
6 1 X IQ-^M 2 0  pi 3 x  10'’ M
7 1 X 10" M 70 pi 1 X 10‘'’M
8 1 X 10'^ M 2 0  pi 3 X lO'^M
9 1 X lO'^M 70 pi 1 X lO'^M
PE was dissolved in saline at a concentration o f 1 x 10'^ M  and all subsequent
dilutions were made with Krebs-Henseleit solution just before use.
Table 2.8 Cumulative administration of ACh into bath chambers
Steps ACh Concentrations (add to bath chambers)
Volume 
(add to bath chambers)
Cumulated ACh 
concentrations 
(in bath chambers)
1 1 X 10'^ M 10  pi 1 X lO'^M
2 1 X IC'^M 2 0  pi 3 X lO'^M
3 1 X 10'^ M 70 pi 1 X 10'* M
4 1 X lO'^M 2 0  pi 3 X 10'*M
5 1 X 1 0 ’’ M 70 pi 1 X lO'^M
6 1 X 10"M 2 0  pi 3 x  1 0 ’’ M
7 1 X lO'^M 70 pi 1 X lO' ’^M
8 1 X 10'^ M 2 0  pi 3 X 10‘'’M
9 1 X 10'^ M 70 pi 1 x 1 0 '^  M
ACh was dissolved in saline at a concentration o f 1x10'^ M  and all subsequent 
dilutions were made with Krebs-Henseleit solution just before use.
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Table 2.9 Cumulative administration o f SNP into bath chambers
Steps SNP Concentrations (add to bath chambers)
Volume 
(add to bath chambers)
Cumulated SNP 
concentrations 
(in bath chambers)
1 1 X lO'^M 10  pi 1 X lO '^M
2 1 X 10"’ M 2 0  pi 3 x  10''“M
3 1 X lO'^M 70 pi 1 X lO'^M
4 1 X 10"'’M 2 0  pi 3 X 10'’ M
5 1 X IC'^M 70 pi 1 X 10'*M
6 1 X 10‘"M 2 0  pi 3 X 10'* M
7 1 X lO'^M 70 pi 1 X lO'^M
8 1 X 10'"M 2 0  pi 3 X lO'^M
9 1 X 10“'M 70 pi 1 X lO' ’^M
SNP was dissolved in saline at a concentration o f 1x10'^ M  and all subsequent 
dilutions were made with Krebs-Henseleit solution just before use.
Figure 2.6 An example of relaxation response curve to SNP
+ S N P  cu m ulative ly  (from  1 to  9)
+ PE
Baseline (passive tension)
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Pre-incubation or treatment on aortic rings
In some experiments, the endothelium-dependent vessel relaxations to ACh 'were 
repeated after pre-incubation with tiron (1 x 10'^ M, 15 minutes) or NO-synthase 
inhibitor Nœ-Nitro-L-arginine methyl ester (L-NAME, 3 x lO'"^  M, SOminutes). In 
some experiments, the endothelium was denuded by passing a brass wire through the 
lumen back and forth 8 - 1 0  times before the aortic rings being mounted on the hooks.
The relaxation results were expressed as the percentage of pre-contracted tension. 
Curves were produced and values were calculated by the GraphPad Prism (version 
4.02) software program. From each aortic ring, EC50 values for each drug dose- 
response relationship were determined by fitting to four parameters logistic dose- 
response curves. Emax represents the maximal response to each drug.
2.3. Biochemistry Methods
2.3.1. Protein extraction from frozen aorta samples
Homogenisation
For homogenisation, a miniaturised mortar and pestle system was utilised at low 
temperatures to preserve the integrity o f biomolecules. The mouse aortas were 
harvested and stored at -80°C as described in 2.2.8. The frozen samples (3-4 aortas 
from each group) were placed into a cryogenically chilled mortar (pre-chilled in - 
80°C for at least 2 hours) and chilled in liquid nitrogen, and then ground with a 
chilled pestle. Due to the cryogenic temperature, samples were rapidly ground into 
dust. Pulverised aorta was collected into a chilled 2 ml microcentrifuge tube and 
suspended in pre-cooled homogenisation solution (see following paragraph) at a 
ration of 200 mg tissue per millilitre. The suspension was mechanically homogenised
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with an ergonomic handheld homogenizer (Polytron, Kinematica Ltd, Swissland) on 
ice with 20 second bursts at 1,000 revolutions per minute (rpm) for 3 times. The 
homogenate was inspected at the end of the homogenisation and should have even 
consistency with no visible chunks. If intact tissue was still apparent, an additional 1-2 
rounds of re-homogenisation was applied.
Table 2.10 Recipe of lucigenin buffer
Reagents Concentration (mM)
Hank's Buffered Salt Solution (HBSS) -
CaCh 1.8
MgClz 0.8
Table 2.11 Recipe o f lysis buffer
Reagents Concentration
Tris-HCl (pH7.4) 50 mM
NaCl 130 mM
EDTA 2 mM
Triton X-100 0.1%
NaF 50 mM
Na3V0 4 1 mM
Na4P207 1 mM
Lucigenin buffer (recipe see table 2.10) or lysis buffer (recipe see table 2.11) was 
used as homogenisation solution and the consequent homogenates were used for 
lucigenin-chemiluminescence and immunoblotting respectively. The homogenisation 
solution was added with a protease-inhibitor cocktail (1:500 dilution, components see
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appendix table 2.16) which has broad specificity for the inhibition o f serine, cysteine, 
aspartic proteases and aminopeptidases.
Sonication
The homogenates were then sonicated to break up any extra particles using an 
ultrasonic processor (VC130PB, Sonics & Materials Inc, USA) at half o f maximal 
amplitude. Sonication was performed 3 times for 15 seconds bursts with 1 minute 
intervals on ice in a cold room (4°C). After sonicating, the homogenates were 
centrifuged for 1 minute at 10,000 x g at 4°C to remove debris and insoluble material. 
The supernatants were ready for quantification for protein content using the Bradford 
Assay as described below.
2.3.2. Bradford protein assay
Total protein concentration was determined using Bradford protein assay (Bio-Rad) 
which is a colorimetric assay based on the binding of Coomassie Brilliant Blue G-250 
dye to various concentrations of protein (Bradford, 1976). The absorbance peak of 
Coomassie Brilliant Blue G-250 solution shifts from 470 nm to 595 nm when dye- 
protein binding occurs under acidic conditions (see figure 2.7). The change of 
absorbance at 595 nm is proportional to the amount o f the dye-protein complex, and 
thus to the amount of protein present in the solution.
The ideal protein to use as a standard in any protein assay is a purified preparation of 
the protein being assayed. In the absence of such an absolute reference protein, 
another protein must be selected as a relative standard. The best relative standard to 
use is one that gives a colour yield similar to that of the protein being assayed.
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Selecting such a protein standard is generally done empirically. The most common 
protein standard used for protein assays is bovine serum albumin (BSA).
In this study, a standard protein quantification curve was graphed by 5 dilutions of 
BSA protein standard (0, 5, 10, 15 and 20 pg/ml) against their values of optimal 
density (OD) at wavelength 595nm in a scattergraph. BSA standards were made by 
serial dilutions of BSA stock solution (100 pg/ml) with Bio-Rad dye reagent and 
distilled water (table 2.12).
Table 2.12 BSA standards with bio-rad dye reagent.
BSA
Standards
Final
concentrations
BSA stock* 
volume
Distilled
water
volume
Bio-Rad
Dye
volume
Total
volume
1 0 pg/ml Opl 800 pi 200 pi 1000 pi
2 5 pg/ml 50 pi 750 pi 200 pi 1000 pi
3 10 pg/ml 100 pi 700 pi 200 pi 1000 pi
4 15 pg/ml 150 pi 650 pi 200 pi 1000 pi
5 20 (ig/ml 200 pi 600 pi 200 pi 1000 pi
*BSA stock solution was made in distilled water with a concentration o f  100 fig/ml.
Each BSA standard was made in duplicate in eppendorf tubes and mixed by vortexing 
and kept in room temperature for 5 minutes before being poured into individual 
disposable cuvettes to determine the OD using a spectrophotometer (UVl 101, WPA, 
Biochrom Ltd, UK). The results and the generated standard protein quantification 
curve were shown in figure 2.8.
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Figure 2.8 BSA standard curve (Bio-Rad)
BSA Standards
Concentration
(iJg/ml)
OD 
Reading 1
OD 
Reading 2
OD
Average
1 0 0 0 0
2 5 0.369 0.341 0.355
3 10 0.667 0.643 0.655
4 15 0.906 0.856 0.881
5 20 1.111 1.098 1.105
1.4
1.2 - y = 0.0547X + 0.052 
R  ^= 0.9888
0.8  -
0.6 -
0.4 -
0.2 -
0 105 15 20 25
Concentration of standard (jig/ml)
Linear regression f i t  performed using Microsoft Office Excel 2003.
The protein Bradford assay was performed to determine total protein concentration. 
Briefly, a 1:5 dilution of the Bio-Rad protein assay dye reagent was prepared by 
mixing with distilled water in a total volume of 1ml. 2 pi of tissue homogenate 
(prepared in 2.3.1) was then added to the mixture and thoroughly mixed. The 
absorbance o f each sample was measured at 595 nm. In Comparison with a BSA 
standard curve (see figure 2.8), protein concentration of each sample was then 
determined from its absorbance values and the protein concentration of the tissue 
homogenate was then calculated by multiplying the corresponding result by 500.
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2.3.3. Measurements of ROS Production
2.3.3.1. Lucigenin chemiluminescence
The detection of ROS production in mouse aorta tissues was assessed by lucigenin 
chemiluminescence assay. Lucigenin reacts with superoxide forming a dioxetane that 
emits light when it decays. The emitted light was detected using a 96-well microplate 
luminometer (BMG Lumistar, Germany). The method used for the assay has been 
well established previously (Li et al., 2007). Generally, aorta tissues were 
homogenised as described in 2.3.1. The appropriate volume of aorta homogenates 
containing 100 pg proteins was added to each well and the volume was made up to 
140 pi with lucigenin buffer. Prior to starting the assay, 1 mM of NADPH solution 
and 25 pM of lucigenin solution were made using lucigenin buffer. To each well, 20pl 
of NADPH solution was added, and the 96-well plate was immediately placed in the 
luminometer to allow the auto-dispenser to add 40pl of lucigenin solution. The total 
reaction volume was 200 pi with final concentration of 5 pM of lucigenin and 100 
pM of NADPH. Measurements were taken at 37°C every 3 seconds per well and a 
total o f 30 cycles reading was recorded.
2.3.3.2. DHE fluorescence
Dihydroethidium (DHE) fluorescence was used to detect intracellular O f  o f aorta 
tissues. DHE, which is also called hydroethidine, is a fiuoroprobe which passively 
diffuses into the cells exhibiting blue fluorescence. After oxidation, predominantly 
with O2 ', DHE is oxidised to ethidium, giving a more polar compound that 
intercalates within DNA and stains the nucleus in fluorescent red (Figure 2.9) which 
can be detected by a fluorescent microscope. Tiron was used as a negative control as 
it is a superoxide scavenger which reacts with O2 ' and stabilises it.
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Figure 2.9 Structure and reaction o f DHE in the presence o f O2 '
NH.HgN
CHLCH,
O:
NK
n+
CHLCH
Dihydroethidium Ethidium
After oxidation with O f', DHE is converted to the polar compound ethidium that 
intercalates into the DNA.
DHE stock solution (2 mM in dimethyl sulfoxide) was prepared and diluted to 2 pM 
in DHE buffer containing HSBB with 50 pM MgCl2 as DHE staining solution and 
kept in the dark. To evaluate the levels of intracellular ROS in aorta tissue, slides with 
fresh-cut frozen aorta cryostat sections (section preparation see 2.3.4) were washed 
with pre-warmed (37°C) DHE buffer and incubated in the dark with DHE staining 
solution for 15 min at 37°C. Parallel sections were treated with tiron (10 mM in DHE 
buffer) for 10 minutes before adding DHE staining solution. The area around each 
aorta section was carefully wiped dry and the slides were covered with cover slips on 
the top after incubation before been examined under the microscope. Fluorescence 
was visualized in a fluorescence microscope (BX61, Olympus, Japan) with excitation 
at 520 nm and emission 605 nm. The images were obtained using the SimplePCI 6 
Software for Scientific Imaging (Digital Pixel Imaging System, UK).
2.3.4. Frozen aorta  section preparation
Aortic rings were prepared for cryosectioning by being embedded in cryo-embedding 
media. Optimal Cutting Temperature compound (O.C.T.), which was then solidified
62
in cold isopentane and stored at -80°C. Briefly, a scoop filled with isopentane was 
placed on liquid nitrogen in a thermos jar until the isopentane solution has become 
semi-solid (approximately 30-60 seconds). A small amount o f O.C.T. was placed onto 
a pre-labelled cork disc without bubbles. Three aortic rings (see 2.2.8 and 2.2.9 for 
aortic ring preparation) were put lengthways into the O.C.T. and kept standing 
closely. The cork containing the tissue was then dipped into the semi-solid isopantane 
until the O.C.T. turns solidified (approximately 10-15 seconds). The cork with frozen 
samples was then stored immediately in -80°C until ready for sectioning.
For cryostat sectioning, 6-pm-thick sections were cut using a cryotome cryostat (OTF 
5000, Bright Instrument Co Ltd, UK), and thaw-mounted onto gelatine-coated slides 
or superfrost plus slides with 3 to 4 sections in each slide. The slides with sample 
sections were labelled and used for DHE staining or stored in sealed boxes at -80°C 
for later use.
2.3.5. Insulin ELISA assay 
Principle of the assay
Mouse serum insulin levels were measured by using an enzyme-linked 
immunosorbent assay (ELISA). It involves the direct sandwich technique in which 
two monoclonal anti-insulin antibodies are directed against separate antigenic 
determinants on mouse insulin molecule. Mouse insulin reacts with peroxidase- 
conjugated antibodies and the antibodies bound to microplate wells. The bound 
conjugate is detected by reaction with tetramethylbenzidine. The reaction is stopped 
by adding acid to give a colorimetric endpoint which is measured by 
spectrophotometry.
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Test procedures
Serum samples were tested by using an ELISA kit (Mouse insulin ELISA enzyme 
immunoassay kit, Mercodia, Sweden) according to the standard protocol that comes 
with the kit. Briefly, 10 pi of samples or Calibrators (mouse insulin standards) was 
added into appropriate wells o f a mouse-anti-insulin-antibody-coated plate with 50 pi 
of enzyme conjugate solution and was incubated for 2 hours with orbital shaking (800 
rpm) at room temperature (18-25°C). The plate was then washed 6 times with wash 
buffer before 200 pi of substrate 3, 3’, 5, 5’-tetramethylbenzidine (TMB) was added 
in to each well and incubated for 15 minutes in dark at room temperature. 50 pi of 
stop solution was added after incubation and the plate was shaked for 5 seconds to 
ensure mixing. The absorbance was then immediately measured and evaluated at 450 
nm using a spectrophotometer (MBA 2000, Perkin-Elmer, USA).
Each sample was measured in duplicate and the average values were taken. The 
standard curve and results were analysed using GraphPad Prism 5 software.
2.3.6. Biochemical determinations of serum samples for metabolic parameters
The determinations o f metabolic parameters including cholesterol, free fatty acids, 
triglyceride, and high-density-lipoprotein (HDL) cholesterol in mouse serum were 
performed using optimised enzymatic colorimetric assays through the ILab 650 
Chemistry Systems. All tests were followed the instruction manual of ILab 650 
Chemistry Systems and performed in this faculty of University o f Surrey and each 
sample was measured in duplicate.
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Total cholesterol TTC)
The cholesterol is determined after enzymatic hydrolysis and oxidation. The principle 
of the test is based on the following reactions.
cholesterol esterase 
cholesterol ester + HgO ------------------------------► cholesterol + fatty acids
cholesterol oxidase 
cholesterol + Og -------------------------- ► cholest-4-en-3-one + HgOg
peroxidase
2 H2 O2 + 4-animoantipyrine + phenol  ► quinoneimine + 4 H2 O (red colour)
The indicator quinoneimine production is proportional to the cholesterol 
concentration in the sample. Absorption measurements are taken at a primary 
wavelength of 510 nm and a blanking wavelength of 700 nm.
Triglvcerides fTG)
The principle o f the test for the serum concentration o f triglycerides is based on the
following reactions.
lipoprotein lipase 
triglycerides  ► glycerol + fatty acids
glycerol kinase
glycerol + ATP --------------------► glycerol-3-phosphate + ADR
glycerophosphate oxidase 
glycerol-3-phosphate + O2 --------------------------------► dihydrocyacetone phosphate + 4 H2O2
peroxidase
H2O2 + 4-chlorolphenol + 4-animoantipyrine ► quinoneimine + H2O (red colour)
The concentration o f quinoneimine generated in the reaction is proportional to the 
concentration o f triglyceride in the sample.
Free fattv acids TFFA)
An optimised enzymatic colorimetric assay was applied for the test for the serum 
concentration of free fatty acids is based on the following reactions.
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Acyl e s
free fatty acids + CoA + ATP ------------ ► acyl-CoA + AMP + pyrophosphate
ACOD
acyl-CoA + Og  enoyl-CoA + HgOg
peroxidase
2 H2 O2 + 4-animoantipyrine + TBHB  ► red dye + 2 H2 O + HBr
High density lipoprotein (HDD cholesterol
Direct clearance methods were applied for measuring HDL. During the first phase, 
LDL, VLDL particles and chylomicrons generate free cholesterol, which through an 
enzymatic reaction, produce hydrogen peroxide. The generated peroxide is consumed 
by a peroxidase reaction with N, N-bis (4-sulphobutyl)-m-toluidine-disodium yielding 
a colourless product. During the second phase, specific detergent solubilises HDL. In 
conjunction with cholesterol oxidase and cholesterol esterase action, peroxidase and 
4-aminoantipyrine develop a coloured reaction which is proportional to HDL 
concentration.
Low density lipoprotein (LDL) cholesterol
LDL was calculated as the difference between total- and HDL-cholesterol 
concentrations based on Friedewald equation (Abudu and Levinson, 2007) as shown 
below.
LDL (mmol/L) = TC -  HDL - (TG/2.17) (Friedewald equation)
When TG <100 mg/dL (1.13mmol/L) a modified equation (Ahmadi et al., 2008) was 
used:
LDL (mmol/L) = TC/1.19 + TG/0.81 -  HDL/1.1 -  0.98 (modified equation)
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2.4. Statistical analysis
Data were expressed as means of at least three independent experiments with standard 
deviation (SD). A student’s t-test or two-way analysis of variance (ANOVA) followed 
by Bonferroni post-tests were performed to determine whether results were 
statistically significant. The value P < 0.05 indicated a significant difference.
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2.5. Appendix
Appendix table 2.13 Instruments and necessary materials
Equipm ent Model Suppliers
96-well Microplate Luminometer Lumistar BMG Labtech, Germany
Adjustable Pippetors Pipetman Gilson Inc, UK
Animal Restraining Holder XBPIOOO Kent Scientific Corp., USA
Binocular Dissection Microscope 
BioSpectrum AC Imaging System
172608
BioSpectrum
310
Vickers Instruments Ltd, UK 
UVP LLC, USA
Blood Glucose Meter Contour Bayer Health Care, UK
Blood Glucose Test Strips Contour Bayer Health Care, UK
Clinical Chemistry System ILab 650 Instrumentation Lab, UK
Cryotome Cryostat OTF Bright Instrument Co Ltd, UK
Cyclone Vortex Mixer CM-1 Nickel Electro Ltd, UK
Digital Analytical Balance CP64 Sartorius Ltd, Germany
Dumont Forceps 91150-20 Inter Focus Ltd., UK
Electronic Top Pan Balance
Electrophoresis System 
(genotyping)
Electrophoresis System (western 
blotting)
Ergonomic Handheld 
Homogenizer
Fluorescent Microscope
OC061
FB300
Mini-protean
II
Polytron
BX61
Oertling Ltd, UK 
Fisher Scientific, UK 
Bio-Rad Inc, UK 
Kinematica Inc, Switzerland 
Olympus, Japan
Infra-red Thermometer IR-101 La Crosse Technology, USA
Mortar (ceramic, 145 ml)
Non-Invasive Blood Pressure 
System
17820-04 
CODA 2
Cole-Parmer Ltd, UK 
Kent Scientific Corp., USA
Organ Bath System ML0146/C-V ADInstruments Ltd, USA
PCR Thermal Cycler 2720 Applied Biosystems, USA
Pestle (ceramic, 157 mm) 17821-04 Cole-Parmer Ltd, UK
pH Meter pH 209 HANNA Instruments Ltd, UK
Semi-dry Trans-Blot SD Cell Trans-Blot Bio-Rad Inc, UK
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Spectrophotometer for ELISA MBA 2000 Perkin-Elmer, USA
Spectrophotometer for protein 
assay UVllOl WPA, Biochrom Ltd, UK
Stainless Steel Wire (0.15mm) FE245102 Goodfellow Cambridge Ltd, UK
Stainless Steel Wire (1.0mm) 40947 Alfa Aesar, UK
Surgical Scalpels 10003-12 Fine Science Tools, Germany
Ultrasonic Processor Vibra-Cell Sonics & Materials Inc, USA
UV Transilluminator Genegenius Syngene Ltd, UK
Vanna’s Spring Scissors 91501-09 Inter Focus Ltd., UK
Water Bath Shaking bath Nickel Electro Ltd, UK
Appendix table 2.14 Reagents for animal experiments and physiological assessments
Reagents Catalogue No. Supplier
(R)-(-)-Phenylephrine Hydrochloride P6126 Sigma-Aldrich, UK
Acetyleholine Chloride A6625 Sigma-Aldrich, UK
Apoeynin A0231788 Fisher Scientific, UK
Calcium Chloride C1016 Sigma-Aldrich, UK
Catalase-polyethylene Glycol C4963 Sigma-Aldrich, UK
D-(+)-Glucose G7528 Sigma-Aldrich, UK
Hanks’ Buffered Salt Solution D8537 Sigma-Aldrich, UK
Magnesium Chloride 68475 Sigma-Aldrich, UK
Manganese (III) tetrakis (l-Methyl-4- 
pyridyl) Porphyrin (MnTMPyP) F R l08-0050 Enzo Life Sciences, UK
Nco-Nitro-L-arginine methyl ester N5751 Sigma-Aldrich, UK
Potassium Chloride S270206 Sigma-Aldrich, UK
Potassium Dihydrogen Phosphate P/4800/53 Fisher Scientific, UK
Sodium Chloride S6546 Sigma-Aldrich, UK
Sodium Hydrogencarbonate S5761 Sigma-Aldrich, UK
Sodium nitroprusside 31444 Sigma-Aldrich, UK
sodium pentobarbital P3761 Sigma-Aldrich, UK
Tiron 89460 Sigma-Aldrich, UK
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Appendix table 2.15 Chemicals, enzymes, and reagents for biochemical experiments
Reagents Catalogue No. Suppliers
1 OObp DNA Ladder 929559 Qiagen, UK
Acrylamide BPE1410-1 Fisher Scientific, UK
Agarose BP1356 Fisher Scientific, UK
Ammonium Persulfate A9164 Sigma-Aldrich, UK
Apoeynin A0231788 Fisher Scientific, UK
Ascorbic Acid A4544 Sigma-Aldrich, UK
Bio-Rad Bradford Protein Dye 500-0006 Bio-Rad Laboratories Inc,UK
Dihydroethidium (DHE) D11347 Invitrogen Corporation, UK
Dimethyl Sulphoxide 154938 Sigma-Aldrich, UK
DPI D2926 Sigma-Aldrich, UK
Ethidium Bromide E7637 Sigma-Aldrich, UK
Formaldehyde F8775 Sigma-Aldrich, UK
GoTaq Flexi PCR Kit M8291 Promega Corporation, USA
Hanks’ Buffered Salt Solution D8537 Sigma-Aldrich, UK
Isopropanol 103616V VWR International Ltd, UK
L-NAME N5751 Sigma-Aldrich, UK
Lucigenin B49203 Sigma-Aldrich, UK
Magnesium Sulfate M7506 Sigma-Aldrich
Methanol M3641 Sigma-Aldrich, UK
Mouse Insulin ELISA Kit 10-1247-01 Mercodia, Sweden
P-Nieotinamide Adenine 
Dinucleotide Phosphate N7785 Sigma-Aldrich, UK
Oxypurinol 06881 Sigma-Aldrich, UK
Protease Inhibitor Cocktail P8340 Sigma-Aldrich, UK
Protein Molecular Marker 50550 Lonza, Switzerland
Proteinase K 03115879011 Roche Diagnostics Ltd, UK
Rotenone R8875 Sigma-Aldrich, UK
N,N,N%N'- T9281 Sigma-Aldrich, UK
tetramethylethylenedi amine
Tiron 89460 Sigma-Aldrich, UK
Tris HCl T5941 Sigma-Aldrich, UK
Xanthine Oxidase X4500 Sigma-Aldrich, UK
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Appendix table 2.16 Components o f Protease Inhibitor Cocktail
Components Concentrations
AEBSF 104 mM
Aprotinin 80 pM
Bestatin 4 mM
E-64 1.4 mM
Leupeptin 2 mM
Pepstatin A 1.5mM
Appendix table 2.17 Ingredients and nutrition information of rodent diet
Diets for Mice
v..uiinjusmuii
Normal chow diet High-fat diet
Diet Code 5LF5 824053
PROTEIN 22% 23%
Arginine 1.35% N/A
Cystine 0.31% N/A
Glycine 0.99% N/A
Histidine 0.53% N/A
Isoleucine 1.12% N/A
Leucine 1.69% N/A
Lysine 1.33% N/A
Methionine 0.37% N/A
Phenylalanine 1.01% N/A
Tryptophan 0.30% N/A
Valine 1.09% N/A
Serine 1.24% N/A
Aspartic Acid 2.57% N/A
Glutamic Acid 5.15% N/A
Alanine 1.15% N/A
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Proline 1.60% N/A
FAT 4.0% 23%
Lard N/A 18%
Soya Oil N/A 5%
Linoleic Acid 1.89% N/A
Linolenic Aeid 0.22% N/A
Total Saturated Fatty Acids 0.67% N/A
Total Monounsaturated 
Fatty Acids 0.72% N/A
CARBOHYDRATES 59% 40%
Crude Fibre 4.1% N/A
Acid Detergent Fibre 5.8% 6.17%
Starch 43.5% 28.34%
Glucose 0.16% N/A
Fructose 0.19% N/A
Sucrose 1.57% 5.49%
MINERALS 4.1% 4.32%
Calcium 0.75% N/A
Phosphorus 0.59% N/A
Phosphorus (non-phytate) 0.30% N/A
Potassium 0.98% N/A
Magnesium 0.20% N/A
Sulphur 0.23% N/A
Sodium 0.26% N/A
Chlorine 0.49% N/A
Fluorine 3.9 ppm N/A
Iron 210 ppm N/A
Zinc 80 ppm N/A
Manganese 75 ppm N/A
Copper 13 ppm N/A
Cobalt 0.54 ppm N/A
72
Iodine 0.81 ppm N/A
Chromium 0.61 ppm N/A
Selenium 0.29 ppm N/A
VITAMINS 1.2% 1.23%
Carotene 1.3 ppm N/A
Vitamin K 3.3 ppm N/A
Thiamine Hydrochloride 9.4 ppm N/A
Riboflavin 8.0 ppm N/A
Niacin 120 ppm N/A
Pantothenic Acid 17 ppm N/A
Choline Chloride 1800 ppm N/A
Folic Acid 2.9 ppm N/A
Pyridoxine 8.0 ppm N/A
Biotin 0.26 ppm N/A
Vitamin B12 25 Meg/kg N/A
Vitamin A 10 lU/gm N/A
Vitamin D3 2.2 lU/gm N/A
Vitamin E llO IU /kg N/A
Calories provide by: (% Real) (% Real)
Protein 25.9 20
Fat 9.3 45
Carbohydrates 64.8 35
Energy (Kcal/g) 3.17 4.54
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3. High-fat Diet-induced Metabolic Disorders and 
Endothelial Dysfunction in Male C57BL/6J Mice 
3.1. Introduction
The present global epidemic of obesity dominating public health issues in many 
modem societies is predominantly generated by environmental influences such as 
dietary changes due to easier access of palatable and high-energy foods (Swinbum et 
al., 2011). Obesity has deleterious effects on the metabolic homeostasis and affects 
numerous organ systems including cardiovascular system (Roberts et al., 2005). 
Clinical observations indicated that dietary obesity is often accompanied with the 
metabolic syndrome and cardiovascular oxidative stress which is associated with the 
development of CVDs in human at middle age and above, although the underlying 
mechanisms are not fully understood (Caballero, 2003; Roberts et al., 2006).
Several animal models in different species have been introduced and investigated to 
elucidate the adverse effects of obesity on metabolic homeostasis and the consequent 
cardiovascular reactivity (Henderson et al., 2004; Molnar et al., 2005; Roberts et al., 
2005; Roberts et al., 2000; Woodman et al., 2003). Among them, C57BL/6J inbred 
mice receiving Westem-type high-fat diet have been widely used as a model for 
studies of dietary obesity (Noronha et al., 2005; Parekh et al., 1998) because they are 
exceedingly susceptible to diet-induced obesity and type 2 diabetes with 
cardiovascular phenotypes such as atherosclerosis and hypertension (Carroll and 
Tyagi, 2005; Petro et al., 2004; Surwit et al., 1995; Surwit et al., 1988).
74
Accumulating evidence has established an association between the metabolic 
syndrome and the development of cardiovascular disease in diet-induced obesity in 
mice and several possible mechanisms were proposed. These studies revealed that 
high-fat consumption impairs endothelium-dependent vasodilations and potentially 
promotes endothelial dysfunction through a range o f metabolic disorders including 
accumulation of adipose tissue, dyslipidemia, hyperglycemia, increased blood 
pressure, and altered NO signaling pathways which are all associated with vascular 
oxidative stress (Barton et al., 2000; Molnar et al., 2005; Mundy et al., 2007; Noronha 
et al., 2005; Roberts et al., 2000; Traupe et al., 2002a).
So far it is well known that obesity promotes vascular oxidative stress and contributes 
to endothelial dysfunction. However, the source(s) of vascular ROS and their effect 
on the vascular function in high-fat diet-induced obesity are still not clear. Thus in 
this first part o f our studies we aimed to characterize high-fat diet-induced metabolic 
disorders and vascular dysfunction in middle-aged C57BL/6J mice to give us some 
baseline and background information for better understanding of this animal model 
and therefore benefit the rest of the studies in this thesis. To do so, male C57BL/6J 
mice at age of 7 months were supplied with a high-fat diet (45% kcal fat) or a normal 
chow diet (9.3% kcal fat) for 16 weeks and used at 11 months of age. Physiological 
and metabolic parameters were measured during the study with vessel functions and 
ROS production examined in the end.
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3.2. Results
3.2.1. Food/energy intake in C57BL/6J mice
Male C57BL/6J mice at the age o f 7 months were purchased from Charles River 
(Margate, England). One week after arrival, the mice were divided into two groups 
and received continuous feeding o f either a high-fat diet (#824053; Special Diets 
Services, UK) or a normal chow diet (5LF5; LabDiet Ltd., UK) for up to 16 weeks. 
On a caloric basis, the high-fat diet consisted of 45% Kcal fat, 20% Kcal protein, and 
35% Kcal carbohydrate (total 4.54 Kcal/g), whereas the normal chow diet contained 
9.3% Kcal fat, 25.9% Kcal protein, and 64.8% Kcal carbohydrate (total 3.17 Kcal/g).
At the beginning of the diet intervention study, male C57BL/6J mice fed with the 
high-fat diet consumed more energy in calories than mice provided with the normal 
chow diet (16.61 ± 2.50 versus 12.24 ± 0.50 Kcal/day; P<0.05) (figure 3.LB) 
although there was no significant difference in food intake between these two diet 
groups (3.66 ± 0.55 versus 3.69 ± 0.15 g/day) (figure 3.1.A). However, mice fed with 
the high-fat diet compensated for the higher-caloric content o f the food by decreasing 
their daily food intake later during the experiment, and the caloric intake in the high- 
fat diet group returned back to normal eventually. Figure 3.1.C and figure 3.1.D show 
that high-fat diet-fed mice consumed significantly less amount o f food than the 
normal chow diet-fed mice (2.70 ± 0.43 versus 3.53 ± 0.26 g/day; P<0.05) but with 
similar caloric intake (12.25 ± 1.96 versus 11.71 ± 0.86 Kcal/day) at week 16 of the 
study.
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Figure 3.1 Differences in food/energy intake of C57BL/6J mice under different diets
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Legend to figure 3.1
Male C57BL/6J mice at the age of 7 months were randomly divided into two diet 
groups and fed with a NCD with 9.3% Kcal fat or a HFD with 45% Kcal fat for 16 
weeks. The consumption o f food was measured using a balance at 6pm before the 
dark cycle every day for the whole week in the first and the last week of diet 
intervention.
Food intake o f mice from the NCD group (empty bars) and the HFD group (filled 
bars) were recorded as the amount of food consumed per mouse per day at week 1 (A) 
and week 16 (C) o f diet intervention (n=8-10 per group). The caloric energy 
consumption of each group at week 1 (B) and week 16 (D) was calculated by 
multiplying the amount o f consumed food with the calories contained in each gram of 
food. Data are given as means ± standard deviation; * P<0.05 was obtained by 
comparing the HFD group with the NCD group using an unpaired Student’s Mest.
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3.2.2. Effect of HFD on weight gain and fat deposit of C57BL/6 J mice
Exposure to the high-fat diet was accompanied by progressive obesity in male 
C57BL/6J mice. Body weights were significantly higher in mice fed with the high-fat 
diet compared with age-matched controls fed with the normal chow diet from the 
second week and throughout the process of diet intervention. Also mice in high-fat 
diet group from the second week experienced weight gain at a rate faster than mice of 
the same age eating the normal chow diet (figure 3.2.C). At end of the study (week 
16), mice consuming the high-fat diet were approximately 30% heavier than their age- 
matched controls on the normal chow diet (56.4 ±3 .1  versus 43.3 ± 2.4 g; P<0.05) 
(figure 3.2.D).
Additionally, epididymal fat weight between the two diet groups was remarkably 
different. Parallel to the increases in body weight, mice consuming the high-fat diet 
had a 2.4-fold greater epididymal fat mass compared with mice fed with the normal 
chow diet (2.56 ± 0.21 versus 1.08 ± 0.30 g; P<0.05) (figure 3.2.E) The epididymal 
fat pat weight adjusted for body weight had approximate 79% increases in mice fed 
with high-fat diet in comparison to mice fed with normal chow diet (5.88 ± 1.52 
versus 3.29 ± 0.80 %; P<0.05) (figure 3.2.F).
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Figure 3.2. Effect of HFD on body weight and fat deposit of C57BL/6J mice
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Legend to figure 3.2
The mouse body weight was recorded weekly throughout the process of diet 
intervention for 16 weeks. At the end of week 16, the mice were sacrificed and the 
epididymal fat pats (EFP) were collected and weighed.
Photographs of bodies (A) and EFP (B) after 16 weeks of diet intervention of male 
C57BL/6J wild-type mice from each diet group. A ruler was put next to the object as 
reference. C, Body weight growth curves (n=13-16 per group) of mice fed with the 
NCD (empty symbols) or the HFD (filled symbols) for 16 weeks. D, Body weight, E, 
EFP mass and F, Percentage of EFP mass relative to body weight of C57BL/6J wild- 
type mice (n=12-14 per group) fed with NCD (empty bars) or HFD (filled bars) after 
16 weeks of diet intervention. Data are given as means ± standard deviation. In panel 
C * P<0.05 was obtained by comparing HFD group with NCD group using two-way 
repeated-measures ANOVA. In panel D, E, and F * P<0.05 was obtained by 
comparing HFD group with NCD group using unpaired Student’s Mest.
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3.2.3. Effect of HFD on fasting blood glucose, serum insulin levels and glucose
intolerance in male C57BL/6J mice
Given these differences in body weight and fat mass, we next measured fasting blood 
glucose in each group before and after diet intervention. There were no differences in 
fasting blood glucose levels before and after the diet intervention within mice from 
the normal chow diet group (6.51 ± 1.27 versus 6.25 ± 1.57 mmol/L). In contrast, 
diet-induced obesity was accompanied by fasting hyperglycaemia in the male 
C57BL/6J mice. After 16 weeks of high-fat diet feeding, fasting blood glucose levels 
were significantly elevated from the levels before the diet intervention in the same 
mice (9.00 ± 1.40 versus 6.03 ± 1.08 mmol/L; P<0.05). Also high-fat diet-fed mice 
had significantly higher fasting blood glucose levels as compared with their age- 
matched controls (9.00 ± 1.40 versus 6.25 ± 1.57 mmol/L; P<0.05) (figure 3.3 A).
Diet-induced hyperglycaemia in the male C57BL/6J mice was associated with 
hyperinsulinemia. Fasting serum insulin levels were measured in each group after 16 
weeks of diet intervention. Compared with the levels of normal chow diet-fed mice, 
the fasting serum insulin levels of mice from high-fat diet group was significantly 
increased as shown in figure 3.4 (3.34 ± 1.86 versus 0.98 ± 0.24 pg/L; P<0.05) (figure 
3.3 B).
The intraperitoneal glucose tolerance test was performed at week 16 of diet 
intervention. The high-fat diet-fed mice had significantly increased fasting blood 
glucose levels compared with the age-matched controls consuming the normal chow 
diet before the glucose administration. 15 minutes following an intraperitoneal 
injection of glucose, mice on both diets displayed blood glucose levels much high
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above pre-administration values at a similar rate. As it kept steady at the 30-minute 
time point in normal chow diet group, the blood glucose level increased further in 
high-fat diet group. Elevated concentrations of blood glucose levels persisted in the 
high-fat diet-fed mice in comparison to the normal chow diet-fed controls. Significant 
differences were identified at 30-, 60-, and 120-minute time points with a higher area 
under the glucose tolerance test curves demonstrating slower elimination o f glucose 
rate (figure 3.3 C).
83
Figure 3.3 The blood glucose levels, serum insulin levels and glucose tolerance tests
for male C57BL/6J mice on diet intervention
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Legend to figure 3.3
A. Fasting blood glucose levels of male C57BL/6J mice before (empty bars) and after 
(filled bars) fed with the NCD or the HFD for 16 weeks. Blood glucose levels were 
determined from 8-hours-starved mice (n = ll ~ 18 per group) using a blood glucose 
meter at the same time of day (~ 9 am). Data are given as means ± standard deviation; 
* P<0.05 was obtained by comparing HFD group after diet intervention with HFD 
group before diet intervention; # P<0.05 was obtained by comparing HFD group with 
NCD after diet intervention using two way ANOVA with Bonferroni post-tests.
B. Fasting serum insulin levels of C57BL/6J mice fed with NCD (empty bar) or HFD 
(filled bar) for 16 weeks. Insulin levels were determined from 8-hour-starved 
C57BL/6J mice (n=9 per group) using an enzyme-linked immunosorbent assay. Data 
are given as means ± standard deviation; * P<0.05 was obtained by comparing the 
HFD group with the NCD group using an unpaired Student’s r-test.
C. Intraperitoneal glucose tolerance tests (IPGTT) for male C57BL/6J mice fed with 
the NCD (empty symbols) or HFD (filled symbols) after 16 weeks o f diet intervention 
(n=6 per group). Overnight-fasted mice from each group received an intraperitoneal 
injection of glucose (2 grams per kg (body weight)) and blood glucose levels were 
determined at 15, 30, 60 and 120 minutes after the injection using blood glucose 
meter. Data are given as means ± standard deviation; # P<0.05 was obtained by 
comparing HFD group with NCD group using two way ANOVA with Bonferroni 
post-tests.
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3.2.4. Effect of HFD on lipoprotein and lipid levels of male C57BL/6 J mice
Compared to age-matched normal chow diet-fed controls, male C57BL/6J mice fed 
with high-fat diet exhibited significant differences in a variety of biochemical 
parameters of lipoprotein and lipid metabolism. Serum total cholesterol levels of 8- 
hour-starved mice from high-fat diet group were markedly increased 76% compared 
with those of the normal chow diet group (4.51 ± 0.65 versus 2.57 ± 0.37 mmol/L; 
P<0.05) (figure 3.4.A). Low density lipoprotein levels in the high-fat die group were 
approximately 4.5-fold higher versus age-matched controls (2.00 ± 0.51 versus 0.44 ± 
0.35 mmol/L; P<0.05) (figure 3.4.B). Similarly, significant increases in serum 
triglycerides and free fatty acids were both determined in mice fed with high-fat diet 
versus mice fed with the normal chow diet (0.87 ± 0.49 versus 0.51 ± 0.24 mmol/L 
and 1.52 ± 0.21 versus 0.92 ±0 .14  mmol/L, respectively; P<0.05) (figure 3.4.D, E). 
However, the high-fat diet did not influence serum high density lipoprotein levels in 
C57BL/6J mice in comparison to normal chow diet-fed controls as shown in figure
3.4.C (1.68 ± 0.15 versus 1.56 ± 0.26 mmol/L).
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Figure 3.4 Effect of HFD on serum lipids levels o f male C57BL/6J mice
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Legend to figure 3.4
Mouse blood was obtained via posterior vena of 8-hour-starved male C57BL/6J mice 
from both the NCD group and the HFD group after 16 weeks o f diet intervention. The 
serum was collected from these blood samples and used to determine metabolic 
parameters using an ILab 650 Chemistry Systems.
(A) Total cholesterol, (B) Low density lipoprotein, (C) High density lipoprotein, (D) 
Triglycerides, and (E) Free fatty acids levels of serum samples o f fasted mice from 
the NCD (empty bars) or the HFD (filled bars) group (n=10 ~ 12 per group). Data are 
given as mean ± standard deviation; * P<0.05 was obtained by comparing HFD group 
with NCD group using unpaired Student’s /‘-test.
88
3.2.5. Effect of HFD on blood pressure of male C57BL/6 J mice
We next measured mouse blood pressure (BP) in both groups before and after the diet 
intervention. There were no differences in either systolic BP or diastolic BP before 
and after the diet intervention within the normal chow diet group (122 ± 7 versus 127 
± 7 mmHg and 99 ± 8 versus 105 ± 8 mmHg, respectively). In contrast, the high-fat 
diet-fed mice exhibited significantly elevated systolic BP after 16 weeks of diet 
intervention in comparison to the levels before diet intervention in the same mice (144 
±11 versus 122 ± 7 mmHg; P<0.05). Also the high-fat diet-fed mice had significantly 
higher systolic blood pressure as compared with the normal chow diet-fed controls 
(144 ± 11  versus 127 ± 7 mmHg; P<0.05) (figure 3.5 left panel). The diastolic blood 
pressure in HFD-fed mice followed the same pattern compared with the normal chow 
diet-fed mice (figure 3.5 right panel).
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Figure 3.5 Effect of HFD on blood pressure o f male C57BL/6J mice
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Legend to figure 3.5
Blood pressure o f male C57BL/6J mice fed with the NCD or HFD was measured by a 
tail cuff non-invasive blood pressure measurement system. The mean o f at least five 
successful recordings per mouse was taken (n=l 1 ~ 14 per group).
Mouse systolic and diastolic blood pressure recorded before (empty bars) and after 
(filled bars) fed with the NCD or the HFD for 16 weeks. Data are given as means ± 
standard deviation; * P<0.05 was obtained by comparing HFD after diet intervention 
with HFD before diet intervention; # P<0.05 was obtained by comparing the HFD 
group with the NCD group using a two way ANOVA with Bonferroni post-tests.
90
3.2.6. Effect of HFD on vascular function of male C57BL/6 J mice
Aortic rings from high-fat diet fed WT mice had increased vasoconstriction to 
phenylephrine as maximal tension to phenylephrine were significantly increased 
(HFD 0.32 ± 0.07 versus NCD 0.23 ±0.08 grams, P<0.05) in aortic rings o f high-fat 
diet fed mice compared with chow diet fed mice.
The high-fat diet promoted endothelial dysfunction in aortic rings from the male 
C57BL/6J mice. Indeed, maximal endothelium-mediated relaxation of the 
phenylephrine-precontracted rings in response to acetylcholine declined by 16.4% for 
mice fed with the high-fat diet in comparison to mice fed with the normal chow diet 
(Emax HFD69.73 ± 5.12% versus NCD 83.40 ± 7.10%; P<0.05). In the high-fat diet- 
fed mice, endothelium-mediated vascular relaxation of phenylephrine-precontracted 
aortic rings in response to acetylcholine was markedly impaired compared with age- 
matched controls fed with the normal chow diet (figure 3.6.A). At the corresponding 
time, endothelium-independent vasodilatory responses to sodium nitroprusside were 
unaltered in both diet groups (figure 3.6.B).
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Figure 3.6 Effect of HFD on vessel relaxation in aortas from male C57BL/6J mice
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Legend to figure 3.6
Aortic rings from male C57BL/6J mice fed with the NCD or the HFD for 16 weeks 
were precontracted with a submaximal concentration of phenylephrine and relaxed by 
cumulative concentrations of acetylcholine (1 nM to 10 pM) or sodium nitroprusside 
(SNP, 0.1 nM to 1 pM) in an organ bath.
A. Endothelium-dependent relaxation curves to acetylcholine in aortas from NCD 
(empty circles) and the HFD (filled circles) groups (n=12 per group). B. Endothelium- 
independent relaxation curves to SNP in aortas from mice fed with NCD (empty 
circles) or HFD (filled circles) (n=12 per group). Data are given as mean ± standard 
deviation; * P<0.05 was obtained by comparing HFD group with NCD group using 
two way ANOVA.
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3.2.7. Effect of tiron on vessel relaxation of male C57BL/6J mice from different
diet groups
To provide evidence for the role o f enhanced superoxide production, the cell- 
permeable superoxide scavenger tiron was administered ex vivo to aortic rings from 
both diet groups, a method that was shown to effectively scavenge superoxide (Li et 
a l, 2004).
In aortic rings from mice fed with high-fat diet, preincubation with tiron (10 mM) 
completely normalized the vascular relaxation in response to acetylcholine to the level 
demonstrated in the normal chow diet group (figure 3.7.B), while tiron has no effect 
on vessel relaxation responses of aortic rings from the normal chow diet group (figure
3.7.A). In addition, organ bath studies showed that vessel relaxation responses to 
nitric oxide donor sodium nitroprusside were identical in the absence and presence of 
tiron within the high-fat diet group as shown in figure 3.7.C.
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Figure 3.7 Effect of tiron on vessel relaxation in aortas from male C57BL/6J mice
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Legend to figure 3.7
In some experiments, aortic rings from male C57BL/6J wild-type mice fed with the 
NCD (empty symbol) or the HFD (filled symbol) for 16 weeks were preincubated 
with or without ROS scavenger tiron (10 mM) for 15 minutes before performing 
endothelium-dependent relaxation assessments to acetylcholine (1 nM to 10 pM) or 
endothelium-independent relaxation assessments to SNP (0.1 nM to 1 pM) in an 
organ bath.
A. Endothelium-dependent relaxation curves to acetylcholine in aortic rings from 
NCD group (n=12 per group) in the presence (triangles) or absence (circles) of tiron.
B. Endothelium-dependent relaxation curves to acetylcholine in aortic rings from 
HFD group (n=12 per group) in the presence (triangles) or absence (circles) of tiron.
C. Endothelium-independent relaxation responses to SNP of aortic rings from HFD 
group in presence (triangles) or absence (circles) o f tiron. Data are given as means ± 
standard deviation; * P<0.05 was obtained by comparing the HFD group with the 
HFD + tiron group using a two way ANOVA.
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3.2.8. Effect of MnTMPyP on vessel relaxation of male C57BL/6J mice from 
different diet groups
To further provide the evidence o f enhanced superoxide production and confirm the 
effect of tiron incubation, the cell-permeable superoxide dismutase mimetic 
MnTMPyP was administered ex vivo to aortic rings from both diet groups.
Pretreatment with MnTMPyP (10 pM) significantly improved vascular relaxation in 
response to acetylcholine in the aortic rings from mice fed with the high-fat diet 
(figure 3.8.B) while MnTMPyP has no effect on vessel relaxation responses of mouse 
aortic rings from the normal chow diet group (figure 3.8.A).
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Figure 3.8 Effect of MnTMPyP on endothelium-dependent relaxation in aortas from 
C57BL/6J mice from different diet groups
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Legend to figure 3.8
In some experiments, aortic rings from male C57BL/6J mice fed with the NCD 
(empty symbols) or the HFD (filled symbols) for 16 weeks were preincubated with or 
without SOD mimetic MnTMPyP (10 pM) for 30 minutes before performing 
endothelium-dependent relaxation responses to acetylcholine (1 nM to 10 pM) in an 
organ bath.
A. Endothelium-dependent relaxation responses to acetylcholine o f aortic rings from 
NCD group (n=6 per group) in the presence (triangles) or absence (circles) of 
MnTMPyP. B. Endothelium-dependent relaxation curves to acetylcholine of aortic 
rings from HFD group (n=6 per group) in presence (triangles) or absence (circles) of 
MnTMPyP. Data are given as means ± standard deviation; * P<0.05 was obtained by 
comparing HFD group with HFD + MnTMPyP group using two way ANOVA.
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3.2.9. Effect of L-NAME on vessel relaxation of male C57BL/6J mice from 
different diet groups
Inhibition of nitric oxide synthesis by incubation of L-NAME with aortic rings for 30 
minutes dramatically diminished acetylcholine induced vasodilations in both diet 
groups (figure 3.9).
Figure 3.9 Effect of L-NAME on endothelium-dependent relaxation o f aortas from 
C57BL/6J mice.
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Legend to figure 3.9
In some experiments, aortic rings from male C57BL/6J mice fed with the NCD 
(empty symbols) or the HFD (filled symbols) for 16 weeks were incubated with or 
without NOS inhibitor L-NAME (10 pM) for 30 minutes before performing 
endothelium-dependent relaxation assessments to acetylcholine (1 nM to 10 pM) in 
an organ bath.
A. Endothelium-dependent relaxation curves to acetylcholine of aortic rings from 
NCD group (n=6 per group) in the presence (triangles) or absence (circles) of L- 
NAME. B. Endothelium-dependent relaxation curves to acetylcholine o f aortic rings 
from HFD group (n=6 per group) in the presence (triangles) or absence (circles) of L- 
NAME. Data are given as means ± standard deviation; * P<0.05 was obtained by 
comparing the NCD + L-NAME group with the NCD group or comparing the HFD + 
L-NAME group with the HFD group using a two way ANOVA.
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3.2.10. Effect of endothelium denudation on vessel relaxation of male C57BL/6J 
mice from different diet groups
Similar to the effect of L-NAME incubation, denudation of the endothelial cells of 
aortic rings radically abolished acetylcholine induced vasodilations in both diet 
groups as shown in figure 3.10.
Figure 3.10 Effect of endothelium denudation on vessel relaxation o f aortas from 
C57BL/6J mice
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Legend to figure 10
In some experiments, the endothelial cells (EC) of aortic rings from male C57BL/6J 
mice fed with the NCD (empty symbols) or the HFD (filled symbols) for 16 weeks 
were rubbed by passing a brass wire through the lumen back and forth 8 ~ 10 times 
before performing vessel relaxation assessment to acetylcholine (1 nM to 10 pM) in 
an organ bath.
A. Endothelium-dependent relaxation responses to acetylcholine o f aortic rings firom 
NCD group (n=6 per group) with intact endothelium (circles) and denuded 
endothelium (triangles). B. Endothelium-dependent relaxation responses to 
acetylcholine o f aortic rings from the HFD group (n=6 per group) with intact 
endothelium (circles) and denuded endothelium (triangles). Data are given as means ± 
standard deviation; * P<0.05 was obtained by comparing intact endothelium group 
with denuded endothelium group of aortic rings from mice fed with either NCD or 
HFD using a two way ANOVA.
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3.2.11. Effect of HFD on vascular ROS production detected by lucigenin 
chemiluminescence
Vascular ROS production was measured in aortic homogenates from the same male 
C57BL/6J mice fed with the high-fat diet and age-matched controls fed with the 
normal chow diet. In Figure 3.11.A, an NADPH-independent assay was carried out 
for the first 10 minutes and ROS production was hardly detected. With the addition of 
NADPH afterwards, a certain level of ROS was detected in the normal chow diet 
group and a significantly higher ROS production was detected in the high-fat diet 
group. This suggests that high-fat diet-induced activation o f ROS production is 
NADPH-dependent in aortas. Quantification of NADPH-dependent ROS production 
shows that there was a 2-fold increase in high-fat diet group compared with the 
normal chow diet group as shown in Figure 3.11.B. When tiron was added into aortic 
homogenates, a dramatic decrease in ROS production was observed in both diet 
groups.
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Figure 3.11 Effect o f HFD on aortic ROS production detected by lucigenin 
chemiluminescence
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Legend to figure 3.11
Aortic tissue from male C57BL/6J mice fed with the NCD or the HFD for 16 weeks 
was homogenised and used for lucigenin chemiluminescence to detect ROS 
production.
A. Kinetic graph o f ROS levels in aortic homogenates from the NCD group (empty 
symbols) and the HFD group (filled symbols) (n=9 per group). The ROS production 
was examined using aortic homogenates with lucigenin (5pM) solution in the absence 
or presence of NADPH at every minute for a total 30 minutes. NADPH (100 pM) was 
added at 10 minutes o f measurement and tiron (10 mM) was added after 20 minutes.
B, The average o f NADPH-dependent ROS levels of aortic homogenates from mice 
fed with NCD (empty bar) or HFD (filled bar) (n=9 per group). Data are given as 
mean ± standard deviation; * P<0.05 was obtained by comparing HFD group with 
NCD group using unpaired Student’s t-test.
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3.2.12. Effect of HFD on vascular ROS production detected by in situ DHE 
fluorescence
The DHE staining method was performed to detect intracellular ROS in the vascular 
wall. Figure 3.12.A shows representative images of the aortic sections with DHE 
staining from both diet groups in absence or presence of tiron. As shown in red 
fluorescence, a certain level o f ROS production was detected in the normal chow diet 
group and a significantly higher ROS production was detected in the high-fat diet 
group.
Quantification of fluorescence intensity shows that there was a significant increase in 
DHE fluorescence intensity in aortic sections from the high-fat diet group compared 
with the normal chow diet group while tiron incubation dramatically decreased ROS 
production in both diet groups to similar low levels as shown in Figure 3.12.B.
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Figure 3.12 Effect of HFD on aortic ROS production detected by in situ DHE 
fluorescence
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Legend to figure 3.12
Cryostat sections o f frozen aorta samples from male C57BL/6J mice fed with the 
NCD or the HFD for 16 weeks were incubated with DHE (2 pM) for 10 minutes in 
the absence or presence of ROS scavenger tiron (10 mM). Intracellular ROS was 
immediately detected under a fluorescent microscope with an excitation at 520 nm 
and an emission at 605 nm.
A. Representative images (200 x magnifications) of intracellular ROS detection in 
aortic sections from mice fed with the NCD or the HFD. Images o f aortic sections 
from each diet group with haematoxylin and eosin staining are listed on the right for 
reference. B. Fluorescence intensities of images of aortic sections from the NCD 
group (empty bars) or the HFD group (filled bars) were quantified. Quantification was 
applied from 18 images o f 6 mice per group using the Digital Pixel Simple PCI6 
software and expressed as means ± standard deviation. * P<0.05 was obtained by 
comparing the HFD group with the NCD group using an unpaired Student’s t-test
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3.3. Discussion
In this part of our studies, the results show that a high-fat diet promoted obesity, 
hyperglycaemia, hyperinsulinemia, hyperlipidaemia, and hypertension in male 
C57BL/6J mice at middle age. Also high-fat diet produced a distinct induction of 
endothelial dysfunction mainly due to an increased ROS production. Our results are in 
good agreement with previous studies indicating a close correlation among high-fat 
diet feeding and the onset of oxidative stress, the development o f metabolic disorders 
and endothelial dysfunction in aortas in C57BL/6J mice (Schreyer et al., 1998).
In previous genetic models of obesity and diabetes, such as in ob/ob mice and db/db 
mice, animals have a non-fiinctional leptin receptor, providing mouse models for 
investigating the effects of overfeeding-induced obesity and diabetes. Because of the 
tremendous amount of food consumption, they developed phenotypes like obesity, 
severe hyperinsulinemia, and hyperglycaemia. By contrast, in this part o f our study, 
C57BL/6J wild-type mice were used and fed with a high-fat diet composed of 45% 
Kcal of fat and obesity resulted from the high-fat consumption. Thus this obesity 
model is likely to be the result o f high-fat content of the diet rather than the highly 
increased food consumption therefore mimicking the natural process o f development 
of obesity and type 2 diabetes of human beings in most modem societies.
After 16 weeks o f intervention with the high-fat diet, mouse body weight was 
significantly increased. This rapid weight gain was accompanied by a larger EFP 
mass although the energy intake was similar in these two diet groups at the end o f the 
study. We found this dietary obesity in C57BL/6J mice was associated with increased 
fasting semm glucose, insulin, and cholesterol levels. Also dietary obese mice
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exhibited higher blood pressure. Together, all these results confirm other researchers’ 
studies that high-fat diet induced complicated metabolic syndrome in C57BL/6J mice 
(Tentolouris et ah, 2006). It is notable that several mechanisms affected the regulation 
of blood pressure in obesity, such as neural (Barnes et al., 2003), hormonal (Bjomtorp 
and Rosmond, 2000), and other mechanisms.
It has been found that dietary obesity increases the prevalence o f cardiovascular 
diseases (Van Gaal et al., 2006). Clinical observation indicates that obesity which is 
associated with the diet of Western style may lead to the metabolic syndrome and 
have been suggested to be involved in the impairment of endothelial function 
(Avogaro and de Kreutzenberg, 2005). Thus animal studies have been established to 
investigate the underlying mechanisms. Collectively, these animal studies have 
revealed a critical role for the HFD in the development of endothelial dysfunction by 
demonstrating impaired endothelium-dependent relaxations o f the large conducting 
arteries (Mundy et al., 2007). In the present study, we used a classical ex vivo vascular 
function approach and investigated isolated aortas to exclude neural and hormonal 
vasoregulatory mechanisms that may also be influenced by high-fat diet (Barnes et al., 
2003; Bjomtorp and Rosmond, 2000). In aortas of high-fat diet-fed mice, 
endothelium-dependent relaxation responses to acetylcholine were significantly 
reduced in comparison to those of control mice while relaxation responses to the nitric 
oxide donor sodium nitropmsside were similar between these two diet groups. These 
results imply selective impairment of endothelium-dependent vasodilations in aortas 
of high-fat diet-fed mice. It has been previously reported that impaired endothelium- 
dependent vasodilation responses in diet-induced obesity are primarily because of 
reduced bioavailability o f the second messenger nitric oxide (Caballero, 2003). In our
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study, the nitric oxide synthase inhibitor L-NAME markedly reduced acetylcholine- 
induced relaxations in both diet groups suggesting a major role o f nitric oxide 
mediation o f agonist-induced vasodilation in mouse aortas.
Previous studies proposed that high-fat diet was linked with a reduction of eNOS 
protein levels in mouse aortas, which was proposed to be responsible for the 
decreased nitric oxide synthesis under this circumstance (Roberts et al., 2005). Other 
studies indicated that increased vascular ROS formation plays a major role of the NO 
inactivation in diet-induced obesity (Noronha et al., 2005). Our results support the 
latter hypothesis because pretreatment with the superoxide scavenger tiron or 
superoxide dismutases mimetic MnTMPyP in aortas of high-fat diet-fed mice 
normalised decreased acetylcholine-induced relaxation responses which indicating the 
impaired endothelium-dependent vasodilation in vessels from high-fat diet group was 
likely to be a result o f increased superoxide production interfering with nitric oxide 
signalling and promoting endothelial dysfunction.
To further validate the primary role for ROS in the vasculature, ROS production in 
aortic tissues was determined by a lucigenin chemiluminescence method which is 
considered as a reliable and sensitive approach to quantify superoxide formation (Li 
and Shah, 2001). The results revealed an increased superoxide production in aortas of 
high-fat diet-fed mice compared with those vessels obtained from controls. This was 
also confirmed by the DHE fluorescence method. In the past, it has been shown that 
the bioavailability o f nitric oxide decreases when the level of superoxide increases. 
Thus we propose that, in aortas of high-fat diet-fed mice the nitric oxide-mediated 
vasodilations are reduced because o f the elevated level o f superoxide.
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In summary, like others’ recent studies, our data suggests that a high fat diet has 
adverse effects on metabolism and cardiovascular system in C57BL/6J mice. The 
mechanisms accounting for the high-fat diet-induced metabolic disorders and 
endothelial dysfunction appeared to involve oxidative stress. Thus in the next part of 
our studies, we aim to classify the possible source(s) of vascular ROS production.
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4. The Effects of Nox2 Knockout and Apocynin (Nox2 
Inhibitor) Treatment on High-fat Diet-induced Metabolic 
Disorders and Endothelial Dysfunction in Male Mice 
4.1. Introduction
In chapter 3, we demonstrated that oxidative stress is involved in the onset and 
development o f high-fat diet-induced metabolic disorders and endothelial 
dysfunction. Indeed, ROS not only help to maintain physiological cellular function 
and vascular integrity in the vasculature but also actively take part in the pathogenesis 
of different cardiovascular diseases (Yung et al., 2006). Recent studies implicated that 
increased ROS production inactivates endothelium-derived nitric oxide and 
upregulates ROS-dependent modulation of intracellular signalling pathways and 
therefore contributes to endothelial dysfunction - a principle pathomechanism for 
many cardiovascular diseases (Li and Shah, 2004). For instance, superoxide can 
impair the endothelium-derived vasodilatation or affect the sensitivity of blood 
vessels to vasodilators by interfering and scavenging nitric oxide (Brandes et al., 
2000). Furthermore, numerous reports demonstrate that superoxide dismutase can 
improve relaxation o f blood vessels (Shimokawa and Morikawa, 2005).
Although several enzymatic sources of ROS have been examined, more recent studies 
have suggested that the family o f NADPH oxidases is the major source o f ROS in the 
vessel wall, especially in response to various stimulators such as angiotensin II and 
TNFa (Li et al., 2002b; Li and Shah, 2003b) which are very likely to be linked with 
obesity. The NADPH oxidases generate superoxide by passing one electron from 
NADPH through the membrane and coupling it with molecular oxygen. All NADPH
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oxidases contain a core subunit, termed Nox, catalyzing the transfer of electrons to O2 
which leads to ROS generation. In the rodent vasculature, 3 Nox (i.e. noxl, nox2, and 
nox4) have been described in research literature so far (Bengtsson et al., 2003). Nox2 
and Nox4 are the major Nox isoforms in the endothelium while Nox4 and Noxl are 
predominately expressed in vascular smooth muscle cells (Bedard and Krause, 2007a; 
Dikalov et al., 2008; Ray et al., 2011; Schroeder et al., 2009). Nox2 is also expressed 
in adventitial fibroblasts. Nox2 is a highly glycosylated protein and normally 
quiescent in vasculature. Its activation is induced by pathophysiological stimulations 
such as shear stress, angiotensin II or inflammatory cytokines (TNFa) in a process 
that causes post-translational modifications and association of regulatory subunits 
(p47phox, p67phox, p40phox and Racl) (Li et al., 2005b). It has recently been shown 
by our group that Nox2-containing NADPH oxidase is a major source of ROS in 
endothelial cells which are essential for vascular oxidative stress and contributes to 
endothelial dysfunction (Li and Shah, 2004). Nox2 and its binding subunits are 
implicated in the development of endothelial dysfunction and hypertension in 
preclinical models and in humans. For instance, studies in tissues from human patients 
have correlated endothelial vasodilator dysfunction with increased Nox2 expression 
and activity (Guzik et al., 2000b). Nox2 is involved in superoxide production and 
early atherosclerotic plaque formation in hypercholesterolemic apoE-deficient mice. 
Nox2 KG mice have improved endothelial dysfunction during experimental 
renovascular hypertension whereas p47 KG mice exhibit reduced hypertension and 
preserved endothelial function after chronic angiotensin II treatment (Grote et al., 
2006). The above studies suggest that endothelial Nox2 and Nox2-generated 
superoxide are important in the pathophysiology of cardiovascular diseases.
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Type 2 diabetes is typically preceded by obesity and is associated with metabolic 
disorders such as insulin resistance and dyslipidaemia. Obesity and Type 2 diabetes 
can be modelled in mice by feeding a high-fat diet as demonstrated in chapter 3. Some 
clinical observations indicated an increasing number o f metabolic syndrome 
components correlated with progressively worse endothelial function. Nevertheless, 
the mechanism accounting for metabolic disorders in patients with diabetes has not 
been fully clarified. Furthermore, several experimental and epidemiological data 
suggest that activation of NADPH oxidase enhances oxidative stress and is involved 
in the progression o f diabetic complications (Lavoie and Sigmund, 2003). Based on 
these results, NADPH oxidase-derived ROS are postulated to contribute to the 
pathogenesis of vascular dysfunction in diabetes.
Apocynin, 4-Hydroxy-3-methoxyacetophenone, is a methoxy-substituted catechol 
extracted originally from the root of the medicinal herb Apocynum cannabinum. 
Apocynin was first described by a pharmacologist Oswald Schmiedeberg in 1883 
(Vejrazka et al., 2005) and primarily used as a treatment for edema, jaundice and 
heart problems. But it was not until the 1990s that apocynin was isolated to a useful 
level for modem pharmacological applications and has been extensively studied in 
many laboratories around the world.
Apocynin proved to be a potent anti-inflammatory agent, based on the selective 
inhibition of the production of ROS by activated human polymorphonuclear 
neutrophils (Vejrazka et al., 2005). The observed inhibitory activity of apocynin 
proved to be a result o f inhibition of NADPH oxidase and subsequent formation of 
superoxide by preventing the assembly of the cytosolic subunits (p47phox and
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p67phox) to the membrane NADPH oxidase complex (Nox2-p22) (Vejrazka et ah, 
2005). Hence this agent has been used extensively on animal models as a potent and 
selective inhibitor o f NADPH oxidases in cardiovascular studies (Cai et al., 2003) 
Although some authors argue that apocynin may not be specific for NADPH oxidases 
because it inhibits thromboxane A2 formation in pulmonary macrophages and induces 
glutathione synthesis in alveolar epithelial cells via AP-1 activation.
Although the action mode of apocynin is not completely elucidated, it has been 
suggested that conversion of apocynin into an active metabolite is needed for 
displaying its pharmacological inhibitory activity (Van den Worm et al., 2001). 
Furthermore, a symmetrical dimer of apocynin, named diapocynin, has been reported 
recently to be the active metabolite which may be responsible for the anti­
inflammatory activity (Kanegae et al., 2010). Apocynin has high bioavailability when 
administered orally (Beswick et al., 2001) and has been shown to have very low 
toxicity (LD50: 9 g/kg) after oral administration in mice and had no observable side 
effects in a phase-I clinical study on treatment of lung emphysema (Stolk et al., 1994).
In this chapter o f my thesis, we aimed to explore the potential role of ROS-generating 
Nox2 in diet-induced metabolic disorders and vascular dysftmction in a mouse model. 
To achieve this, we investigated Nox2 KO mice under conditions o f normal chow and 
high-fat diet for 16 weeks. We determined in detail the effects of Nox2 deficiency on 
high-fat diet-induced metabolic disorders and vascular function. We also examined 
the effect o f apocynin, a Nox2 inhibitor, on high-fat diet-fed C57BL/6J WT mice to 
investigate potential therapeutic mechanisms that could be involved in this mouse 
model. To do so, apocynin solution (5mM) was freshly prepared by dissolving 425mg
114
of apocynin powder to 500ml of drinking water in a foil covered bottle daily and 
suppling to high-fat diet-fed WT mice. According to the average volume of water 
intake of mice, this corresponds to a dose of approximately 74 mg/kg/day of apocynin 
intake for each mouse.
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4.2. Results
4.2.1. Differences in food and energy intake of Nox2 KO and WT mice treated
with apocynin under different diets
Littermates of male Nox2 KG and WT mice were propagated in our animal unit. At 
the age of 7 months, Nox2 KG mice were divided into two groups and received 
continuous feeding o f either high-fat diet or normal chow diet for 16 weeks (diet 
information see appendix table 2.5, chapter2). Age matched WT mice were also fed 
with high-fat diet for 16 weeks while treated with apocynin (5 mM) in drinking water 
throughout the dietary regime. Water intake results showed there were no difference 
in WT mice fed with high-fat diet and high-fat diet-fed WT mice with apocynin 
treatment group (HFD 4.1 ± 1.2 versus HFD+apocynin 4.2 ± 0.4 ml/day/mouse).
In the first week of the diet intervention, there was no significant difference in food 
intake between the normal chow diet group and the high-fat diet group in Nox2 KG 
mice (HFD 3.10 ± 0.67 versus NCD 3.72 ± 0.52 g/day) (figure 4.1.A). However Nox2 
KG mice on high-fat diet tended to eat less, therefore they consumed similar energy 
levels in calories as Nox2 KG mice provided with the normal chow diet (HFD 14.09 ± 
3.03 versus NCD 12.34 ± 1.74 Kcal/day) (figure 4.1.B) while high-fat diet-fed WT 
mice treated with apocynin consumed as much food as WT mice on high-fat diet but 
without apocynin treatment (WT HFD+apocynin 3.63 ± 0.62 versus WT HFD 3.69 ± 
0.15 g/day) and consequently received same energy as WT mice on high-fat diet (WT 
HFD+apo 16.48 ± 2.81 versus WT HFD 16.61 ± 2.50 Kcal/day). High-fat diet-fed 
Nox2 KG mice kept decreasing their daily food intake later during the experiment and 
consumed significantly less food than Nox2 KG mice on normal chow diet (HFD 2.56 
± 0.40 versus NCD 3.37 ± 0.48 g/day; P<0.05). WT mice fed with high-fat diet with
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apocynin treatment ate a similar amount of food as WT mice on high-fat diet in the 
last week of the study (figure 4.1.C and results from 3.2.1) which results in same 
energy consumption among all these three groups (figure 4.1.D).
Figure 4.1 Differences in food and energy intake of Nox2 KO and WT mice treated 
with apocynin under different diets
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Legend to figure 4.1:
Male Nox2 KO mice at the age of 7 months were randomly divided into two diet 
groups and fed with normal chow diet (NCD) or high-fat diet (HFD) for 16 weeks. 
Age-matched male C57BL/6J mice fed with HFD were treated with apocynin (5 mM) 
in drinking water throughout the dietary regime. The consumption o f food was 
measured using a balance at 6 pm before the dark cycle every day for the whole week 
in the first and the last week of study.
Food intake of Nox2 KO mice (filled bars) from the NCD group and the HFD group 
and WT mice from HFD+apocynin group (éïnpty bars) were recorded as the amount 
of food consumed per mouse per day at week 1 (A) and week 16 (C) of diet 
intervention (n=8-10 per group). The caloric energy consumption o f each group at 
week 1 (B) and week 16 (D) was calculated by multiplying the amount o f consumed 
food with the calories contained in each gram of food. Data are given as means ± 
standard deviation; * P<0.05 was obtained by comparing the HFD group with the 
NCD group in Nox2 KO mice using unpaired Student’s Mest.
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4.2.2. Effect of Nox2 KO and apocynin treatment on weight gain and fat deposit
of mice under different diets
Similar to WT mice, Nox2 KG mice were progressively overweight after exposure to 
the high-fat diet. Body weights were significantly higher in Nox2 KG mice fed with 
the high-fat diet compared with age-matched controls on normal chow diet from the 
second week and throughout the rest o f study (figure 4.2.A). And at end of the diet 
intervention (week 16) Nox2 KG mice on high-fat diet were approximately 21% 
heavier than their age-matched controls on normal chow diet (HFD 48.3 ± 5.7 versus 
NCD 39.9 ± 1.8 g; P<0.05) (figure 4.2.B). Interestingly, the growth curve o f WT mice 
from high-fat diet + apocynin treatment group showed a significant decrease of 
weight gain compared with WT mice fed high-fat diet during the study (Figure 3.2) 
and matched precisely the curve of HFD-fed Nox2 KG mice as shown in figure 4.2.A.
Epididymal fat pat weight between the two diet groups in Nox2 KG mice was 
significantly different. Parallel to the increases in body weight, epididymal fat pat 
(EFP) mass from Nox2 KG mice on high-fat diet was approximately 35% greater 
compared with mice consuming the normal chow diet (HFD 1.73 ± 0.19 versus NCD 
1.28 ± 0.46 g; P<0.05) (figure 4.2.C). Due to the similar rate of increase in EFP mass 
and body weight gain in HFD-fed Nox2 KG mice, the epididymal fat pat weight 
adjusted for body weight had no difference between these two diet groups. (HFD 3.72 
± 0.62 versus NCD 3.17 + 1.15 %) (figure 4.2.D). Additionally, there were significant 
differences in both EFP mass (WT HFD+apocynin 1.45 ± 0.34 versus WT HFD 2.56 
± 0.61 grams) and in EFP/body weight ratio (WT HFD+apocynin 2.88 + 0.59 versus 
WT HFD 5.88 + 1.52%) between WT mice fed with high-fat diet with apocynin
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treatment and WT mice consuming the high-fat diet as shown in figure 4.2.C and D 
compared with the results from figure 3.2.2.
Figure 4.2 Effect of Nox2 KO and apocynin treatment on weight gain and fat deposit 
of mice under different diets
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Legend to figure 4.2
The mouse body weight was recorded weekly throughout the process of diet 
intervention for 16 weeks. At the end of week 16, mice were sacrificed and the 
epididymal fat pats (EFP) were collected and weighed.
A, Body weight growth curves (n=9-12 per group) o f Nox2 KO mice fed with NCD 
(filled circles) or HFD (filled triangles) and WT mice from HFD+apocynin group 
(empty circles). B, Body weight, C, EFP mass and D, Percentage o f EFP mass 
relative to body weight o f Nox2 KO mice (filled bars) (n=9-12 per group) fed with 
NCD or HFD and WT mice with HFD+apocynin (empty bars) after 16 weeks of diet 
intervention. Data are given as means ± standard deviation; in panel A, * P<0.05 was 
obtained by comparing HFD group with NCD group in Nox2 KO mice using two way 
ANOVA; in panel B, C, and D, *, # P<0.05 was obtained by comparing either Nox2 
KO mice from NCD group with Nox2 KO mice from HFD group or WT mice from 
HFD+apocynin group with WT mice from HFD group using unpaired Student’s r-test.
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4.2.3. Effect of Nox2 KO and apocynin treatment on fasting blood glucose,
serum insulin levels and glucose intolerance in mice under different 
diets
We next measured fasting blood glucose in each group before and after diet 
intervention. Surprisingly, despite the increase in body weight and fat mass, high-fat 
diet-fed Nox2 KG mice had similar fasting blood glucose levels compared with 
normal chow diet-fed controls (HFD 7.08 ± 1.52 versus NCD 7.28 ± 0.84 mmol/L). 
Also fasting blood glucose levels in Nox2 KG mice showed no significant changes 
before and after high-fat diet feeding. In contrast, in WT mice from high-fat diet + 
apocynin treatment group, fasting blood glucose levels were significantly elevated 
from those measured before diet intervention (After 8.56 ± 1.59 versus Before 5.66 ±
1.80 mmol/L; P<0.05) (figure 4.3.A).
We then measured fasting serum insulin levels in each group after 16 weeks of diet 
intervention. Interestingly, compared with the levels of normal chow diet-fed controls, 
the fasting serum insulin levels of Nox2 KG mice from the high-fat diet group was 
significantly increased (HFD 3.01 ± 1.00 versus NCD 0.74 ± 0.63 pg/L; P<0.05) 
while there was no significant difference between high-fat diet-fed WT mice and 
high-fat diet-fed WT mice with apocynin treatment (WT HFD 3.34 ± 1.86 versus WT 
HFD+apocynin 3.42 ± 1.05 pg/L) as shown in the figure 4.3.B with the results from
3.2.3.
The intraperitoneal glucose tolerance test was performed in Nox2 KG mice at week 
16 of diet intervention. There was no significant difference in fasting blood glucose 
levels between HFD group and NCD group before the glucose administration. 15
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minutes following intraperitoneal injection of glucose, mice on both diets 
demonstrated blood glucose levels high above pre-administration values at a similar 
rate. While blood glucose levels start to fall at the 30-minute time point in the normal 
chow diet group, the levels kept increasing further in the high-fat diet group. Elevated 
concentrations of blood glucose levels persisted in high-fat diet-fed mice in 
comparison to normal chow diet-fed controls as significant differences were identified 
at 30-, 60-, and 120-minute time points with a higher area under the glucose tolerance 
test curves showing slower glucose clearance rate (figure 4.3.C).
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Figure 4.3 Effect of Nox2 KO and apocynin treatment on fasting blood glucose,
serum insulin levels and glucose intolerance in mice under different diets
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Legend to figure 4.3
A. Fasting blood glucose levels o f male Nox2 KO mice and age-matched male WT 
mice before (empty bars) and after (filled bars) 16 weeks of diet intervention. Blood 
glucose levels were determined from 8-hours-starved mice (n=9-15 per group) using a 
blood glucose meter at the same time every day (~ 9 am). Data are given as means ± 
standard deviation; * P<0.05 was obtained by comparing HFD+apocynin group after 
diet intervention with HFD+apocynin group before diet intervention in WT mice 
using unpaired Student’s r-test.
B. Figure shows fasting serum insulin levels of Nox2 KO mice (filled bars) fed with 
NCD or HFD and WT mice from HFD+apocynin group (empty bar). Insulin levels 
were determined from 8-hour-starved mice (n=6-9 per group) using an enzyme-linked 
immunosorbent assay. Data are given as means ± standard deviation; * P<0.05 was 
obtained by comparing HFD group with NCD group in Nox2 KO mice using unpaired 
Student’s Mest.
C. Intraperitoneal glucose tolerance tests (IPGTT) for male Nox2 KO mice fed with 
the NCD (grey circles) or HFD (filled circles) after 16 weeks o f diet intervention (n=6 
per group). Overnight-fasted mice from each group received an intraperitoneal 
injection of glucose (2 grams per kg (body weight)) and blood glucose levels were 
determined at 15, 30, 60 and 120 minutes after the injection. Data are given as means 
± standard deviation; # P<0.05 was obtained by comparing HFD group with NCD 
group using two way ANOVA with Bonferroni post-tests.
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4.2.4. Effect of Nox2 KO and apocynin treatment on lipoprotein and lipid levels 
of mice under different diets
Male Nox2 KO mice fed with high-fat diet demonstrated slight but significant 
differences in a variety o f biochemical parameters of lipoprotein and lipid metabolism 
compared with age-matched controls on normal chow diet. Serum fasting total 
cholesterol levels o f Nox2 KO mice from high-fat diet group were slightly increased 
compared with those from the normal chow diet group (HFD 2.75 ± 0.92 versus NCD
1.80 ± 0.40 mmol/L; P<0.05) (figure 4.4.A). Low density lipoprotein levels in the 
high-fat diet group were increased approximately 65% versus age-matched controls 
(HFD 0.94 ± 0.32 versus NCD 0.57 ± 0.24 mmol/L; P<0.05) (figure 4.4.B). 
Interestingly, significant increases in serum high density lipoprotein levels were 
determined in Nox2 KO mice fed with high-fat diet versus normal chow diet-fed 
controls (HFD 1.59 ± 0.45 versus NCD 1.08 ± 0.17 mmol/L; P<0.05) (figure 4.4.C) 
while there were no significant differences in either triglycerides or free fatty acids 
levels in both diet groups in Nox2 KO mice (HFD 0.55 ± 0.22 versus NCD 0.39 ± 
0.10 mmol/L and HFD 0.78 ± 0.22 versus 0.66 ± 0.06 mmol/L, respectively) (figure
4.4.D, E). In addition, in WT mice from HFD+apocynin group, the levels of 
aforementioned biochemical parameters of lipid metabolism except HDL levels 
demonstrated significant decreases compared with those from high-fat diet-fed WT 
mice as shown in figure 4.4 and figure 3.4 in chapter 3 (Total cholesterol: HFD 4.35 ± 
0.63 versus HFD+apocynin 3.06 ± 0.27 mmol/L P<0.05; LDL: HFD 2.00 ± 0.51 
versus HFD+apocynin 0.96 ± 0.83 mmol/L P<0.05: HDL: HFD 1.68 ± 0.15 versus 
HFD+apocynin 2.02 ± 0.40 mmol/L; Tryglycerides: HFD 0.83 ± 0.42 versus 
HFD+apocynin 0.41 ± 0.12 mmol/L; and FFA: HFD 1.44 ± 0.54 versus 
HFD+apocynin 0.69 ±0 .16  mmol/L).
126
Figure 4.4 Effect of Nox2 KO and apocynin treatment on lipoprotein and lipid levels
of mice under different diets
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Legend to figure 4.4
Mouse blood was obtained via posterior vena of 8-hour-starved male Nox2 KO mice 
and age-matched WT mice from all diet groups after 16 weeks o f diet intervention. 
The serum was collected from these blood samples and used to determine metabolic 
parameters using an ILab 650 Chemistry Systems.
Serum (A) Total cholesterol, (B) Low density lipoprotein, (C) High density 
lipoprotein, (D) Triglycerides, and (E) Free fatty acids levels o f Nox2 KO mice (filled 
bars) ftrom the NCD or the HFD group (n=9-12 per group) and WT mice (empty bars) 
(n=9). Data are given as mean ± standard deviation; * P<0.05 was obtained by 
comparing HFD group with NCD group in Nox2 KO mice; # P<0.05 was obtained by 
comparing WT mice from HFD+apocynin group with WT mice from HFD group 
using unpaired Student’s r-test.
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4.2.5. Effect of Nox2 KO and apocynin treatment on BP of mice under different
diets
We next measured mouse BP in all groups before and after 16 weeks o f diet 
intervention. There were no differences in systolic BP levels before and after diet 
intervention in Nox2 KO mice from either normal chow diet group or high-fat diet 
group (NCD, after 120 ± 10 versus before 122 ± 6 mmHg and HFD after 127 ± 8 
versus before 120 ± 5 mmHg, respectively) (figure 4.5 A). Also, high-fat diet-fed WT 
mice with apocynin treatment exhibited no differences in systolic BP levels before 
and after diet intervention (After 119 + 6 versus before 119 + 5 mmHg) (figure 4.5 
A). Similarly, the diastolic BP levels after diet intervention in all these three groups 
followed the same pattern as the systolic BP and demonstrated no difference in 
comparison to the diastolic BP levels from the same mice before diet intervention 
(figure 4.5 B).
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Figure 4.5 Effect of Nox2 KO and apocynin treatment on blood pressure of mice
under different diets
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Blood pressure o f male Nox2 KO mice fed with the NCD or HFD and age-matched 
WT mice from HFD+apocynin group was measured by a tail cuff non-invasive blood 
pressure measurement system. The mean o f at least five successful recordings per 
mouse was taken (n=9-12 per group). Mouse systolic (A) and diastolic (B) blood 
pressure were recorded before (empty bars) and after (filled bars) diet intervention. 
Data are given as means ± standard deviation; two way ANOVA.
130
4.2.6. Effect of Nox2 KO and apocynin treatment on vascular function of mice
under different diets
Compared with normal chow diet group, aortic rings from high-fat diet fed Nox2 KO 
mice had no significant difference of vasoconstriction to phenylephrine as maximal 
tension to phenylephrine were only slightly increased (HFD 0.25 ± 0.05 versus NCD 
0.20 ±0.04 grams, P<0.05) in aortic rings of high-fat diet fed mice compared with 
chow diet fed mice.
Deficiency of Nox2 helps preserve endothelial function in aortic rings from the effect 
of a high-fat diet. Endothelium-dependent relaxation responses to acetylcholine of 
phenylephrine-precontracted aortic rings from high-fat diet-fed Nox2 KO mice were 
very similar to those from Nox2 KO mice fed with the normal chow diet (Emax HFD
79.38 ±4.01%  versus NCD 79.06 ± 7.62%) (figure 4.6.B). Endothelium-independent 
vasodilatory responses to sodium nitroprusside in aortas of Nox2 KO mice were also 
similar in both diet groups (figure 4.6.A). Furthermore, apocynin treatment to HFD- 
fed WT mice markedly improved endothelium-mediated vascular relaxation of 
phenylephrine-precontracted aortic rings in response to acetylcholine in comparison 
to the age-matched high-fat diet-fed WT mice without any treatment (Emax 
HFD+apocynin 82.08 ± 8.37% versus HFD 74.41 ± 1.74%) (figure 4.6.C).
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Figure 4.6 Effect o f Nox2 KO and apocynin treatment on vascular function of mice
under different diets
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Legend to figure 4.6
Aortic rings from male Nox2 KO mice fed with the NCD or the HFD for 16 weeks 
and male WT mice from the HFD+apocynin group were precontracted with a 
submaximal concentration o f phenylephrine and relaxed by cumulative concentrations 
of acetylcholine (1 nM to 10 pM) or sodium nitroprusside (SNP, 0.1 nM to 1 pM) in 
an organ bath.
A. Endothelium-independent relaxation curves to SNP in aortas from NCD (empty 
circles) and the HFD (filled circles) groups in Nox2 KG mice (n=9-12 per group). B. 
Endothelium-dependent relaxation curves to acetylcholine in aortas from Nox2 KG 
mice fed with NCD (empty circles) or HFD (filled circles) in Nox2 KG mice (n=9-12 
per group). C. Endothelium-dependent relaxation curves to acetylcholine in aortas 
from WT mice fed with HFD (filled circles) or HFD+apocynin (grey triangles) (n=9- 
12 per group). Data are given as mean ± standard deviation; * P<0.05 was obtained by 
comparing HFD+apocynin group with HFD group (data from chapter 3) in WT mice 
using two way ANGVA.
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4.2.7. Effect of L-NAME on vessel relaxation of Nox2 KO mice under different
diets
Inhibition o f nitric oxide synthesis by incubation of L-NAME with aortic rings for 30 
minutes dramatically abolished acetylcholine induced vasodilations in both diet 
groups in Nox2 mice (figure 4.7).
Figure 4.7 Effect of L-NAME on endothelium-dependent relaxation o f aortas from 
Nox2 KG mice
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Legend to figure 4.7
In some experiments, aortic rings from male Nox2 KO mice fed with the NCD (empty 
symbols) or the HFD (filled symbols) for 16 weeks were incubated with or without 
the NOS inhibitor L-NAME (10 pM) for 30 minutes before performing endothelium- 
dependent relaxation assessments to acetylcholine (1 nM to 10 pM) in an organ bath.
A. Endothelium-dependent relaxation curves to acetylcholine of aortic rings from 
NCD group (n=6 per group) in presence (triangles) or absence (circles) o f L-NAME.
B. Endothelium-dependent relaxation curves to acetylcholine o f aortic rings from 
HFD group (n=6 per group) in presence (triangles) or absence (circles) of L-NAME. 
Data are given as means ± standard deviation; * P<0.05 was obtained by comparing 
L-NAME group with control group from Nox2 KO mice fed with NCD or HFD using 
two way ANOVA.
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4.2.8. Effect of Nox2 KO and apocynin treatment on vascular ROS production 
of mice under different diets detected by lucigenin 
chemiluminescence
To investigate whether Nox2 is involved in vascular ROS formation, lucigenin 
chemiluminescence was applied in aortic homogenates from Nox2 knockout and 
wild-type mice (results of WT mice see chapter 3). Vascular ROS production was 
measured in aortic homogenates from male Nox2 knockout mice fed with the high-fat 
diet and age-matched controls fed with the normal chow diet and wild-type mice from 
HFD+apocynin group. In Figure 4.8.A, for the first 10 minutes basal ROS formation 
was close to the detection limit in all diet groups and the ROS production was hardly 
detected as assessed by chemiluminescence. With the addition of NADPH afterwards, 
slightly increased levels o f ROS were detected in both diet groups of Nox2 KO mice 
and there were no significant differences between these two groups while there was a 
significant increase o f ROS production observed in high-fat diet-fed WT mice with 
apocynin treatment. Quantification of NADPH-dependent ROS production shows the 
same levels in the normal chow diet group and in the high-fat diet group in Nox2 KO 
mice as shown in Figure 4.8.B while there is a significant decrease in high-fat diet-fed 
WT mice with apocynin treatment compared with WT mice fed with high-fat diet 
(WT HFD 130 + 22 versus WT HFD+apocynin 83 + 9 MLU/O.lmg protein) (data 
from 3.2.11).
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Figure 4.8 Effect o f Nox2 KO and apocynin treatment on vascular ROS production of
mice under different diets detected by lucigenin chemiluminescence
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Legend to figure 4.8
Aortic tissue from male Nox2 KO mice fed with the NCD or the HFD and age- 
matched WT mice fed with HFD with apocynin treatment for 16 weeks was 
homogenised and used for lucigenin chemiluminescence to detect ROS production.
A. Kinetic graph of ROS levels in aortic homogenates from Nox2 KO mice in NCD 
group (empty circles) and HFD group (filled circles) (n=9 per group) and WT mice 
from HFD+apocynin group (grey triangles). The ROS production was examined using 
aortic homogenates with lucigenin (5pM) solution in the absence or presence of 
NADPH at every minute for total 20 minutes. NADPH (100 pM) was added at 10 
minutes of measurement. B. The average NADPH-dependent ROS levels of aortic 
homogenates from Nox2 KO mice (filled bars) fed with NCD or HFD and WT mice 
(empty bar) fed with HFD with apocynin treatment (n=9 per group). Data are given as 
mean ± standard deviation; * P<0.05 was obtained by comparing WT mice from 
HFD+apocynin group with Nox2 KO mice from HFD group; # P<0.05 was obtained 
by comparing WT mice from HFD+apocynin group with WT mice from HFD group 
using unpaired Student’s ^-test.
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4.3. Discussion
The results reported in this part o f the study are evidence for direct involvement of 
Nox2 in mediating dietary obesity-related hyperglycaemia, dyslipidaemia, 
hypertension and endothelial dysfunction in middle-aged mice. The results also show 
that apocynin treatment attenuated the HFD-induced increases in body weight, 
metabolic parameters and blood pressure and improved the endothelium-dependent 
relaxation.
To measure ROS formation, we mainly used lucigenin chemiluminescence. Our data 
show that aortic homogenates are able to generate low levels of ROS with addition of 
NADPH in Nox2 KO mice but chemiluminescence intensity was not significantly 
different between the HFD group and the NCD group, suggesting that knockout of 
Nox2 attenuates the high-fat diet-associated oxidative stress on mouse aortas. Thus, 
Nox2 appears to be crucial for the ROS generation observed in the blood vessels in 
diet-induced obesity model, as knockout of the Nox2 gene abolished ROS generation 
in aortas of mice fed with high-fat diet.
We previously showed that high-fat diet caused a significant increase in weight gain 
as well as EFP mass in WT mice which was accompanied by hyperglycaemia, 
hyperinsulinemia, abnormal serum lipoprotein levels and blood pressure elevation. 
Our data in this part o f study show some similar profiles of Nox2 KO mice on high- 
fat diet, for instance, increased body weight gain and EFP mass, and 
dyslipoproteinemia. Interestingly, high fat diet had less effect on body weight gain in 
Nox2 KO mice compared with that in WT mice and also there was a significant 
increase in EFP/body weight ratio in WT mice while no difference was determined in
139
Nox2 KO mice which indicates that Nox2 KO mice on high-fat diet had less visceral 
fat depot than WT mice receiving food in the same style. One possible explanation for 
this phenomenon is that Nox2 KO mice consumed less energy therefore had less fat 
depot than WT mice. In fact we found that Nox2 KO mice on high-fat diet tented to 
eat less food from the first week o f diet intervention and consequently consumed the 
same energy in calories as those normal chow diet-fed controls while WT mice in the 
high-fat diet group received more energy than those from control group in the first 
week. Noticablely, oral treatment with apocynin in high-fat diet-fed WT mice 
significantly slowed down the speed o f their body weight gain and at the end of study 
they had the same body weight level as the Nox2 KO mice fed with high-fat diet 
indicating that activated Nox2 may play an important role in the balance of body 
weight gain to high-fat diet in mice although further studies are needed to investigate 
the underlying mechanisms.
Despite high-fat diet-fed WT mice having increased blood pressure, we found that 
blood pressure of Nox2 KO mice failed to elevate after high-fat diet intervention. This 
was consistent with a previous report by O. Jung et al. showing that renovascular 
hypertension was more severe in WT mice than in Nox2 KO mice (Jung et al., 2004). 
In their 2-Kidneys-1-Clip-induced hypertension model, Nox2 deficiency was capable 
of partially attenuating the experimental hypertension and endothelial dysfunction. In 
our study, hypertension was abolished in high-fat diet-fed Nox2 KO mice and 
application of apocynin in vivo attenuated the hypertensive effect of high-fat diet on 
WT mice, elucidating the importance of Nox2-derived ROS for blood pressure 
control. Considering the data obtained, the suggestion o f a role o f Nox2 in the 
development o f obesity-associated hypertension can be only speculative in this study.
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One reason might be an increased generation of angiotensin II resulted from high-fat 
diet feeding. Angiotensin II increases blood pressure via several different pathways 
including the induction and activation of Nox family in all vascular cells. The 
increased Nox-derived ROS then can scavenge endothelium-derived NO and 
subsequent impair endothelium-dependent relaxation as well as vascular remodeling 
and hypertrophy. Given that all vascular layers have the capacity to produce ROS in 
response to angiotensin II via different NADPH oxidase isoforms, why should Nox2 
be so important? One possible explanation could be the close spatial relationship 
between endothelial NO formation and Nox2 activation. Endothelial Nox2-mediated 
NO scavenging might be o f greater relevance for NO bioavailability than scavenging 
of NO in the smooth muscle cells by other isoforms of NADPH oxidase.
Using an experimental model of diet-induced obesity, we previously found that 
development of obesity-associated cardiovascular diseases accompanied with an 
increase of NADPH-dependent ROS production resulted in impaired relaxation to 
acetylcholine in WT mouse aortas. To address the possible source and functional 
relevance o f this observed increase in ROS generation, vascular reactivity studies 
were performed in Nox2 KO mice in the present study. Preserved relaxation to 
acetylcholine o f aortas from high-fat diet-fed mice was achieved by knockout of 
Nox2. This indicates that Nox2 is very likely to be the main source of ROS and more 
importantly responsible for the endothelial dysfunction in the diet-induced obesity 
model via affecting endothelial NO since vessel relaxation to exogenously applied 
NO (SNP) kept unaltered in our study. These data suggest that superoxide formed by 
an endothelial Nox2-containing NADPH oxidase mediates endothelial dysfunction in 
diet-induced obesity model. Furthermore we demonstrated that apocynin treatment
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improved acetylcholine-induced relaxation in HFD-fed WT mice, confirming this 
detrimental effect of NADPH-dependent ROS production in this model.
The dose of apocynin applied in this study (5mM) was recommended by previous 
publications (Lu et al., 2007; Stolk et al., 1994) which showed no obvious side-effects 
on liver metabolism in rodents. In our study, apocynin solution was freshly prepared 
by dissolving apocynin powder to drinking water directly without predissovlving it in 
ethanal by which could introduce potential uncontrolled factors to liver metabolism. 
No difference o f food and water intake in both HFD group and HFD+apocynin group 
indicates minimum effects on mouse appetite. More importantly, oral administering 
apocynin to HFD-fed mice significantly reduced NADPH dependent ROS in aortas 
which supports its inhibitory characteristic of Nox2.
In summary, we identified the mechanism underlying attenuated endothelium- 
dependent relaxation in a diet-induced obesity mouse model. Genetic deletion of the 
Nox2 subunit o f NADPH oxidase prevented the obesity-associated endothelial 
dysfunction and to some extent improved metabolic disorders. The lack o f Nox2 also 
prevented high-fat diet-induced hyperglycemia and the underlying mechanisms need 
to be further investigated.
142
5. Investigation of the Effects of High-Fat Diet on Metabolic 
Disorders and Endothelial Dysfunction using apoE
Knockout Mice
5.1. Introduction
In the previous chapters of this thesis, we showed that high-fat diet causes obesity and 
has adverse effects on glucose and lipids metabolism and on endothelial function in 
middle-aged C57BL/6J wild-type mice via oxidative stress. However these effects 
were significantly attenuated in wild-type mice treated with an inhibitor to Nox2 
(apocynin) or in mice deficient of Nox2. We then wanted to investgate the 
relationship of dietary obesity, metabolic disorders and endothelial dysfunction under 
the pathological conditions of CYD such as atherosclerosis. Also it is important to 
characterise an experimental model which could be used in the future to investigate 
the role Nox in atherosclerosis.
Atherosclerosis is a vascular disease characterised by the formation and development 
o f atherosclerotic lesions in the arterial wall (Patterson et al., 2001). It has been 
described that impaired vasodilating effect is observed in patients with the early stage 
of atherosclerosis (Chowienczyk et al., 1992). Moreover, studies in patients who have 
risk factors for coronary artery disease but with angiographically normal coronary 
arteries have also exhibited a vasoconstrictor response in epicardial arteries after 
acetylcholine infusion (Reddy et al., 1994). In animal studies, hypercholesterolemia, 
hypertension and diabetes which are the risk factors for atherosclerosis have been 
revealed to attenuate endothelium-dependent vessel relaxation, even in the absence of 
atherosclerotic narrowing of the vessel (Laursen et al., 2001; Williams et al., 1996).
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Therefore, endothelial dysfunction has been considered as a characteristic of the early 
stages of atherosclerotic plaque formation and implies the presence of the minimal 
structural changes in the arterial wall o f plaque lesions (Quyyumi et al., 1992). So 
evaluation of endothelial function may provide a unique approach to interfere very 
early in the process of atherogenesis in people at high risk for developing 
atherosclerosis. Currently the role of cholesterol in the development o f atherosclerosis 
is also under scrutiny. It is well known that hypercholesterolemia is a risk factor for 
the development o f atherosclerosis although the underlying mechanisms are still 
unclear (Wolfle and de Wit, 2005). Some studies have reported that high cholesterol 
levels attenuate nitric oxide-dependent relaxant responses in the cerebral circulation 
o f experimental animals (Kitayama et al., 2007; Rossitch et al., 1991), while others 
show that decreasing LDL levels may give rise to only small changes in atheroma 
volumes (Williams et al., 2008) which proposes that cholesterol may not be as 
influential in the progress of this disease as previously thought.
Previously, the experimental mouse models of atherosclerosis seemed to have a main 
drawback because of their cholesterol profile that HDL fraction dominates plasma 
cholesterol components which results in high resistance to atherosclerosis given the 
absence of atherogenic plasma lipoproteins such as LDL. (Hofker et al., 1998). A 
breakthrough came with the generation of apoE KO mice using targeted mutagenesis 
via homologous recombination in embryonic stem cells (Tangirala et al., 1995).
ApoE is a 34-kDa glycoprotein with strong heparin-binding properties. It circulates in 
blood as a crucial component of various serum lipoproteins, such as chylomicrons, 
VLDL, and HDL in mice and humans (Hofker et al., 1998). ApoE is considered as the
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essential lipoprotein determining serum lipid levels. It is also involved in the uptake 
and clearance o f these atherogenic lipoproteins (Curtiss and Boisvert, 2000). Apart 
from its role in lipoprotein metabolism, apoE tributes in other biological functions 
such as macrophage differentiation and mobilization and utilization of lipids in the 
central nervous system (Mahley, 1988). Genetic deficiency of apoE in humans has 
demonstrated increase of plasma remnant lipoproteins and development of 
atherosclerosis (Ghiselli et al., 1981). Knockout apoE in mice causes tremendously 
elevated serum cholesterol levels, and unlike other rodent models of atherosclerosis, 
apoE KO mice spontaneously and prematurely develop atherosclerotic lesions in the 
aorta and arterial branches (Breslow, 1996; Curtiss and Boisvert, 2000; Osada et al., 
2000). The hypercholesterolemia and atherosclerosis in these mice are diet responsive 
as they are augmented by feeding a Western-type high-fat diet (d'Uscio et al., 2001). 
The histopathology o f lesions in this animal model progress with age from early fatty 
streaks to complex fibrous lesions with necrotic cores showing similar features to 
those observed in humans (d'Uscio et al., 2001). Due to the above described 
properties, apoE knockout mice are excellent model for evaluating the impact of 
dietary factors on the pathogenesis and progression of atherosclerosis.
Recent reviews point out that ROS plays an important role in atherosclerotic lesion 
development, even though the underlying mechanisms are not yet totally understood 
(Li and Shah, 2004). It is becoming increasingly clear that oxidative stress due to 
elevated vascular ROS production contribute to the pathogenesis o f atherosclerosis 
(Baynes, 1991) based on strong evidence that oxidation of LDL is a key factor 
required for the initiation of atherosclerosis. Moreover, overproduction o f ROS is 
proposed to be an early triggering mechanism for atherosclerosis by activation of
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proinflammatory signalling cascades and breakdown o f vasoprotective nitric oxide. 
Recently studies showed, in hypercholesterolemia, increased ROS production by 
vascular Nox may play a key role in compromised nitric oxide function and promote 
the development of atherosclerosis (Kitayama et al., 2007). However, clinical trials 
evaluating the effects o f antioxidants/ROS scavengers on the progression of 
atherosclerosis have been devastatingly disappointing (Bleys et al., 2006). Thus the 
identification of the sources o f ROS in atherogenesis may pave the way for other 
therapies that combat vascular oxidative stress by abolishing ROS production from 
the outset.
Recently convincing evidence for involvement of NADPH oxidase in the atherogenic 
lesion progression is accumulatively reported. Barry-Lane et al. provided evidence 
that p47P^°^ is required for SMC proliferation in apoE KO mouse aorta, an important 
event in the atherosclerotic lesion formation (Barry-Lane et al., 2001). Others used 
p47phox/apoE double KO mice demonstrating that p47 contributes to atherogenesis 
mainly in the descending aorta while has little effect on lesion development in the 
aortic sinus of apoE KO mice (Hsich et al., 2000; Vendrov et al., 2007). These studies 
established a cause and effect relationship between NADPH oxidase and the 
development of atherosclerosis. Furthermore, the specific roles o f the Nox2 in the 
development o f atherosclerosis was investigated by using Nox2/apoE double KO 
mice (Judkins et al., 2009). The results indicate that Nox2 activity is elevated in aortic 
endothelial cells well as in macrophages very early in the atherogenic progress, even 
before the appearance of atherosclerotic lesions. More importantly, deletion of Nox2 
reduced atherosclerotic plaque formation up to 50% along the whole length o f the 
aorta while had least influence on serum lipid profiles in apoE KO mice.
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Although the underlying mechanisms of pathogenesis of atherosclerosis has been 
intensively investigated, little is known from the literature that the link among dietary 
obesity, metabolic disorders and endothelial dysfunction under this pathological 
condition. Given the incidence o f atherosclerosis is accelerated increasing worldwide, 
a detailed understanding of the relationship of dietary obesity, metabolic disorders and 
endothelial dysfunction in the onset and progression of atherosclerosis, especially in 
the early stages o f lesion growth, is critical to our ability to detect and manage this 
cardiovascular disease.
In this chapter of my thesis, we aimed to elucidate the detailed relationship between 
high fat diet and onset of atherosclerosis and investigate the diet-induced metabolic 
disorders and vascular dysfunction in the early stage of atherosclerosis in a mouse 
model. To do so, 16 male apoE knockout mice at age of 6 weeks were split into two 
groups, feeding with the high-fat diet or the normal chow diet (rodent diet information 
details see appendix table 2.17 in Chapter 2) for 10 weeks. Mouse blood pressure and 
some metabolic parameters were measured during the study with vessel functions 
examined in the end. In addition, serum lipid levels and vessel functions o f another 6 
apoE knockout mice (littermates of above mice) at age o f 6 weeks (all fed with 
normal chow diet) were examined as controls at the correspondent time point.
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5.2. Results
5.2.1. Differences in food and energy intake of apoE KO mice with different
diets
Colonies of wild-type and apoE KG mice on C57BL/6 background were purchased 
from Charles River (Margate, England) and bred in our animal unit. Mice were 
genotyped and only male mice were used for the study. At the age of 6 weeks, the 
mice were divided into two groups and received continuous feeding o f either the high- 
fat diet (#824053; Special Diets Services, UK) or the normal chow diet (5LF5; 
LabDiet Ltd., UK) for 10 weeks.
By the end o f the first week of the dietary intervention, there was no significant 
difference in food intake between the normal chow diet group and the high-fat diet 
group in apoE KO mice (HFD 3.87 ± 0.34 versus NCD 3.41 ± 0.50 g/day) (figure 5.1 
A). Meanwhile, mice fed with the high-fat diet consumed more energy in calories 
than mice provided with the normal chow diet (HFD 15.49 ± 2.29 versus NCD 12.83 
±1.13 Kcal/day; P<0.05) (figure 5.1 B) However, apoE KO mice fed with the high- 
fat diet compensated for the higher-calorie content o f the food by decreasing their 
daily food intake later during the dietary intervention. There was a significant 
decrease in food intake in high-fat diet group in week 10 compared with normal chow 
diet group (HFD 2.90 ± 0.57 versus NCD 3.86 ± 0.61 g/day; P<0.05) (figure 5.1 C) 
and the caloric intake between these two diet groups was similar at the same period of 
time (HFD 13.15 ± 2.60 versus NCD 12.80 ± 2.01 Kcal/day).
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Figure 5.1 Differences in food/energy intake of apoE KO mice with different diets
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Legend to figure 5.1:
Male apoE KO mice at the age o f 6 weeks were randomly divided into two diet 
groups and fed with normal chow diet (NCD) or high-fat diet (HFD) for 10 weeks. 
The consumption o f food was measured using a balance at 6 pm before the dark cycle 
every day for the whole week in the first and the last week of study.
Food intake o f apoE KO mice from the NCD group (empty bars) and the HFD group 
(filled bars) were recorded as the amount of food consumed per mouse per day at 
week 1 (A) and week 10 (C) of diet intervention (n=8-10 per group). The caloric 
energy consumption o f each group at week 1 (B) and week 10 (D) was calculated by 
multiplying the amount o f consumed food with the calories contained in each gram of 
food. Data are given as means ± standard deviation; * P<0.05 was obtained by 
comparing the HFD group with the NCD group using unpaired Student’s r-test.
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5.2.2. Effect of high-fat diet on weight gain and fat deposit of apoE KO mice
We measured body weight every week for the 10-week study period. As illustrated in 
figure 5.2 A, exposure to the high-fat diet was accompanied by progressive 
overweight in male apoE KG mice compared with age-matched controls fed with the 
normal chow diet from the second week and throughout the rest o f study (figure 5.2 
A). At end of the study (week 10), mice eating the high-fat diet were approximately 
10% heavier than their age-matched controls on the normal chow diet (HFD 31.3 ± 
1.14 versus NCD 27.9 ± 1.50 g; P<0.05) (figure 5.2 B).
Moreover, epididymal fat weight between the two diet groups was remarkably 
different. Parallel to the increases in body weight, mice consuming the high-fat diet 
had a 2.3-fold greater epididymal fat pat mass compared with mice fed with the 
normal chow diet (HFD 0.75 ± 0.28 versus NCD 0.32 ± 0.09 g; P<0.05) (figure 5.2 
C). Due to the excessive increase in epididymal fat pat mass in HFD-fed apoE KG 
mice, the epididymal fat pat weight adjusted for body weight (EFP/BW ratio) had 
approximate 2.2-fold increases in mice fed with high-fat diet compared with mice fed 
with normal chow diet (HFD 2.67 ± 0.91 versus NCD 1.19 ± 0.34 %; P<0.05) (figure 
5.2 D).
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Figure 5.2 Effect o f high-fat diet on weight gain and fat deposit o f apoE KO mice
with different diets
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Legend to figure 5.2
The mouse body weight was recorded weekly throughout the process of diet 
intervention for 10 weeks. At the end of week 10, mice were sacrificed and the 
epididymal fat pat (EFP) were collected and weighed.
A, Body weight growth curves (n=7 per group) o f apoE KO mice fed with the NCD 
(empty circles) or the HFD (filled circles) for 10 weeks. B, Body weight, C, EFP 
mass and D, Percentage of EFP mass relative to body weight of apoE KO mice (n=7 
per group) fed with NCD (empty bars) or HFD (empty bars) after 10 weeks of diet 
intervention. Data are given as means ± standard deviation; in panel A, * P<0.05 was 
obtained by comparing HFD group with NCD group in apoE KO mice using two way 
ANOVA; in panel B, C, and D, * P<0.05 was obtained by comparing HFD group with 
NCD group in apoE KO mice using unpaired Student’s /-test.
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5.2.3. Effect of high-fat diet on fasting blood glucose, serum insulin levels and
glucose intolerance in male apoE KO mice
We then measured mouse fasting blood glucose before and after dietary intervention 
in each group. There were no differences in mice fed with the normal chow diet 
before and after the diet intervention (before 5.60 ± 0.77 versus after 6.23 ± 1.01 
mmol/L). In contrast, diet-induced obesity in apoE mice was accompanied by fasting 
hyperglycaemia. In mice fed with high-fat diet, fasting blood glucose levels were 
significantly elevated from those measured before diet intervention (before 6.21 ± 
0.68 versus 8.88.03 ± 0.53 mmol/L; P<0.05). (Figure 5.3 A).
Diet-induced hyperglycaemia in apoE KO mice was accompanied by elevations in 
serum insulin levels at 10 weeks of high-fat diet intervention. Compared with the 
levels of normal chow diet-fed mice, the fasting serum insulin levels from high-fat 
diet group had a 2.3-fold increase (HFD 1.66 ± 0.57 versus NCD 0.72 ± 0.57 pg/L; 
P<0.05) while there was no difference between 6 weeks old mice and 16 weeks old 
mice both fed normal chow diet as shown in figure 5.3 B. Also after 10 weeks of 
high-fat diet feeding, apoE KO mice developed impaired glucose tolerance. After 15 
minutes o f intraperitoneal injection of glucose, mice on both diets exhibited blood 
glucose levels high above pre-administration values. As it started to decrease in 
normal chow diet group at the 30-minute time point, the blood glucose level kept 
increasing further in high-fat diet group and reached its peak. Elevated concentrations 
of blood glucose levels persisted in the high-fat diet-fed mice in comparison to the 
normal chow diet-fed controls as significant differences were identified at 15-, 30-, 
60-, and 120-minute time points with a higher area under the glucose tolerance test 
curves showing a decreased glucose clearance rate (figure 5.3 C).
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Figure 5.3 Effect o f high-fat diet on fasting blood glucose, serum insulin levels and
glucose intolerance in male apoE KO mice
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Legend to figure 5.3
A. Fasting blood glucose levels of male apoE KO mice before (empty bars) and after 
(filled bars) 10 weeks o f diet intervention. Blood glucose levels were determined from 
8-bour-starved mice (n=7 per group) using a blood glucose meter at tbe same time of 
day (~ 9 am). Data are given as means ± standard deviation; * P<0.05 was obtained 
by comparing HFD group after diet intervention with HFD group before diet 
intervention; # P<0.05 was obtained by comparing HFD group with NCD group after 
diet intervention using two way ANOVA with Bonferroni post-tests.
B. Fasting serum insulin levels o f apoE KO mice fed with NCD (empty bars) or HFD 
(filled bars). Insulin levels were determined from 8-bour-starved mice (n=7 per group) 
using an enzyme-linked immunosorbent assay. Data are given as means ± standard 
deviation; # P<0.05 was obtained by comparing tbe HFD group witb tbe NCD group 
in apoE KO mice using unpaired Student’s ^-test.
C. Intraperitoneal glucose tolerance tests (IPGTT) for male apoE KO mice fed witb 
tbe NCD (empty circles) or HFD (filled circles) after 10 weeks of diet intervention 
(n=6 per group). Ovemigbt-fasted mice from eacb group received an intraperitoneal 
injection of glucose (2 grams per kg (body weight)) and blood glucose levels were 
determined at 15, 30, 60 and 120 minutes after tbe injection. Data are given as means 
± standard deviation; # P<0.05 was obtained by comparing HFD group witb NCD 
group using unpaired Student’s ^-test at eacb time point respectively.
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5.2.4. Effect of high-fat diet on lipoprotein and lipid levels of apoE KO mice
Total cholesterol levels were substantially higher in apoE KG mice than in WT mice 
both fed with normal chow diet (Cholesterol levels of WT mice see Chapter 3). 
Meanwhile 10 weeks o f high-fat diet feeding did not change total cholesterol levels 
further in apoE KO mice compared with mice fed normal chow diet (HFD 12.01 ± 
2.92 versus NCD 9.66 ± 2.70 mmol/L; P>0.05) (Figure 5.4 A) although there was a 
slight but non-significant increase in total cholesterol levels in high-fat diet group 
mainly resulted from marked increases in levels of circulating LDL cholesterol as 
showed in figure 5.4 B (HFD 10.61 ± 1.58 versus NCD 8.05 ± 2.17 mmol/L; P<0.05). 
There were no differences in serum HDL levels between these two diet groups in 
apoE KO mice (HFD 1.40 ± 0.37 versus NCD 1.18 ± 0.30 mmol/L; P>0.05) (Figure 
5.4 C). Serum triglyceride levels were unaltered in high-fat diet-fed apoE KO mice 
compared with those from normal chow diet group (HFD 1.32 ± 0.50 versus NCD
1.38 ± 0.54 mmol/L; P>0.05).
On the other hand, there were slight but non-significant increases in total cholesterol, 
LDL and HDL levels in apoE KO mice at age of 16 weeks in comparison to apoE KO 
mice at age of 6 weeks both fed with normal chow diet. Serum triglyceride levels 
were similar in these two different age groups.
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Figure 5.4 Effect of high-fat diet on lipoprotein and lipid levels of apoE KO mice
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Legend to figure 5.4
Mouse blood was obtained via posterior vena of 8-hour-starved male apoE KO mice 
at 6 weeks o f age and from both diet groups after 10 weeks of diet intervention. The 
serum was collected from these blood samples and used to determine metabolic 
parameters using an ILab 650 Chemistry Systems.
Serum (A) Total cholesterol, (B) Low density lipoprotein, (C) High density 
lipoprotein, and (D) Triglycerides levels of apoE KO mice from the NCD group 
(empty bars) or the HFD group (filled bars) (n=7 per group). Data are given as mean 
± standard deviation; * P<0.05 was obtained by comparing the 6 weeks old mice with 
the 16 weeks old mice both fed with normal chow diet; # P<0.05 was obtained by 
comparing HFD group with NCD group after diet intervention; using unpaired 
Student’s r-test.
159
5.2.5. Effect of HFD on blood pressure of male apoE KO mice
We measured mouse BP in both diet groups of apoE KG mice before and after 10 
weeks of the dietary intervention. There were no differences in either systolic BP or 
diastolic BP before and after the diet intervention in the normal chow diet group 
(before 115 ± 7 versus after 114 ± 4 mmHg and before 92 ± 6 versus after 92 ± 6 
mmHg, respectively) (Figure 5.5 A and B). In contrast, the high-fat diet-fed mice 
exhibited significantly elevated systolic BP after 10 weeks of dietary intervention in 
comparison to the levels before diet intervention in the same mice (after 130 ± 7 
versus before 113 ± 5 mmHg; P<0.05) (Figure 5.5 A). Similarly, the high-fat diet-fed 
mice had significantly higher diastolic BP as compared with the same mice before 
diet intervention (after 107 ± 9 versus before 92 ± 6 mmHg; P<0.05) (Figure 5.5 B).
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Figure 5.5 Effect of HFD on blood pressure of male apoE KO mice
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Blood pressure of male apoE KO mice fed with the NCD or HFD was measured by a 
tail cuff non-invasive blood pressure measurement system. The mean o f at least five 
successful recordings per mouse was taken (n=7 per group). Mouse systolic (A) and 
diastolic (B) blood pressure were recorded before (empty bars) and after (filled bars) 
diet intervention. Data are given as means ± standard deviation; * P<0.05 was 
obtained by comparing HFD after diet intervention with HFD before diet intervention; 
# P<0.05 was obtained by comparing the HFD group with the NCD group using a two 
way ANOVA with Bonferroni post-tests.
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5.2.6. Effect of HFD on endothelial-dependent relaxation in aortas from apoE
KO mice
Aortic rings from high-fat diet fed apoE KG mice had significant increase of 
vasoconstriction to phenylephrine as maximal tension to phenylephrine were 
significantly increased (HFD 0.29 ± 0.04 versus NCD 0.22 ±0.04 grams, P<0.05) in 
aortic rings o f high-fat diet fed mice compared with chow diet fed mice.
The high-fat diet promoted endothelial dysfunction in aortic rings from the male apoE 
KG mice. In the high-fat diet group, endothelium-dependent relaxation responses to 
acetylcholine of phenylephrine-precontracted aortic rings were markedly impaired 
compared with age-matched controls fed with the normal chow diet (figure 5.6 A). 
The maximal endothelium-mediated relaxation of the phenylephrine-precontracted 
rings in response to acetylcholine declined by 17.5% for mice fed with the high-fat 
diet in comparison to mice fed with the normal chow diet (HFD 68.68 ± 10.73% 
versus 82.25 ± 5.52%; P<0.05). While in high-fat diet group, preincubation of tiron, a 
RGS scavenger, partly preserved the endothelium-dependent vessel relaxation 
responses as shown in figure 5.6 B.
Meantime, there were no differences in endothelium-dependent relaxation responses 
to acetylcholine between 16 weeks old apoE KG mice and 6 weeks old apoE KG mice 
both fed with the normal chow diet as shown in figure 5.6 C.
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Figure 5.6 Effect o f HFD on endothelial-dependent relaxation in aortas from apoE
KO mice
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Legend to figure 5.6
Aortic rings from male apoE KO mice fed with the NCD or the HFD for 10 weeks 
were precontracted with a submaximal concentration of phenylephrine and relaxed by 
cumulative concentrations o f acetylcholine (1 nM to 10 pM) in an organ bath. In 
some experiments, aortic rings were incubated with or without ROS scavenger tiron 
(10 mM) for 15 minutes before performing endothelium-dependent relaxation 
assessments.
A. Endothelium-dependent relaxation curves to acetylcholine in aortas from NCD 
(empty circles) and the HFD (filled circles) groups (n=7 per group) in apoE KO mice.
B. Endothelium-dependent relaxation curves to acetylcholine in aortic rings from 
high-fat diet fed apoE KO mice (n=7 per group) in the presence (triangles) or absence 
(circles) of tiron. C. Endothelium-dependent relaxation curves to acetylcholine in 
aortas from 6 weeks old (empty triangles) or 16weeks old (empty circles) apoE KO 
mice fed with NCD (n=7 per group). Data are given as means ± standard deviation; * 
P<0.05 was obtained by comparing HFD group with NCD group using two way 
ANOVA; # P<0.05 was obtained by comparing HFD + tiron group with HFD + 
vehicle group using using two way ANOVA.
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5.2.7. Effect of HFD on endothelial-independent vessel relaxation in aortas from
apoE KO mice
We then examined the endothelium-independent vasodilatroy responses to sodium 
nitroprusside in aorta rings jfrom all groups of apoE KG mice. As shown in figure 5.7 
A, the endothelium-independent relaxation responses were unaltered in high-fat diet 
group compared with normal chow diet group. And there were no differences between 
16 weeks old mice and 6 weeks old mice in endothelium-independent vasodilatory 
responses to sodium nitroprusside either (figure 5.7 B).
Figure 5.7 Effect of HFD on endothelial-independent vessel relaxation in aortas from 
apoE KG mice
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Legend to figure 5.7
Aortic rings from male apoE KO mice fed with the NCD or the HFD for 10 weeks 
were precontracted with a submaximal concentration o f phenylephrine and relaxed by 
cumulative concentrations of sodium nitroprusside (SNP, 0.1 nM to 1 pM) in an 
organ bath.
A. Endothelium-independent relaxation curves to SNP in aortas from apoE KG mice 
fed with NCD (empty circles) or HFD (filled circles) (n=7 per group). B. 
Endothelium-independent relaxation curves to SNP in aortas from 6 weeks old 
(triangles) and 16 weeks old (circles) apoE KG mice fed with NCD (n=7 per group). 
Data are given as means ± standard deviation; two way ANGVA.
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5.3. Discussion
The results from this part of study detailed elucidated the effects o f high-fat feeding 
on a mouse model of atherosclerosis. The dietary fat promoted obesity, 
hyperglycaemia, hyperinsulinemia, type 2 diabetes-like insulin resistance and 
accelerated the accumulation o f low density lipoprotein in male apoE KO mice. The 
results also show that dietary obesity attenuated the endothelium-dependent relaxation 
responses o f aortas accompanied with higher blood pressure in the early stage of 
atherosclerosis of apoE KO mice.
ApoE KO mice have premature and severely-elevated lipoprotein profiles which 
cause extreme vulnerability to atherosclerosis. On a normal chow diet, foamy cell 
lesions will develop in about 10 weeks with complex lesions appear as early as 16 
weeks while large calcific deposits are detectable in older mice (10 months) (Plump et 
al., 1992; Reddick et al., 1994). Accordingly, the starting and ending point in present 
study were chosen because 6 weeks of age represented a time point at which 
atherosclerotic plaque burden along the aorta was still insignificant thus allowing us 
to determine whether 10 weeks o f high-fat containing dietary intervention was evident 
from early in the disease procession while the atherosclerotic lesion was detectable on 
16 weeks of age at the end of study.
Some researchers have found both more and less intense overweight in different 
studies of high-fat diet in apoE KO mice (Ebara et al., 1997; Reckless et al., 1997) 
while others showed that a high-fat diet induced insulin resistance in apoE KO mice 
without significant weight gain (Cefalu et al., 2004). In our study apoE KO mice 
responded acutely with 45% Kcal of dietary fat as obtained 2.3-fold more EFP mass
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with extra 10% of body weight compared with mice fed normal chow diet for 10 
weeks. Our results clearly show that mice lacking apoE ligand is sensitive to dietary 
manipulations.
Although high-fat diet is considered to be one of the risk factors for cardiovascular 
diseases, it is not fully understood whether a high-fat component in diet has an effect 
on lipid metabolism and on atherosclerotic lesion development in apoE KO mice. In 
the present study, elimination of apoE gene resulted in significant increases in serum 
total cholesterol, LDL and HDL levels. Under the condition of HFD consumption, the 
total cholesterol levels of apoE KO mice kept high while low density lipoprotein 
levels markedly elevated further which indicating an even higher risk of incidence of 
atherosclerosis. These results are in agreement with previous studies (Calleja et al., 
1999; Kitayama et al., 2007).
Acetylcholine causes vasodilation by the release of endothelium-derived nitric oxide 
when the endothelium is intact (Wolfle and de Wit, 2005) and conversely causes 
vasoconstriction in angiographically atherosclerotic vessels (Reddy et al., 1994), 
suggesting that clinically evident atherosclerosis results in endothelial dysfunction. 
Therefore, in present study, we investigate the effect o f dietary fat on the onset o f 
early stage o f atherosclerosis via examining endothelium-dependent relaxation 
responses in the aorta o f hypercholesterolemic apoE KO mice. We found impaired 
acetylcholine-induced vessel relaxation of aortas occurred in high-fat diet-fed apoE 
KO mice and it could partly be restored to normal when applied in the presence of 
tiron. This acute improvement of endothelial function in high-fat diet fed-apoE KO 
mice by tiron incubation proposes a role for the ROS in promoting early stage of
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atherosclerosis. Although epidemiologic studies in humans and in vitro experimental 
research have suggested ROS generation plays an important role in the development 
o f atherosclerosis, the data from in vivo studies are still missing to support the 
hypothesis that ROS in general, and specifically NADPH oxidase, is required for the 
atherogenic phenotype. Our present findings provide evidence that high-fat diet 
increases the extent of early stage of atherosclerosis via endothelial dysfunction in 
apoE KO mice while further investigation need to be done to elucidate the role of 
aortic ROS production under this circumstance.
In summary, in chapter 5 we found that apoE KO mice showed increased 
susceptibility to diet-induced metabolic disorders such as obesity, hyperglycaemia, 
hyperinsulinemia, and type 2 diabetes-like insulin resistance and promotes endothelial 
dysfunction and high blood pressure. The results provide further insights in the 
relationship among dietary obesity, metabolic disorders and endothelial dysfunction in 
apoE KO mice. Based on these results, it allows a wide variety of targets to be tested 
for their potential involvement in atherogenesis in this animal model.
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6. General Discussion and Future Work
6.1. General discussion
The incidence o f obesity is rapidly increasing globally (Parikh et ah, 2007) and the 
epidemic of obesity and its cardiovascular complications is one of the main causes of 
morbidity and mortality in modem societies (AmericanDiabetesAssociation, 2008; 
Petersen, 2003). It becomes one of the most essential health problems which have 
already been caught attention in the last decades. Clinical observations show that 
obesity associated with Western style high-fat diet together with genetic 
predisposition induces metabolic disorders and endothelial dysfunction (Traupe et al., 
2002a). The ultimate outcome is the incidence of cardiac occlusion or atherosclerosis 
which is a major contributor to cardiovascular related mortality (Bugiardini et al., 
2004). Although studies have been done extensively in this field, the underlying 
mechanisms are still not fully understood (Hagiwara et al., 2009; Parekh et al., 1998). 
Recently, an increased oxidative stress caused by accumulated fat and 
hyperglycaemia has been determined to be one of major pathological changes in 
obesity-associated clinical complications (Berry et al., 2001; Roberts et al., 2006; 
Urakawa et al., 2003). For instance, there is considerable evidence that 
hyperglycaemia gives rise to the generation of ROS via multiple pathways (Cai and 
Harrison, 2000a) and oxidative stress caused by hyperglycaemia leads to dismption of 
nitric oxide synthase dimers, inactivated NO bioavailability and impaired endothelium 
dependent vasodilatation in patients with obesity and type 2 diabetes (Steinberg et al., 
1996).
In the vasculature, generation of ROS is necessary in maintaining cardiovascular 
homeostasis while excessive ROS generation (oxidative stress) results in endothelial
170
dysfunction and is closely linked to various cardiovascular diseases such as 
hypertension, atherosclerosis and diabetes (Bauersachs and Schafer, 2004; Cai and 
Harrison, 2000b; MacCarthy et ah, 2001b; Potenza et ah, 2009; Victor et ah, 2009). 
Several sources o f ROS generation in the vasculature have been discovered, including 
mitochondria (Therade-Matharan et al., 2005), xanthine oxidase (Meneshian and 
Bulkley, 2002), uncoupled NO synthases (Vasquez-Vivar et al., 1998a), cytochrome 
p450 (Fleming, 2001) and NADPH oxidase. Among them, accumulating evidences 
have shown that NADPH oxidase, the only known enzyme family solely dedicated to 
ROS production, is the major source in the vasculature (Babior, 2000; Griendling et 
al., 2000; Ray and Shah, 2005; Rueckschloss et al., 2003).
There are 3 Nox isoforms of NADPH oxidase (Noxl, Nox2 and Nox4) found in 
rodent vasculature with distinct distribution in different styles of vascular cells and 
play critical functions (Bedard and Krause, 2007b; Kawahara et al., 2007; Nauseef, 
2008). Nox2 is mainly expressed in endothelial cells (Li et al., 2007) with low levels 
under physiological condition but is upregulated in cardiovascular risk settings 
including hypertension, diabetes, and hyperlipidemia. In addition, high levels of Nox2 
are also expressed in immune cells such as monocytes, macrophages and lymphocytes 
which may also take up residence in the vessel wall under pathophysiological 
conditions. It is now knovm that excessive ROS production from activated Nox2 in 
the vasculature outstrips endogenous antioxidant defense and causes endothelial 
dysfunction which is involved in the pathogenesis o f cardiovascular diseases such as 
atherosclerosis and hypertension (Fan et al., 2009b; Li et al., 2002c). However, it still 
remains unclear whether or not Nox2 is involved in the dietary obesity related 
metabolic disorders and endothelial dysfunction. Furthermore, definitive evidence for
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a functional role o f Nox2 in diet-induced obesity with its cardiovascular 
complications is lacking. Thus, in this Ph.D project, we have used diet-induced 
obesity model in WT mice and gene modified mice with Nox2 deficiency and a 
specific inhibitor for this enzyme, apocynin, to identify a direct link between Nox2, 
metabolic disorders and endothelial dysfunction in middle-aged obese mice; also we 
have undertaken the investigation o f the effects of high-fat diet-induced obesity on 
metabolic disorders and vascular function in apoE KO mice, a well-known mouse 
model for atherosclerosis. We characterised an experimental model in which the role 
of ROS/Nox2 could be further investigated in high-fat diet induced metabolic 
disorders and endothelial dysfunction in the development of atherosclerosis.
In obesity, increased ROS generation from accumulated fat leads to an increase in 
oxidative stress which links with dysregulation of lipids and vascular dysfunction, 
(Carmiel-Haggai et al., 2005; Furukawa et al., 2004). Other study showed that 
hyperglycaemia leads to oxidative stress in various tissues including cardiovascular 
system ((Roesen et al., 2001). My Ph.D research provides further evidence that a 
significant increased ROS production occurs in aortas of diet-induced obese WT mice 
and associates with hyperglycaemia, insulin resistance and endothelial dysfunction. 
Treatment with apocynin in these mice significantly reduced the levels o f vascular 
ROS with attenuated metabolic parameters and preserved endothelial function which 
is in similar levels as those observed in Nox2 KO mice fed with high-fat diet. ROS 
measurement by lucigenin chemiluminescence has come under scrutiny because 
lucigenin itself increases formation of ROS in certain conditions (Liochev and 
Fridovich, 1997). We therefore performed experiments using low concentrations of 
lucigenin (5 pmol/L), which have been previously shown not to produce additional
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ROS (Li and Shah, 2001). Measurements were also made using DHE fluorescence 
detection on aortic sections, recently shown to detect ROS with a high sensitivity and 
specificity. Both approaches demonstrated same results which are in line with 
previous study showing that increased vascular levels of ROS accompany with 
hypertension in obese WT mice which leads to reduced bioavailability of NO, 
resulting in a loss o f its vasoprotective effects and endothelial dysfunction (Cai and 
Harrison, 2000a).
Metabolic syndrome is strongly associated with obesity which is characterised by 
impaired glucose homeostasis, dyslipidaemia, hypertension, and insulin resistance 
(Lorenzo et al., 2007). It is well established that impaired insulin signalling in the 
vasculature is associated with obesity and endothelial dysfunction. Recently it has 
been proved that the endothelial cell is a target o f insulin and insulin resistance can 
therefore exist at the level of endothelium (Symons et al., 2009). However, the 
specific pathway o f vascular insulin resistance to the pathogenesis of endothelial 
dysfunction has not been well elucidated. Furthermore, the relative importance o f the 
other components of the metabolic syndrome in the determination of endothelial 
function is unknown. Here we proved detailed biochemical measurements of glucose 
and insulin levels and lipids metabolism and compared these data with in vivo and ex 
vivo assays of vascular function in mice with 3 different genotypes under high-fat diet 
intervention. Our results demonstrated that high cholesterol levels, especially high 
LDL levels with high triglycerides levels in serum are associated with endothelial 
dysfunction and elevated blood pressure whereas deletion or inhibition of Nox2 
reverses these biochemical parameters and preserves vascular functions. Although the 
serum cholesterol levels are already extremely high in normal chow diet-fed apoE KG
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mice, high-fat diet significantly increases the LDL levels further which are associated 
with accelerated endothelial dysfunction in apoE KO mice. Results from WT and 
Nox2 KO mice studies clearly showed the protective effects of Nox2 deficiency 
against metabolic disorders, suggesting a critical role of Nox2 in the development of 
these complications o f diet-induced obesity.
In my Ph.D project, I have shown that high-fat diet significantly impaired aortic 
relaxation responses to acetylcholine via an effect that was mediated by high levels of 
ROS. Indeed, the ROS scavenger tiron selectively enhanced the endothelium- 
dependent relaxation o f aortic rings from high-fat diet-fed WT mice, so that there was 
no longer a difference in the ACh-induced relaxation from these 2 diet groups in WT 
mice. Furthermore, application of apocynin, an inhibitor of Nox2, to high-fat diet-fed 
WT mice in vivo improved relaxation to a similar extent in the control group with a 
reduction of aortic ROS formation. Additionally, in Nox2 KO mice, the ACh-induced 
relaxation responses of aortic rings from the Nox2 KO mice were unaltered after 
high-fat diet intervention showing that the reduced scavenging of endothelial NO by 
ROS in the aortas from Nox2 KO mice could account for the enhanced relaxation. At 
last, using an experimental model of atherosclerosis, we showed that dietary obesity 
attenuated the endothelium-dependent relaxation responses o f aortas in the early stage 
of atherosclerosis in apoE KO mice. This endothelial dysfunction could partly be 
restored to normal by incubation of tiron which implies a role for the ROS in 
promoting early stage of atherosclerosis. Of importance, we propose that development 
of endothelial dysfunction required a concomitant presence o f Nox2 and increase of 
ROS production.
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Endothelial dysfunction associated with elevated blood pressure. This is clearly 
shown in my thesis that the difference in BP between WT and KO mice both fed with 
high-fat diet was attributable to Nox2 and Nox2-associated ROS generation per se in 
that treatment with apocyinin, a Nox2 inhibitor, attenuated the elevation of BP in diet- 
induced obese WT mice. Our results are compatible with increased NADPH oxidase 
activity in aging-related hypertension (Hamilton et al., 2001) and extend previous 
work showing that Nox2 and vascular NADPH oxidase-derived ROS overproduction 
are crucial in the development of hypertension (Fujii et al., 2006). We propose that 
Nox2 plays an important role in the pathogenic mechanism in hypertension related 
with dietary obesity and the targeting of Nox2 is a promising therapeutic approach for 
controlling blood pressure of dietary obese objects.
6.2. Conclusions
In summary, the studies in this thesis have provided valuable evidence for the roles of 
Nox2 and oxidative stress on metabolic disorders and endothelial dysfunction in diet- 
induced obesity. Activated Nox2 and induced oxidative stress by diet-induced obesity 
contribute to impaired lipids metabolism, endothelial dysfunction. Deletion or 
inhibition o f Nox2 attenuates these detrimental pathological progresses. Therefore, 
Nox2 may be a pharmacological target to counteract oxidative stress and retard the 
development of cardiovascular complications caused by diet-induced obesity. Finally, 
these studies have prompted new questions concerning the role o f ROS and Nox2 in 
atherosclerosis which remain to be answered.
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6.3. Limitations of the study and future work
The present studies in this thesis have certain limitations that need to be taken into 
account when considering the results and their contributions. However, some of these 
limitations can be seen as fruitful avenues for future research under the same theme.
As a main approach o f measuring ROS production in this thesis, lucigenin 
chemiluminescence has come under scrutiny because lucigenin itself increases 
formation of ROS in certain conditions (Liochev and Fridovich, 1997). We therefore 
also applied DHE fluorescence detection to estimate the ROS levels on aortic 
sections, recently shown to detect ROS with a high sensitivity and specificity(Li et al., 
2005b). However, in both of these appoaches of measurement, the role of superoxide 
could not be specified from other formations of ROS production such as hydrogen 
peroxide which may have different function in vascular system under pathological 
conditions (Anilkumar et al., 2008). Therefore, new approach o f ROS measurement 
should be considered in the future research.
Apocynin is an effective inhibitor of phagocyte Nox2-containing NADPH oxidase 
that has also been described to inhibit ROS production in endothelial cells (Meyer et 
al., 1999) although it is still unclear how apocynin is activated in endothelial cells. On 
the other hand, there is evidence proved that apocynin stimulates ROS production in 
non-phagocytic cells (Vejrazka et al., 2005).Thus data obtained with apocynin have to 
be taken with caution. For instance, Rey et al have been unable to show the inhibitory 
effects of apocynin on ROS generation in rat aortic smooth muscle cells and 
fibroblasts (Rey et al., 2001). Nevertheless, in our studies, administration apocynin 
via drinking water demonstrates a potent inhibitory effect to Nox2 by showing lower
176
ROS production, improved lipids metabolism, preserved blood pressure and 
endothelial function in diet-induced obese WT mice. Howerver, more specific 
inhibitors o f Nox2 should be applied in this study if  available.
My study has shovm that deletion or inhibition of Nox2 attenuates detrimental 
pathological progresses of obesity-associated metabolic disorders, such as 
hyperglycemia, dislipidemia and insulin resistance. Therefore, Nox2 and Nox2- 
derived ROS may play a key role in mediating dietary obesity-related metabolic 
disorders. However, the underlying machanisms are needed to clarify. The role of 
Nox2 in metabolism-related signalling pathways, such as insulin receptor signalling 
pathway, need further investigation.
Future investigation should be focused on the role of Nox2 in the relationship of diet- 
induced obesity and the development of atherosclerosis. The exact underlying 
mechanisms of Nox2 and Nox2-derived ROS in dietary obesity-related metabolic 
disorders in mice also need to be confirmed. Therefore the future work is listed 
below:
1. Nox2/other Nox expression in WT/Nox2 KO/apoE KO mice;
2. H2O2 generation in vasculature of mice;
3. eNOS expression/activity in endothelial cells/serum;
4. Expression o f insulin receptor signalling pathway and downstream pathways;
5. Complementary endothelial/pancreatic cell cuture experiments.
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